<SEC-DOCUMENT>0001628280-19-006841.txt : 20190515
<SEC-HEADER>0001628280-19-006841.hdr.sgml : 20190515
<ACCEPTANCE-DATETIME>20190515171259
ACCESSION NUMBER:		0001628280-19-006841
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20190331
FILED AS OF DATE:		20190515
DATE AS OF CHANGE:		20190515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		19829574

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20190331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2017 Workiva--><!--r:031f68bb-a3b6-4ac5-91de-52b2b78765c7,g:bb439603-ef46-4aac-8075-326b08cd6501--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:cpix="http://www.cumberlandpharma.com/20190331" xmlns:xlink="http://www.w3.org/1999/xlink"><head><meta http-equiv="Content-Type" content="text/html"></meta>


<title>Document</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF80LTEtMS0xLTA_4900aee7-74aa-44d1-92ec-3f2fedcb8c3c">Non-accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" format="ixt:datemonthdayyear" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF82LTEtMS0xLTA_f85a612a-39da-4273-a2c1-d0b2b14e80d6">3/31/2019</ix:nonNumeric><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF83LTEtMS0xLTA_b34e029a-574a-4a4c-a8ef-85d0e3a35cad">2019</ix:nonNumeric><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF84LTEtMS0xLTA_b8066440-7c6b-4e00-a5a6-9c87d483b1d9">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF85LTEtMS0xLTA_dd7c3cc1-a3fa-479f-b78b-8e0da279b5dc">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF8xMC0xLTEtMS0w_91299625-508c-41e5-ac41-83757536e945">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" format="ixt:booleanfalse" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF8xMS0xLTEtMS0w_b9eab33b-9933-4bd4-a342-dc6ae07f9ecf">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGV4dHJlZ2lvbjplZjQxYzlkYTc1MTY0MzIxYjNhMzNlYTgyNGQzNTgzOV83OQ_b20ed109-74b3-4262-8dea-7d0d1d319a2f">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGV4dHJlZ2lvbjplZjQxYzlkYTc1MTY0MzIxYjNhMzNlYTgyNGQzNTgzOV84MA_c23d00bf-55cf-41c9-9e5e-7d803502caea">0001087294</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMS0xLTEtMS0w_f5faa35f-6352-4f9d-946d-073735174be6">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMS0yLTEtMS0w_089e5776-3150-4f21-bd1d-39a50f3df098">&#8212;</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMi0xLTEtMS0w_76bd57b5-5683-4af4-9e13-6c1d3621aa0b">100,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMi0yLTEtMS0w_49ca4bf4-1676-441c-a0a6-29e1b1c67ad4">100,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMy0xLTEtMS0w_6e6a50f5-1d1c-486e-a7e4-47ad05c2ce56">15,547,517</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMy0yLTEtMS0w_094c5160-ebb9-46ba-abab-a3dd506f0b2e">15,481,497</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfNC0xLTEtMS0w_02f81989-7ff5-400d-9938-cc55bc2015a6">15,547,517</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfNC0yLTEtMS0w_11f5c09f-0101-45ee-8452-28a177ab55d2">15,481,497</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i1f6ebe33ae304eed860a6b42f65a094e_I20181231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MDUvZnJhZzowYzkwYmM3OWQ5MzU0ZDRlYTIzYzE3YTJhM2RhMWFkNS90ZXh0cmVnaW9uOjBjOTBiYzc5ZDkzNTRkNGVhMjNjMTdhMmEzZGExYWQ1XzI3NDg3NzkwNjk2MjI_dfa4c8e1-90cf-43ed-9292-665db1b2f04e">14.9</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i4a7a3ae6831347ca9db4b51688a19d28_I20190101" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81OTcvZnJhZzo0YTdiZTllZDhlN2U0NzM4YTM4ODA0YzM2NGNiNjIyZC90ZXh0cmVnaW9uOjRhN2JlOWVkOGU3ZTQ3MzhhMzg4MDRjMzY0Y2I2MjJkXzI3NDg3NzkwNjk2NTA_b6e46ad4-534a-4821-9673-42cd2e2f604f">3.8</ix:nonFraction><ix:nonNumeric contextRef="i73dec12684ff4570ac1aabaab6122f44_D20180101-20180930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81Mi9mcmFnOmExNGEzZWYwNDI5ZTRjNzJiNjMzZTI2ZDYyYWUwZGM3L3RhYmxlOjg3NWE1Y2ZjNGRlNTQxMDVhZmI1NzkzZGJmNDYwNTZiL3RhYmxlcmFuZ2U6ODc1YTVjZmM0ZGU1NDEwNWFmYjU3OTNkYmY0NjA1NmJfMi0xLTEtMS0w_ee6823dd-ab14-4a33-94f5-c49f2936d1f6">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i305b99fbf5894aaf821bf1146e80ed93_D20170731-20170731" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81Mi9mcmFnOmExNGEzZWYwNDI5ZTRjNzJiNjMzZTI2ZDYyYWUwZGM3L3RhYmxlOjQ4YzE1ZmI4MmYzYjRjM2Y5NDE3ODYxNTBlOTNlODE0L3RhYmxlcmFuZ2U6NDhjMTVmYjgyZjNiNGMzZjk0MTc4NjE1MGU5M2U4MTRfMS0xLTEtMS0w_93352549-7d61-4b5a-aeb7-6568c69624c8">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cpix-20190331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5158372b305c4614aa0e20e98ba862b3_I20190510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2320adaf662e4fe7b2b901c919253249_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i848ee9d3c9f34469b15767182f876fc8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99cee5905d2948288d5318dfe9649ac8_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb57fafd80b474c9f813bc964247527_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d3a0b7de7d4850a22eb0c312577e70_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6cb7f2cc5dd4238b2a9d6617534f1c5_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8fc137f89494506ab1761e45418560b_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b393de430de456b88a023c44f518e62_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eaee2725c7b484a92409dfc296be077_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie792e7fc787e424b892699bd22d3b60a_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf4dd1c7ae144628548a35b3f32ab80_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief772ccce21d46749407b4179204d621_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e5b3921e9b84154a1a03c334464f1a1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f13ca7b3e540f88ef7b7ea26c993de_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic77dc97e15d04aea946527778eb040f7_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9d2de0b92954151b3696fa7f4de637a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c9a2ee4d55b4e2cafb63a948d79be7f_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8b31f7594ba4472a1565ad62133aa90_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if33b370a2f3346fbbcba4fad695d45d2_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="i20c891e9fb7e4eae99cfa383cb0f92f7_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8b0db4e0d604245836d3b9282efa85b_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i765abef4a83f4226a84e14bc2ae33d8c_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d82faed6d35438f93182aff8a5ab296_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d7faf7c40c47348e3a5958acb6d2bb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e7b988036874b36afb60617609a7f43_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i133c730e71a944cc8b92b73f899eeb24_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1b5019d5ea04548859133f6e118e6d4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i206e669953a243e5b52cf9f148b89afe_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbedc37caa7c48e18842745320a00757_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb24625818ae442c902643c2b8ef1809_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00188b3841bf4d549fea497c3b5035bb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b827162bfcb459c97277850d39b0195_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bcfe452ec854bb39d09e29c93466eb8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca7e00066094ffc8fc51be0ceeee303_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i786c17fe2e7b4dff8a5b3561c9d7c296_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0315ef2832504837ac981b0b26e5db25_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i931504f50ce44f4193f3ef5928d9a8ba_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1e185405caf46dab422666fb5150a6d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1765b684cd844ab1a94fc477dd7eca3d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7a0bdf9b7dc4e5c951f95a88b27da7a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd15aa51095453da10d48a05a1af738_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f5f73eef27d4e28a3f1b9e8d10e3ec1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e179a6466142a0ad009b252e132a12_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ad98a5cb1834507bd141b4549bc2663_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i281bcc8e4da642aabc6d3614911c0e2b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79fc34567df54ab59aba1ba9220cd321_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i399eff68fe09475f8d1927e1b24e18f5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c62c25d6b474aec82dbe3df361574c8_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78fd08901b304e87862ea793372612cc_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i243a8f22302543b491cf4c23088a5b78_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2abb15b10ea141c0a13f38e41acbfd58_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf2ebe21504f48ce9df5029e04867fb4_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992c3adfb7cf4dea8988359b85080c0e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f711131cff84f42b7542874e5a8c211_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e1587978634f259217537b16f87828_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0f500556b04514907e14932d06b892_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida8fc49ce7b346adb56f00c51bb7dbd5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i546e97edc09840048611ed807a57b0d6_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6d51fc324234a1c807f02d120cac973_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic45f1596255243a5b3a837136a21297d_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51174cd0c9b8448c9fdeac2a3c7adb13_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a65212ca148417c818133e73d4e6e7e_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187b59007ba34807a5a064a86071efa7_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3677ad66cce4a5a86c6214572f63329_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i370fbb3a09b94f55b491f2c991a0a56a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f6ebe33ae304eed860a6b42f65a094e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a7a3ae6831347ca9db4b51688a19d28_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icec24700d0ae4b5c96e743134dc74822_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d16aac31044218bb5b9daf893c454a_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c518feb5474c11b67fefc2bfc51704_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d1dca0050148988cc1661e80f74884_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a32d6eb05e04225a17c4afc1836f061_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a16259aa7064665beb60a659a9e175f_I20181017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575d0c767db6474b8c9ab64d88e752e3_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f348e2b52e9422cb8037060ca5972d0_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2048c5597798442694e3f3970659f9e9_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44a6e15c3f574e3db1922e1ad5b5b56d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2182d9e6420b4100b344f9c6cc077aa0_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73dec12684ff4570ac1aabaab6122f44_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i305b99fbf5894aaf821bf1146e80ed93_D20170731-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-31</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2424f11376147c9af04e9c63133c333_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1788a3b19df415c95d49112f2d872f8_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifda35f731b37450782fc5c338eb2a4a8_I20181112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c62ad8b23f4059be803e962f97748f_D20181113-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-13</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9204f2031142428a1963d884e11716_D20181112-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-12</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if53f00afbc0c44d78276b75547af3d20_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:3pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:700;line-height:120%;">WASHINGTON, DC 20549</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xL2ZyYWc6Mjg4ZDI3NjFjYTM1NGE1OWI1OTBlZWQ5NzNjZWQxZWQvdGV4dHJlZ2lvbjoyODhkMjc2MWNhMzU0YTU5YjU5MGVlZDk3M2NlZDFlZF8xOTQ1_6e1afdc0-8f80-45b2-b7b6-5b9f6305a5ef">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:12pt;font-weight:400;line-height:100%;">&#253;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:100%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended March 31, 2019 </span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:12pt;font-weight:400;line-height:100%;">&#168;</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:100%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Commission file number: 001-33637</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:20pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xL2ZyYWc6Mjg4ZDI3NjFjYTM1NGE1OWI1OTBlZWQ5NzNjZWQxZWQvdGV4dHJlZ2lvbjoyODhkMjc2MWNhMzU0YTU5YjU5MGVlZDk3M2NlZDFlZF8xOTQ2_4798a91b-18f2-432c-a38b-c761094e95e8">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified In Its Charter)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:47.632893%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.443172%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:45.723935%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Tennessee</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">62-1765329</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">(State or Other Jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Incorporation or Organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr><tr><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">2525 West End Avenue, Suite 950,</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:100%;">Nashville, Tennessee</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">37203&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(615) 255-0068</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;line-height:120%;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;line-height:120%;">&#168;</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;line-height:120%;"> Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;line-height:120%;">&#253;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;line-height:120%;">&#168;</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:21.529412%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.300000%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:41.088235%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.447059%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.941176%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.447059%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.447059%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;font-weight:400;line-height:100%;">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;font-weight:400;line-height:100%;">&#168;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;font-weight:400;line-height:100%;">Accelerated&#160;filer</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;font-weight:400;line-height:100%;">&#168;</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;font-weight:400;line-height:100%;">Non-accelerated filer</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:Wingdings;color:#000000;background-color:rgb(255,255,255, 0.0);">&#253;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;font-weight:400;line-height:100%;">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;font-weight:400;line-height:100%;">&#168;</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;font-weight:400;line-height:100%;">Emerging growth company</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;font-weight:400;line-height:100%;">&#168;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;line-height:120%;">&#168;</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;line-height:120%;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;line-height:120%;">&#168;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Wingdings;font-size:9.5pt;line-height:120%;">&#253;</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9.5pt;line-height:120%;">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269006%;"><tr><td style="width:1.0%;"></td><td style="width:22.594993%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389102%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.727541%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389102%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.315169%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389102%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:22.594993%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of exchanged on which registered</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding&#160;at May 10, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Common stock, no par value</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">CPIX</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">NASDAQ Global Select Market</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5158372b305c4614aa0e20e98ba862b3_I20190510" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xL2ZyYWc6Mjg4ZDI3NjFjYTM1NGE1OWI1OTBlZWQ5NzNjZWQxZWQvdGFibGU6YTNkMDc0Y2U3ZDczNGQwMTllMWFhNzMwZDEwOWVkMDYvdGFibGVyYW5nZTphM2QwNzRjZTdkNzM0ZDAxOWUxYWE3MzBkMTA5ZWQwNl8xLTItMS0xLTA_56bdf145-f910-4b5f-847b-62e7cfe79978">15,537,130</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span><br/></span></div><div id="i_0_7"></div><div style="-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">INDEX</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:81.431085%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.568915%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_10">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:-18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_13">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_16">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_22">2</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_25">3</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">Condensed Consolidated Statement</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">s</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28"> of Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_28">4</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_31">5</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_64">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_64">14</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_85">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_85">22</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_88">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_88">22</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_91">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_91">23</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_94">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_94">23</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_97">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_97">23</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_100">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_100">23</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_103">Item 5.: Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_103">23</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_106">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_106">24</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_109">SIGNATURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i_0_109">25</a></span></div></td></tr></table></div><div><span><br/></span></div><div id="i_0_10"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="i_0_13"></div><div style="margin-top:14pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="i_0_16"></div><div style="text-align:center;margin-top:18pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:58.029499%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMy0xLTEtMS0w_fd18a463-a75e-40bc-bee0-b8d5bf36e3e5">24,609,415</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMy0zLTEtMS0w_967ae735-3cf9-482b-a456-3b29e13cbfb6">27,938,960</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNC0xLTEtMS0w_d09d159c-625a-4582-94d7-b20b278f26cd">9,667,073</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNC0zLTEtMS0w_878a62bd-b219-4e94-879d-0ec09f3b16d3">8,290,679</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNS0xLTEtMS0w_24a39a62-0e5e-4bb3-b0ae-5d407baa230f">9,973,995</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNS0zLTEtMS0w_c27adc65-38c4-4c0a-b820-46dd8d25a824">7,844,249</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNi0xLTEtMS0w_741cf3a3-abc2-4c5e-a80d-de0de03c9e9e">11,259,233</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNi0zLTEtMS0w_aa69a738-e8c4-46d4-a157-8724e8af66b4">12,078,343</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid and other current assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNy0xLTEtMS0w_1eacaeac-10bf-4ffb-b2b0-ae8d49423d33">2,456,453</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNy0zLTEtMS0w_f6c79d8c-04f1-4f0b-bd2e-1c9de4859957">2,963,806</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOC0xLTEtMS0w_38f73b82-c3da-4ca0-91f6-814d6113bf4f">57,966,169</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOC0zLTEtMS0w_13b87298-4953-46aa-b6b9-ff98538baf79">59,116,037</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current inventories</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOS0xLTEtMS00MDY_fd71f290-e3f7-4fc7-8669-7c64444bf25e">15,862,092</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOS0zLTEtMS0xOTgz_32cad8d0-d4f3-4688-abce-c6f806a8d6cd">15,749,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOS0xLTEtMS0w_1d8e9e88-1505-4696-80b7-e9c62e0708f1">744,085</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOS0zLTEtMS0w_9927847a-99bf-4a3a-a4b8-eb5c92cd404e">771,213</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTAtMS0xLTEtMA_467cb10e-1f3e-48e5-9238-49b5314b166f">32,910,261</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTAtMy0xLTEtMA_aa8e189f-6738-43c4-9e5c-d83abe25ab61">33,655,099</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTEtMS0xLTEtMzk5_5249827f-fa19-49d6-9808-73340ae0e0c6">882,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTEtMy0xLTEtMTE_942f7c4b-a06f-4cbf-94c5-76cf3be8e477">784,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets, net</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTEtMS0xLTEtMA_7434345c-b36d-43a9-932b-3d3a3526bb48">43,605</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTEtMy0xLTEtMA_b95d7d15-08e9-4053-9cb0-4a7948c1129e">87,210</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTItMS0xLTEtMA_bcf96f24-3681-4318-ab56-f96dac1a49f7">6,209,417</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTItMy0xLTEtMA_315e863a-77ae-4523-8e51-4504304a3f3d">2,531,309</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTMtMS0xLTEtMA_bdd1a573-1f67-46f4-99c8-2dae06645ad9">114,617,629</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTMtMy0xLTEtMA_f8309603-e1f0-42f9-b0fd-43e76c8071af">112,693,868</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTYtMS0xLTEtMA_f223bbeb-4ae4-4f7f-9c0b-6adbaa366008">9,292,014</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTYtMy0xLTEtMA_bc2d29ce-e732-4bdd-864d-277ce6228bce">11,093,297</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTctMS0xLTEtMA_6354bc5e-0a30-4016-a8d6-c7677de82837">18,706,631</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTctMy0xLTEtMA_6f845629-138d-4a21-a245-a6a7757d5869">16,710,927</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTgtMS0xLTEtMA_29e1fd1f-3005-459b-8377-696becca2e01">27,998,645</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTgtMy0xLTEtMA_3253c57b-ce82-45a4-90ed-cefd99c969d1">27,804,224</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolving line of credit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTktMS0xLTEtMA_5160c64e-98f6-44db-8940-c1f90fbfca58">20,000,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTktMy0xLTEtMA_fd4dc959-057f-4c6f-b271-693085f3e461">20,000,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjAtMS0xLTEtMA_b1310aa2-2e91-44eb-98f8-b32ab83f5184">11,428,257</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjAtMy0xLTEtMA_326e0c82-d115-4f75-8a91-e836fb12276d">9,319,143</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjEtMS0xLTEtMA_9e9964cc-f6ac-4fa0-89f5-845636bd4f84">59,426,902</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjEtMy0xLTEtMA_bc9f72e3-644f-4622-841a-28710eb4e398">57,123,367</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjItMS0xLTEtMA_8577b57a-1c54-4c05-8d09-6e67b65b446a"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjItMy0xLTEtMA_5ad7ae08-77e9-4fc1-a523-e4d7a9affff8"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,547,517 and 15,481,497 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjUtMS0xLTEtMA_bad0ce48-bc3c-4c54-abfc-491080c1cc28">50,759,257</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjUtMy0xLTEtMA_a75f9f26-c71c-42f7-beb4-318bb00057c9">51,098,613</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjYtMS0xLTEtMA_e53069b5-fec3-402d-9de1-267695bc40e4">4,672,276</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjYtMy0xLTEtMA_11248f25-29af-45af-a560-9d3438bf8f31">4,746,154</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total shareholders&#8217; equity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjctMS0xLTEtMA_51a165f2-6f84-4a58-9939-e8d6111cd5fa">55,431,533</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjctMy0xLTEtMA_d69f5988-9496-4f80-a31b-934ddc84ef49">55,844,767</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjgtMS0xLTEtMA_d043ad55-5a91-4b00-81ac-95d10247f5bd">240,806</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjgtMy0xLTEtMA_67c20715-5264-4ddb-b900-44b5d8a1669b">274,266</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjktMS0xLTEtMA_59d3e9a6-07ba-4e20-bc44-0e12d382787b">55,190,727</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjktMy0xLTEtMA_0949339c-bae2-4d03-b886-0da5018662fe">55,570,501</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMzAtMS0xLTEtMA_255ff69e-f885-406b-928a-b2d965ed6f34">114,617,629</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMzAtMy0xLTEtMA_9227d6f6-dc70-4bac-a58b-43d84ae8a38a">112,693,868</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div id="i_0_22"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:57.590044%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.472914%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.472914%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMi0xLTEtMS0w_20379df8-23f2-4ba6-822b-4189951145ad">11,902,747</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMi0zLTEtMS0w_11ec3a9e-95fb-41be-8e62-837a8954fe0b">8,587,605</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNC0xLTEtMS0w_22ecb181-107e-469a-89ce-1caf18598bf5">1,999,736</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNC0zLTEtMS0w_82afd672-1094-48ee-9b72-11462e1d9020">1,527,961</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNS0xLTEtMS0w_f6930b0b-62ba-4a76-aa57-cdb9b28ed95b">5,120,505</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNS0zLTEtMS0w_13f15279-15be-4c11-9473-a2b8ccc69e24">4,670,511</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNi0xLTEtMS0w_6b2daa7d-f75d-46b8-a95a-ca38cdc4e461">1,267,601</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNi0zLTEtMS0w_5587312e-0f6f-476d-9858-2d1bca90f8a5">1,874,939</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNy0xLTEtMS0w_c4defb49-33c8-4393-93ef-d8cf1bf40435">2,670,056</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNy0zLTEtMS0w_b3903f4b-dc38-4c85-a254-bbfd34bdb75c">2,330,281</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfOC0xLTEtMS0w_bcde21ff-1bda-4e6f-9a24-b308f4b47c40">1,021,645</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfOC0zLTEtMS0w_c93d31c6-5cb8-4605-97c7-aaa2d5d22628">636,135</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfOS0xLTEtMS0w_c215d073-9ed0-43c6-9d1f-0f9020cba7d5">12,079,543</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfOS0zLTEtMS0w_5dd020c2-b016-4d9b-80e4-2e982830a389">11,039,827</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTAtMS0xLTEtMA_9c8a7d4d-89ce-42a8-ba2c-cc174f557888">176,796</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTAtMy0xLTEtMA_b641687c-60d3-44bc-923d-63c39b3b2268">2,452,222</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTEtMS0xLTEtMA_92cff2f2-798d-455b-86b9-f4be4389dc3c">115,861</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTEtMy0xLTEtMA_4a5abb4d-1cd7-4e6a-af06-c369ef79c992">82,494</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTItMS0xLTEtMA_fdb100c3-8158-4668-acf0-29b079968578">60,911</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTItMy0xLTEtMA_aee32b17-5c90-4ed7-b1ae-b4f8d0a31cce">18,302</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTMtMS0xLTEtMA_3024492f-9a2d-421f-bedd-c8d0829d9416">121,846</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTMtMy0xLTEtMA_435b8a76-860c-497d-bfba-6b2fd135748e">2,388,030</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTQtMS0xLTEtMA_564d7aee-1a27-4b65-99a9-9b871543812d">81,428</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTQtMy0xLTEtMA_18cdb447-7bcc-4173-9abd-b16653b6ff36">4,159</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTUtMS0xLTEtMA_8ca97719-29c0-4502-b02e-8ad01e6e6852">40,418</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTUtMy0xLTEtMA_3991026d-257c-4db9-aad9-562833edc792">2,392,189</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTYtMS0xLTEtMA_ce4a3156-9ce0-47d9-9167-d0896a8c3b14">33,460</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTYtMy0xLTEtMA_0dec5184-e0a4-48ca-a41c-05fc25d19135">12,950</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTctMS0xLTEtMA_a2c774aa-2585-4468-9391-4c8e4df40232">73,878</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTctMy0xLTEtMA_d49afcbd-8cfd-499b-8098-96260641b2f0">2,379,239</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">- basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="2" format="ixt:zerodash" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTktMS0xLTEtMA_d30fad80-6beb-4b45-9fb8-18cf7f2db846">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTktMy0xLTEtMA_a28f9e57-485e-4271-9e61-836d64fa5664">0.15</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">- diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="2" format="ixt:zerodash" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjAtMS0xLTEtMA_f783b750-1ecb-46fc-8600-c4fe7cac24f3">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjAtMy0xLTEtMA_891b50a2-b298-4f7e-8c4a-bb43ddca9243">0.15</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">- basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjItMS0xLTEtMA_c7c6e4d2-f491-4f8c-8be8-4c4e28bf1673">15,472,952</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjItMy0xLTEtMA_e103876d-d300-457a-8164-ba91713a57a3">15,689,240</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">- diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjMtMS0xLTEtMA_972fa6c1-414d-4dac-ab73-62fbb8e486e9">15,472,952</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjMtMy0xLTEtMA_9626accd-a58d-4dc8-823a-ea4399ce9c57">15,689,240</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjUtMS0xLTEtMA_f05dbbe1-9633-4e53-9f9c-7494e01768e4">73,878</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjUtMy0xLTEtMA_0e01c1ce-9056-49b6-8321-09a62074a150">2,379,239</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjYtMS0xLTEtMA_ef6c6256-6cb4-44f2-837d-7822201ee8e6">33,460</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjYtMy0xLTEtMA_b3e0d822-1892-4367-8d8a-9d1ef8a0a410">12,950</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total comprehensive income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjctMS0xLTEtMA_183f4502-79b8-4720-9445-ba4da91a334e">40,418</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjctMy0xLTEtMA_03c23398-f928-4a11-aadb-fd3aaea04eda">2,392,189</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-top:17pt;margin-bottom:17pt;"><span><br/></span></div><div id="i_0_25"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:58.029499%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMy0xLTEtMS0w_6d4def0f-8080-4964-8632-9246038f34bc">40,418</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMy0zLTEtMS0w_1afe989e-2379-4404-839f-617d66c709ec">2,392,189</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNS0xLTEtMS0w_20d2c088-89c2-450a-b393-6d1ced3ac45f">1,076,246</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNS0zLTEtMS0w_ba1d2fdf-389a-45d1-9871-ddb2615a2126">692,991</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNi0xLTEtMS0w_4dea2f8e-f9d1-47ea-a002-3c95d80f78cc">43,605</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNi0zLTEtMS0w_8cd5411f-fe87-447a-ac39-849e5c817f93">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNy0xLTEtMS0w_f201c7f9-608f-4275-b495-b607c935e5bd">364,434</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNy0zLTEtMS0w_4fd8cb37-6a2b-477f-a5c1-5a374e99dc0e">339,209</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(Decrease) increase in non-cash contingent consideration</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfOC0xLTEtMS0w_67581ceb-f26f-4b40-be4d-a8af8a21769a">269,422</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:zerodash" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfOC0zLTEtMS0w_ce521c06-b14e-4062-bc44-0eec3e7b06dd">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncash interest expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfOS0xLTEtMS0w_08a8b88c-5e15-4f32-af70-f6334a2b06e0">10,497</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfOS0zLTEtMS0w_1dccd48e-9486-484f-81d1-16f7feab992c">18,303</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncash investment gains</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTAtMS0xLTEtMA_6528aa3c-8967-4fbc-82a4-f1181afcea9c">44,191</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTAtMy0xLTEtMA_96d91590-0b77-4587-b1ef-4b8697ad4548">43,338</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTItMS0xLTEtMA_37249ded-9e44-457a-bf92-83c764a11d07">2,129,746</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTItMy0xLTEtMA_614e6812-ff0a-45b8-8578-ceb28a9765af">2,093,950</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTMtMS0xLTEtMA_8ce5c30b-b52c-4cde-9605-2d84e864f422">819,110</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTMtMy0xLTEtMA_6299c2a5-e549-4f33-8501-b852ea65233a">76,323</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets and other assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTQtMS0xLTEtMA_aee6af7b-33d2-45b4-b727-1cc08dacb789">134,578</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTQtMy0xLTEtMA_76efdda9-66b4-4032-a140-f2ed4dc3b010">600,884</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and other current liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTUtMS0xLTEtMA_17905410-622d-425a-89fc-1ec6da5ae03d">3,499</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTUtMy0xLTEtMA_11968850-7331-4e28-a796-9bb3445556df">1,254,535</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTYtMS0xLTEtMA_24d35a39-bd7a-45fb-8fe4-f1535aa1f1ca">353,925</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTYtMy0xLTEtMA_87b4a6de-a5ae-476d-8fb8-1e2a769a1af6">103,991</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) operating activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTctMS0xLTEtMA_6d3fcb16-cfc7-490e-adac-fbd54010ab60">385,733</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTctMy0xLTEtMA_7032356c-81e7-4e61-b0e7-1d9f81ebf8f7">235,589</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to property and equipment</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTktMS0xLTEtMA_015eac2f-d906-48da-928c-8f0fc019d8bb">27,474</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTktMy0xLTEtMA_b2a998b3-64ff-4f32-9d10-9371505bd063">94,881</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjAtMS0xLTEtMA_050f443b-8802-46a8-9173-afe389c23823">7,816,191</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjAtMy0xLTEtMA_8d678002-0034-44de-9332-04d4f0d04114">15,151,948</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjEtMS0xLTEtMA_3638dd33-fd81-473b-b127-073d482de385">6,483,988</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjEtMy0xLTEtMA_1d62442d-e45a-4181-bcc9-3d2def85528b">4,257,657</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to intangible assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjMtMS0xLTEtMA_61a06048-e364-4be0-8bbf-1cb7b3482899">363,711</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjMtMy0xLTEtMA_10009b04-1f35-453f-a133-960fbc16978f">532,954</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjQtMS0xLTEtMA_943b4640-d5c6-4488-b7cd-936b9bcc104d">1,723,388</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjQtMy0xLTEtMA_0f3de51b-9d04-499b-a094-6de999ca9ee9">11,522,126</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Borrowings on line of credit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjctMS0xLTEtMA_e18842fe-ae11-4d8a-88da-294b7bb66ee6">19,000,000</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjctMy0xLTEtMA_e1f54621-671e-41fe-9345-a736ced472fe">12,000,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayments on line of credit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjgtMS0xLTEtMA_24cea24e-3ccb-4e55-8015-aba569c37ff2">19,000,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjgtMy0xLTEtMA_c41a9f12-32a0-4a36-8b5b-7da6af775b27">9,800,000</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sales of common stock, net of offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjktMS0xLTEtMA_25c3501b-9832-4406-b1ab-f483141e0b51">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjktMy0xLTEtMA_0d4995da-ad08-40a1-8012-de57d78c5885">200,909</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments of deferred offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzAtMS0xLTEtMA_71b36207-3148-419e-b407-e0db3d8648d0">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzAtMy0xLTEtMA_69f36966-9eb2-4a78-b2b3-24ded3879107">248,108</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of contingent consideration</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzEtMS0xLTEtMjEzOQ_87af59f4-3667-4a38-a0fa-b191b006c83a">507,505</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzEtMy0xLTEtMA_8036c5b8-5f50-4335-98aa-cef64da83ab9">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzUtMS0xLTEtMA_e93301bd-799a-4bad-bc6c-44005f761d56">712,919</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzUtMy0xLTEtMA_c103343b-f036-4538-b909-f6e75a734f1e">1,016,156</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in)  financing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzYtMS0xLTEtMA_4118cfca-de7d-48c9-84be-826d4b7d93af">1,220,424</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzYtMy0xLTEtMA_1b037671-8d4b-4582-aa17-2f29aacf43c4">1,136,645</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzctMS0xLTEtMA_9a647d0b-c195-487f-8ddf-775f4e64d01c">3,329,545</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzctMy0xLTEtMA_14d93643-7b99-482d-8fa5-31fa4a41e93a">10,149,892</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzgtMS0xLTEtMA_dab70f5a-fe8b-4677-aea9-377108bce4ba">27,938,960</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i848ee9d3c9f34469b15767182f876fc8_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzgtMy0xLTEtMA_4c157f44-dd62-43ed-a15a-2f25f3ca4086">45,412,868</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzktMS0xLTEtMA_946587ef-cc6d-45a8-92d1-03bf26421ca7">24,609,415</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99cee5905d2948288d5318dfe9649ac8_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzktMy0xLTEtMA_eebe8f03-877d-4174-9f42-45d211c2a21b">35,262,976</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of operating lease assets and liabilities through adoption of ASC 842</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNDItMS0xLTEtMzIwNw_195d8a6b-f943-4105-8070-ea601ca38227">3,629,320</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNDItMy0xLTEtMzIwOQ_b6ab05ec-e43b-447e-a143-1b9ee5315cf8">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-top:17pt;margin-bottom:17pt;"><span><br/></span></div><div id="i_0_28"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976608%;"><tr><td style="width:1.0%;"></td><td style="width:30.496307%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737075%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390842%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850812%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="3" style="height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:24pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2017</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idcb57fafd80b474c9f813bc964247527_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMi0xLTEtMS0zMTYw_3fd8101b-1cd4-4c6c-b4be-f4daf2d37a47">15,723,075</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcb57fafd80b474c9f813bc964247527_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMi0zLTEtMS0zMTYy_fa991154-fad4-45db-9083-20b2960ba685">52,410,941</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01d3a0b7de7d4850a22eb0c312577e70_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMi01LTEtMS0zMTY0_9797efb5-7b94-4efb-b90d-6a61ee808a8f">11,709,222</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic6cb7f2cc5dd4238b2a9d6617534f1c5_I20171231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMi03LTEtMS0zMTY2_75fc8379-1323-4434-94aa-750dadadce91">198,562</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i848ee9d3c9f34469b15767182f876fc8_I20171231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMi05LTEtMS0zMTY4_83c0c328-823d-4ee6-ada5-bce545ba3712">63,921,601</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sales of common stock, net of offering costs</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMy0xLTEtMS0zMTc0_2cc4c036-2f32-46b1-9c61-e37827a2bb3d">30,704</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMy0zLTEtMS0zMTcy_28dbfec9-5e42-423f-9fe2-54a519ebada3">200,909</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMy05LTEtMS0zMTcw_cd350809-c7d1-4410-8a5d-59a66108060a">200,909</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNC0xLTEtMS0zMTc2_c77e8c99-bb4e-4c5f-a40d-e7f09a72a16d">145,550</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNC0zLTEtMS0zMTc4_0ba7d1cd-b872-460c-9a53-e8e60039c9fd">339,209</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNC05LTEtMS0zMTgw_47ac4265-10a4-4823-8092-be65b01be1e7">339,209</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNS0xLTEtMS0zMTgy_abd6d4e9-02ba-4901-b11e-3a942a4e3548">172,079</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNS0zLTEtMS0zMTg0_b5426d1c-acfb-459c-9dde-ac0fd7e89e0b">1,195,225</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNS05LTEtMS0zMTg2_63c7efcb-9cc3-47ae-8c61-b038bea589a0">1,195,225</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib8fc137f89494506ab1761e45418560b_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNi01LTEtMS0zMTky_0aab5f47-8a62-4a92-9325-9db80650de03">2,379,239</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7b393de430de456b88a023c44f518e62_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNi03LTEtMS0zMTk2_740054fb-d356-4f5c-b432-5792fb77bcb5">12,950</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNi05LTEtMS0zMjAw_795b44ad-7b23-4fe0-8384-d398b26f0ea6">2,392,189</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1eaee2725c7b484a92409dfc296be077_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNy0xLTEtMS0zMTg4_51fd2f73-30ca-4a6e-aeed-97a6742615cb">15,727,250</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1eaee2725c7b484a92409dfc296be077_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNy0zLTEtMS0zMTkw_8ec65c4a-e532-4501-ac0f-f2adfc715759">51,755,834</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie792e7fc787e424b892699bd22d3b60a_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNy01LTEtMS0zMTk0_0766a399-6d58-4966-a010-ac8cfc33da61">9,329,983</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaaf4dd1c7ae144628548a35b3f32ab80_I20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNy03LTEtMS0zMTk4_74db452e-b4a1-400d-8a09-a59974904892">211,512</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99cee5905d2948288d5318dfe9649ac8_I20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNy05LTEtMS0zMjAy_d5c071e0-c61d-47bc-820b-d17b4a7b23f6">60,874,305</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr></table></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:30.448378%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.946903%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.831858%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.831858%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.749263%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.831858%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;height:9pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ief772ccce21d46749407b4179204d621_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMy0xLTEtMS0w_463756db-ee55-4359-87d2-e44748b04e33">15,481,497</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief772ccce21d46749407b4179204d621_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMy0zLTEtMS0w_908631cb-467a-44f3-a4e0-e6603c08eab1">51,098,613</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3e5b3921e9b84154a1a03c334464f1a1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMy01LTEtMS0w_db113d11-6cc1-4194-ba9d-0a8b32c308c9">4,746,154</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i47f13ca7b3e540f88ef7b7ea26c993de_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMy03LTEtMS0w_305ff98e-6b4a-42f6-ad25-ad688e0f58a7">274,266</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMy05LTEtMS0w_270918ca-0992-4db9-9eb8-355be89d6287">55,570,501</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfNi0xLTEtMS0w_b6c58042-2b8b-4b46-ba88-32d497478af7">187,486</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfNi0zLTEtMS0w_33f9897a-7b27-4522-b191-1bf7cfccef25">364,434</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfNi05LTEtMS0w_df0d4428-f6ec-4ecb-965e-d42a365bfd22">364,434</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfOS0xLTEtMS0w_cb2635d2-655b-4f56-972e-ae3c2873385b">121,466</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfOS0zLTEtMS0w_75ea2dbe-6a9a-4874-af6b-8a848605685d">703,790</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfOS05LTEtMS0w_40293af5-9d9b-4ce9-bc5d-e651f5cd0298">703,790</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic77dc97e15d04aea946527778eb040f7_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTAtNS0xLTEtMA_551ab4bb-48ec-4c5b-8248-6fafafe77000">73,878</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9d2de0b92954151b3696fa7f4de637a_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTAtNy0xLTEtMA_38fa895d-ec4b-41e8-81e8-c088a06287d7">33,460</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTAtOS0xLTEtMA_08cbf81c-ff52-4fb7-8506-0fad548ef981">40,418</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1c9a2ee4d55b4e2cafb63a948d79be7f_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTEtMS0xLTEtMA_992a00a8-57d8-4918-829f-263713bea562">15,547,517</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c9a2ee4d55b4e2cafb63a948d79be7f_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTEtMy0xLTEtMA_a8dd8063-700d-42b1-9588-d3d060de82b0">50,759,257</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8b31f7594ba4472a1565ad62133aa90_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTEtNS0xLTEtMjAzOQ_f525c305-2b91-4de4-8bbc-5913a97d6d8b">4,672,276</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if33b370a2f3346fbbcba4fad695d45d2_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTEtNy0xLTEtMA_cf4b4d06-6d5d-4457-b1f0-b6a831c47a90">240,806</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTEtOS0xLTEtMjA0Nw_deee7eca-c3ea-44ba-8139-710e2941a700">55,190,727</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-top:17pt;margin-bottom:17pt;"><span><br/></span></div><div id="i_0_31"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">4</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="i_0_34"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(1) <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNC9mcmFnOjAyYjhhNGE0YzIzMjRlMTU4NmEyOTE0NzZhNjMxMGE4L3RleHRyZWdpb246MDJiOGE0YTRjMjMyNGUxNTg2YTI5MTQ3NmE2MzEwYThfMTI4NjM_726ef9ef-a411-46c7-b5bf-cce95883eeb0" continuedAt="i6686b56937a54aac89bc3a548d2db3e3" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i6686b56937a54aac89bc3a548d2db3e3" continuedAt="i532412e5fd574a329eb751287626bc38"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2018 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 (the &#8220;2018 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Total comprehensive income (loss) consisted solely of net income (loss) for the three months ended March 31, 2019 and 2018.</span></div><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNC9mcmFnOjAyYjhhNGE0YzIzMjRlMTU4NmEyOTE0NzZhNjMxMGE4L3RleHRyZWdpb246MDJiOGE0YTRjMjMyNGUxNTg2YTI5MTQ3NmE2MzEwYThfMTI4NjQ_a9e88ae6-ff36-47ff-aa1c-26cc8b106522" continuedAt="i04c1b434ab4149cd8ec8d99fac79b9a6" escape="true"><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 6.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i532412e5fd574a329eb751287626bc38" continuedAt="i8b0b037e2f2c4d39a649dfd1252645e0"><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i04c1b434ab4149cd8ec8d99fac79b9a6">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</ix:continuation></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Policies:</span></div><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNC9mcmFnOjAyYjhhNGE0YzIzMjRlMTU4NmEyOTE0NzZhNjMxMGE4L3RleHRyZWdpb246MDJiOGE0YTRjMjMyNGUxNTg2YTI5MTQ3NmE2MzEwYThfMTI4NjE_7997df88-82a5-42d6-a3b8-c7627be720d6" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;"><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNC9mcmFnOjAyYjhhNGE0YzIzMjRlMTU4NmEyOTE0NzZhNjMxMGE4L3RleHRyZWdpb246MDJiOGE0YTRjMjMyNGUxNTg2YTI5MTQ3NmE2MzEwYThfMTI4NjI_5b151ba5-e582-492c-a6c1-e17fd6b31aab" continuedAt="i118361b3928247b7a27f13538e6030d7" escape="true">Operating Segments</ix:nonNumeric></span></div></ix:continuation><div style="text-align:justify;margin-top:8pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i8b0b037e2f2c4d39a649dfd1252645e0"><ix:continuation id="i118361b3928247b7a27f13538e6030d7">The Company has <ix:nonFraction unitRef="segment" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNC9mcmFnOjAyYjhhNGE0YzIzMjRlMTU4NmEyOTE0NzZhNjMxMGE4L3RleHRyZWdpb246MDJiOGE0YTRjMjMyNGUxNTg2YTI5MTQ3NmE2MzEwYThfMTIwNTQ_9ca8656d-2487-4b92-bbff-6346f203f478">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div id="i_0_37"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(2) <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RleHRyZWdpb246MzA0N2JlY2E1ZDkwNDNiMjlhOWI2NjM2MDY4YjE5OWNfMzQxMw_2d1bcdc3-ddab-4aba-851d-6ca02c3e6bf3" continuedAt="i365057086ff34620bfcc224def10d038" escape="true">MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i365057086ff34620bfcc224def10d038" continuedAt="if7418d43929840e29a97f5109fb35419"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (&#8220;SBA&#8221;) loan pools, corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of March 31, 2019 and December&#160;31, 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Level 3 -   Significant inputs to the valuation model are unobservable.</span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="if7418d43929840e29a97f5109fb35419"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"> </span></div><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RleHRyZWdpb246MzA0N2JlY2E1ZDkwNDNiMjlhOWI2NjM2MDY4YjE5OWNfMzQxMA_852abe9b-256d-4cb3-a109-d2d26684efc1" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:27.368576%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534214%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160059%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i20c891e9fb7e4eae99cfa383cb0f92f7_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi0xLTEtMS0w_890ee92b-ad89-43f4-995e-e9b06c0b6f99">5,088,386</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8b0db4e0d604245836d3b9282efa85b_I20190331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi0zLTEtMS0w_9a6a078c-03af-4437-a5df-951f01f61ef3">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i765abef4a83f4226a84e14bc2ae33d8c_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi01LTEtMS0w_a2ed0a5a-c522-4597-b70b-7665d5a8b4ce">5,088,386</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d82faed6d35438f93182aff8a5ab296_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi03LTEtMS0w_72291424-a697-4516-b70c-09750d0e0d31">5,034,955</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i04d7faf7c40c47348e3a5958acb6d2bb_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi05LTEtMS0w_95094722-eabe-4bd9-a2fa-72a9309f7c5b">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e7b988036874b36afb60617609a7f43_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi0xMS0xLTEtMA_d817ec1d-1bee-4cee-9778-8c1e6e219494">5,034,955</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i133c730e71a944cc8b92b73f899eeb24_I20190331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS0xLTEtMS0w_7d72e5e7-b3ea-4c64-b161-b5ebc79435e9">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic1b5019d5ea04548859133f6e118e6d4_I20190331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS0zLTEtMS0w_77003e95-e2c1-4bb8-857a-bde7bdb84201">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i206e669953a243e5b52cf9f148b89afe_I20190331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS01LTEtMS0w_fb0cd8d2-5a71-4982-bea8-15cfac9953f8">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idbedc37caa7c48e18842745320a00757_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS03LTEtMS0w_90dcadfc-1f28-4303-9076-8068f1e6421d">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb24625818ae442c902643c2b8ef1809_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS05LTEtMS0w_8e28dd84-28b5-44c2-b39b-0339c7e7ea7b">2,504,551</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i00188b3841bf4d549fea497c3b5035bb_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS0xMS0xLTEtMA_f864adde-e93a-4202-bbe2-d3bf4cca404e">2,504,551</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b827162bfcb459c97277850d39b0195_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNC0zLTEtMS02NjE_beed51c1-1cd8-41ce-aba6-36d9ea1af963">2,256,191</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3bcfe452ec854bb39d09e29c93466eb8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNC01LTEtMS02NjE_81c6c4f5-3bc3-4509-bc3c-64251fda5980">2,256,191</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ca7e00066094ffc8fc51be0ceeee303_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNC03LTEtMS0zMjQ1_8976a7a1-c3f9-49a3-8c6f-40c11ef1e40c">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i786c17fe2e7b4dff8a5b3561c9d7c296_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNC05LTEtMS0zMjQ3_9d0a4512-ec47-4bee-a107-c389e9e48a51">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0315ef2832504837ac981b0b26e5db25_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNC0xMS0xLTEtMzI0OQ_7d60dceb-46e3-443a-b6c2-8a8d843a4fb0">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i931504f50ce44f4193f3ef5928d9a8ba_I20190331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy0xLTEtMS0w_49028cfc-22b7-469c-bb0a-acb72665f82b">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1e185405caf46dab422666fb5150a6d_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy0zLTEtMS0w_cf83a25a-0d02-44ef-bb85-a266fd8c5e47">2,322,496</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1765b684cd844ab1a94fc477dd7eca3d_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy01LTEtMS0w_e863332c-a6f7-470f-8e82-b8d87f018521">2,322,496</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic7a0bdf9b7dc4e5c951f95a88b27da7a_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy03LTEtMS0w_0da62942-0896-4a52-883b-7e33308a2096">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cd15aa51095453da10d48a05a1af738_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy05LTEtMS0w_2294f1f0-e2d5-46cf-bd69-75f850351a61">751,173</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f5f73eef27d4e28a3f1b9e8d10e3ec1_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy0xMS0xLTEtMA_49972c9c-2b21-4d2d-ad38-684d9a150937">751,173</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45e179a6466142a0ad009b252e132a12_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC0xLTEtMS0w_1becdd60-fee8-42d0-bd16-fb97c422c696">5,088,386</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ad98a5cb1834507bd141b4549bc2663_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC0zLTEtMS0w_2c95975c-3c1b-4353-ba5f-a5ff5b7f22cc">4,578,687</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC01LTEtMS0w_983b4d37-3f01-4c9f-89cc-5e5c75c75b8e">9,667,073</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i281bcc8e4da642aabc6d3614911c0e2b_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC03LTEtMS0w_4a7599d2-0c6f-47f0-bbed-61cc2091fc0f">5,034,955</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79fc34567df54ab59aba1ba9220cd321_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC05LTEtMS0w_268a7a6e-c175-4221-a0fb-c4ef5a91c7f5">3,255,724</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC0xMS0xLTEtMA_4e31432d-0b29-4322-a06c-8410a297861b">8,290,679</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_40"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(3) <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RleHRyZWdpb246NGVkMGRlNDE5MzRjNDhjNWIzZmVhYWYyMzAwMjUwYzNfNDMw_b6d8bba4-3e80-4cb5-a2c6-fc306449917c" continuedAt="ia8814100f3404d2da74207a73b49038e" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ia8814100f3404d2da74207a73b49038e"><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RleHRyZWdpb246NGVkMGRlNDE5MzRjNDhjNWIzZmVhYWYyMzAwMjUwYzNfNDI4_97c1a118-c345-49ac-ac4b-7928f213cea2" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"></td><td style="width:58.029499%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537463%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.616519%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfMy0xLTEtMS0w_a2c774aa-2585-4468-9391-4c8e4df40232">73,878</ix:nonFraction>)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfMy0zLTEtMS0w_d49afcbd-8cfd-499b-8098-96260641b2f0">2,379,239</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNS0xLTEtMS0w_c7c6e4d2-f491-4f8c-8be8-4c4e28bf1673">15,472,952</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNS0zLTEtMS0w_e103876d-d300-457a-8164-ba91713a57a3">15,689,240</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNi0xLTEtMS0w_3d7fcd9d-a6d6-435e-8dd6-caf62fa58dfe">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNi0zLTEtMS0w_06a92c49-21d1-49c5-9530-e9e9e23b3242">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNy0xLTEtMS0w_972fa6c1-414d-4dac-ab73-62fbb8e486e9">15,472,952</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNy0zLTEtMS0w_9626accd-a58d-4dc8-823a-ea4399ce9c57">15,689,240</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of March 31, 2019 and 2018, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RleHRyZWdpb246NGVkMGRlNDE5MzRjNDhjNWIzZmVhYWYyMzAwMjUwYzNfMjUy_5b5eca14-f346-478d-b139-185d87217730">263,919</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RleHRyZWdpb246NGVkMGRlNDE5MzRjNDhjNWIzZmVhYWYyMzAwMjUwYzNfMjU5_e3d223a6-8195-4973-b608-dc59b401a1f5">247,530</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="i_0_43"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(4) <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RleHRyZWdpb246Y2IyNzVkNWY5ZjM0NDY1NThlODI4ZTk5NjVhNTY5NTBfMTgwMA_7f720eae-5212-4a76-9aaa-c3a795b96b18" continuedAt="i87803d2c683d491ea18084dee3fbfa8d" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i87803d2c683d491ea18084dee3fbfa8d" continuedAt="i61108850fae9418e9c4d7501c7449b47"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Product Revenues</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. However, no cumulative effect adjustment to historical retained earnings was necessary as no revenue recognition differences were identified when comparing the revenue recognition criteria under ASC 606 to previous requirements.  </span></div></ix:continuation><div style="margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i61108850fae9418e9c4d7501c7449b47" continuedAt="i664a34bc4df341e5bdbef984aabd2de9"><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RleHRyZWdpb246Y2IyNzVkNWY5ZjM0NDY1NThlODI4ZTk5NjVhNTY5NTBfMTgwMg_f5e64e6c-ee06-447c-a162-d8e7e006b774" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:57.502924%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.298246%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i399eff68fe09475f8d1927e1b24e18f5_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMy0xLTEtMS0w_a01e2bef-f480-4b1f-9dda-91b9d716ea08">849,502</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c62c25d6b474aec82dbe3df361574c8_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMy0zLTEtMS0w_88f32b5f-f133-44cb-a029-3db825988b70">1,273,764</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i78fd08901b304e87862ea793372612cc_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNC0xLTEtMS0w_c3a8f343-71b0-42cd-8a55-dcf21601417f">199,537</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i243a8f22302543b491cf4c23088a5b78_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNC0zLTEtMS0w_20a4e0ac-bca9-41ab-9b9d-64dafba8e2c3">141,392</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2abb15b10ea141c0a13f38e41acbfd58_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNS0xLTEtMS0w_4d951de2-83c0-4a80-9921-f917cc3f935a">3,307,658</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibf2ebe21504f48ce9df5029e04867fb4_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNS0zLTEtMS0w_3bd3808e-125b-496f-919f-550c9f1af126">3,269,901</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i992c3adfb7cf4dea8988359b85080c0e_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNi0xLTEtMS0w_2d8245f6-131c-40a0-8839-f8b28d1025c3">286,676</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f711131cff84f42b7542874e5a8c211_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNi0zLTEtMS0w_5ff1c096-4796-4810-85ed-98e4d22e8873">93,890</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia3e1587978634f259217537b16f87828_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNy0xLTEtMS0w_4fa54a45-76c7-4978-961e-e0dc4b691b66">1,317,074</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd0f500556b04514907e14932d06b892_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNy0zLTEtMS0w_292e5b42-a850-40be-b248-3040e245ff8f">1,039,747</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida8fc49ce7b346adb56f00c51bb7dbd5_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfOC0xLTEtMS0w_f0e00469-bffd-4b26-94ff-7638b24a66d3">3,091,991</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i546e97edc09840048611ed807a57b0d6_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfOC0zLTEtMS0w_0eb7a7d3-0c1e-48ca-a65b-1db3018435b4">2,256,073</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Totect</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia6d51fc324234a1c807f02d120cac973_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfOS0xLTEtMS0w_46ded999-b73b-4db7-b07b-96c054e6439c">80,896</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic45f1596255243a5b3a837136a21297d_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfOS0zLTEtMS0w_f78aad36-91e4-45a6-9ccb-6fc096e6d558">412,774</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51174cd0c9b8448c9fdeac2a3c7adb13_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTAtMS0xLTEtMzI1OA_81ab069b-8051-4564-973a-b6b46a74cd0c">2,060,195</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a65212ca148417c818133e73d4e6e7e_D20180101-20180331" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTAtMy0xLTEtMzI2MA_e1cbfd37-5aee-4b43-a40a-253426ab32b3">&#8212;</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i187b59007ba34807a5a064a86071efa7_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTAtMS0xLTEtMA_a5834272-660e-401f-9121-4e25936d9803">709,218</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib3677ad66cce4a5a86c6214572f63329_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTAtMy0xLTEtMA_d0778f52-67af-43e5-b8d4-6c7cc9ecc5f4">100,064</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTEtMS0xLTEtMA_9f22830e-c0e1-4f0e-ac60-0f25f0a0910d">11,902,747</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTEtMy0xLTEtMA_945467d5-2469-49ab-9630-853e5cfd0878">8,587,605</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Other Revenues</span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="i664a34bc4df341e5bdbef984aabd2de9">The Company has agreements with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is typically entitled to receive a non-refundable, up-front payment at the time each agreement is entered into and additional payments upon the partners' achievement of defined regulatory approvals, sales milestones or both. The Company may also be entitled to receive royalties on future sales of the products under the agreements and a transfer price on supplies.</ix:continuation> </span></div><div id="i_0_46"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(5) <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfMjc0ODc3OTA3NDcyMw_ec4bf27f-8037-4c00-9295-c7150da84d40" continuedAt="i45c3e47d6bf84a5488564966d61f95f8" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i45c3e47d6bf84a5488564966d61f95f8" continuedAt="ib0a38ba0f8c549e888a9dc4ea6177576"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2019 and December 31, 2018, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfOTkz_712db7b0-370a-44c3-a71d-ff6001a3e0a2">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfMTAwMQ_254dd052-f5fb-47d5-8b7f-0b0133cccf12">0.3</ix:nonFraction> million, respectively. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total.  Consigned inventory represents Authorized Generic inventory stored until shipment.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="i370fbb3a09b94f55b491f2c991a0a56a_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfNTQ5NzU1ODE5MTg2_57b9348e-aebc-4caa-b15e-ce71327034f2">14.9</ix:nonFraction> million that are classified as non-current inventories at March 31, 2019 and December 31, 2018. Non-current inventories also include $<ix:nonFraction unitRef="usd" contextRef="i370fbb3a09b94f55b491f2c991a0a56a_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfNTQ5NzU1ODE5MjAw_ed1fe114-6c56-44df-89b1-0ff8203eb23c">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f6ebe33ae304eed860a6b42f65a094e_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfNTQ5NzU1ODE5MjE0_462bf95d-4345-4fb6-8e82-025b3c0618cb">0.8</ix:nonFraction> million in Vibativ finished goods at March 31, 2019 and December&#160;31, 2018, respectively.  </span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ib0a38ba0f8c549e888a9dc4ea6177576"><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfMjc0ODc3OTA3NDc3MA_d812bd84-6b45-4118-8413-6ae79b876276" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:56.737151%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121586%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.530103%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.681057%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.530103%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfMi0yLTEtMS0xNzc_f8159b60-6222-47bc-93ad-e1c5f109f77f">18,383,018</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfMi00LTEtMS0xNzc_5077de3a-3868-4d72-a190-5db934ba82dd">18,378,450</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfMy0yLTEtMS0xNzc_f56512eb-8ada-440e-9717-63db6b471b7b">683,733</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfMy00LTEtMS0xNzc_dfb08c02-7cb9-437f-9637-8145823ae767">937,006</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNC0yLTEtMS0xNzc_f8161480-f302-4dbd-b80c-a593c10b34ea">8,054,574</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNC00LTEtMS0xNzc_e2e3d5fb-9e9d-49c9-b641-c80c72109230">8,511,887</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNS0yLTEtMS0xNzc_de6b4e13-b6b0-41bd-a322-b2998b026dc1">27,121,325</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNS00LTEtMS0xNzc_b00f6d50-56cd-4f52-a0b3-5ceb158e73a2">27,827,343</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNi0yLTEtMS0zMjcx_a54a24c5-8bea-4a0b-8a8d-23055f7c8021">15,862,092</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNi00LTEtMS0zMjc3_b9271f0b-f280-414b-8a68-83beb049197a">15,749,000</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNy0yLTEtMS0zMjcz_21877af2-6848-486d-9980-55b90681d725">11,259,233</ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNy00LTEtMS0zMjc5_950f64c8-6674-4f2b-b05e-4a04b2697468">12,078,343</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_560"></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(6) <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQzNTc_a700a015-b46a-4cc6-88de-b95e86010012" continuedAt="if7923046787849378de98bc4ddde0974" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="if7923046787849378de98bc4ddde0974" continuedAt="iaae9479bb72a4893857f880b9b479fe6"><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 under the alternative transition method (the effective date approach). It allowed the Company to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Prior periods have not been adjusted.   </span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. The Company did not have any leases classified as finance leases at January 1, 2019 or March 31, 2019.  The new lease accounting standard did not have a significant impact on the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for any period presented. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs at the adoption date. </span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">These operating leases resulted in initial ROU assets of $<ix:nonFraction unitRef="usd" contextRef="i4a7a3ae6831347ca9db4b51688a19d28_I20190101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzE2NDkyNjc0NDY3MTI_9020d24c-9332-4bb1-8fe3-e69999a56915">3.6</ix:nonFraction> million and lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i4a7a3ae6831347ca9db4b51688a19d28_I20190101" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzE2NDkyNjc0NDY3Mzk_b6e46ad4-534a-4821-9673-42cd2e2f604f">3.8</ix:nonFraction> million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is <ix:nonNumeric contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQ0NDA_6e0d427b-7c3b-48e6-a57c-00050a1f47c1">3.7</ix:nonNumeric> years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQ0NDc_a4c044ac-30f2-466a-a398-09d641b5927c">7.42</ix:nonFraction>%.</span></div></ix:continuation><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="iaae9479bb72a4893857f880b9b479fe6"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Lease Position</span></div><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQzNTg_a51014e3-1b93-423c-9676-bfd432bf2e2e" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At March 31, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: </span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"></td><td style="width:34.036036%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:38.090090%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.969970%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo5NDA0ZDNhNjg5NDg0ZGRkYTM1OTI3YjgwZmY3NGNjOS90YWJsZXJhbmdlOjk0MDRkM2E2ODk0ODRkZGRhMzU5MjdiODBmZjc0Y2M5XzEtNC0xLTEtMzQ0MQ_7afa60f3-ef50-472b-9a68-d5911974ff24">3,487,977</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo5NDA0ZDNhNjg5NDg0ZGRkYTM1OTI3YjgwZmY3NGNjOS90YWJsZXJhbmdlOjk0MDRkM2E2ODk0ODRkZGRhMzU5MjdiODBmZjc0Y2M5XzItNC0xLTEtMzQ0Mw_5f244461-e46f-43ca-8fc6-9f261b0c9e7e">3,487,977</ix:nonFraction>&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"></td><td style="width:34.036036%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:38.090090%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.969970%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTphOWVhOWJjNzE2OWY0NzY3YmM2YjkxYjY1MzMzYjk0NS90YWJsZXJhbmdlOmE5ZWE5YmM3MTY5ZjQ3NjdiYzZiOTFiNjUzMzNiOTQ1XzItNC0xLTEtMzQ0OQ_eeba9fde-ad4a-4d44-8ae2-358e8cf24c26">1,023,603</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTphOWVhOWJjNzE2OWY0NzY3YmM2YjkxYjY1MzMzYjk0NS90YWJsZXJhbmdlOmE5ZWE5YmM3MTY5ZjQ3NjdiYzZiOTFiNjUzMzNiOTQ1XzQtNC0xLTEtMzQ1MQ_16ea01d5-5e11-42df-bf31-5dbe0d811f5b">2,605,717</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTphOWVhOWJjNzE2OWY0NzY3YmM2YjkxYjY1MzMzYjk0NS90YWJsZXJhbmdlOmE5ZWE5YmM3MTY5ZjQ3NjdiYzZiOTFiNjUzMzNiOTQ1XzUtNC0xLTEtMzQ1Mw_5f53cb68-b61d-43f8-94d3-a496b544737a">3,629,320</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQzNTk_243d9e35-a5d4-470f-ad5f-4726dd98b3e0" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"></td><td style="width:76.078078%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.969970%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity of Leases Liabilities at March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzEtMi0xLTEtMzQ4Nw_bdd34c51-6598-4798-97e9-fa37b41e6a54">825,712</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzItMi0xLTEtMzQ4OQ_ec48e3d4-45c0-4462-a7c6-d13990044c13">1,120,067</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzMtMi0xLTEtMzQ5MQ_062a1110-187b-4f4d-a993-328815875168">1,144,889</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzQtMi0xLTEtMzQ5NA_71c602e3-c903-4f2d-8a06-df852b84f2cd">1,019,313</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzUtMi0xLTEtMzQ5Ng_72561782-3919-47db-9d91-be654f9a16e2">92,478</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzYtMi0xLTEtMzQ5OQ_a1f7306f-28cd-4766-b88b-aedbaf29dd5a">0</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzctMi0xLTEtMzUwMQ_8b034f63-eede-4923-b0a8-f948072426e2">4,202,459</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzgtMi0xLTEtMzUwMw_f89f3bc9-8893-4d6e-93e5-086e3bb0141f">573,139</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzktMi0xLTEtMzUwNQ_1ea5a555-b595-4167-ad6e-08fda0cbacdd">3,629,320</ix:nonFraction>&#160;</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQzNjA_b5ffabdf-286a-48d6-ad42-e4b9bbbbe41c" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's future minimum lease commitments as of December 31 2018, under Accounting Standards Codification 840, predecessor to the newly adopted lease accounting guidance, are as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"></td><td style="width:76.078078%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751952%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.969970%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzEtMi0xLTEtMzUwNw_01d2156a-b349-4ea7-9b20-58a30e280fe4">959,902</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzItMi0xLTEtMzUwOQ_6d5bcd7b-dc1c-4c36-9579-275cd0dddfe8">980,720</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzMtMi0xLTEtMzUxMQ_b396a405-91c5-4c5f-b48b-4e592898f312">1,001,603</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzQtMi0xLTEtMzUxMw_84862e61-11ed-4cb0-84c8-aef2b5db09a3">871,969</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzUtMi0xLTEtMzUxNQ_c8f2305a-7cb7-409b-a985-ad0225741b8a">44,508</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzYtMi0xLTEtMzUxNw_d8373755-ffe9-4514-b3c0-3809a9510e3b">&#8212;</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total future minimum lease payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzctMi0xLTEtMzUxOQ_7da17104-41b4-4119-bb58-040e68094e3f">3,858,702</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:14.619883%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div id="i_0_49"></div><div style="margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(7) <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMzQ4Ng_0d4bc273-de97-430e-ae99-8dc9e4235867" continuedAt="i0549248e7e95451d82c55871f9fab245" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="i0549248e7e95451d82c55871f9fab245" continuedAt="i1fe22adbddae4f8983bb60d6133c5fab"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Share repurchases</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="icec24700d0ae4b5c96e743134dc74822_I20100513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTMw_2c9e5d30-c611-4462-ad30-e6a5f6d839ff">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="ib7d16aac31044218bb5b9daf893c454a_I20160131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMjkx_294b7ed1-5f09-4290-b640-9c36cb8e5805">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2019 and March 31, 2018, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMzk3_80de4085-f64b-428c-a8e1-d7329e163c60">121,466</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfNDEx_56e7eb69-c028-40ec-9064-55a08ce6da7a">172,079</ix:nonFraction> shares, respectively, of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfNDcw_5ec0e313-4f87-4d06-b342-0bdc561137ea">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfNDg1_91bdb09f-ca39-4031-8281-93ce6c3083b2">1.2</ix:nonFraction> million, respectively. </span></div></ix:continuation><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="i1fe22adbddae4f8983bb60d6133c5fab"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Share purchases and sales</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the March 2019 trading window, several members of the the Company's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to further the amount of ownership by the Board of Directors. During the March 2019 trading window, one Board member entered into a share sale agreement, as required by a policy change by his employer, which now prohibits his ownership in the Company.  The policy did not impact his ability to serve on the Company's Board of Directors. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Share Sale</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="ie1c518feb5474c11b67fefc2bfc51704_D20171101-20171130" decimals="-6" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfNjM5_4df810a9-7a5d-48a8-bb69-c2d7a164e92e">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018. During the three months ended March 31, 2018, the Company issued <ix:nonFraction unitRef="shares" contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ2NDg2Mg_0925f4b3-c33c-4ba3-a5a8-20be30ba71f9">30,704</ix:nonFraction> shares of common stock for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfODEy_53153241-4b77-447e-8dc1-98920e44d7d0">0.2</ix:nonFraction> million as part of its At-The-Market (&#8220;ATM&#8221;) sales agreement with B. Riley FBR. The Company did not issue any shares under the ATM during the three months ended March 31, 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Restricted Share Grants </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the three months ended March 31, 2019,  and March 31, 2018, the Company issued <ix:nonFraction unitRef="shares" contextRef="i42d1dca0050148988cc1661e80f74884_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfOTYz_6c25fd5e-9afd-4d1f-9418-13ecd9d0ae56">222,269</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i1a32d6eb05e04225a17c4afc1836f061_D20180101-20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfOTc3_d6128f4c-9ba2-43c6-a309-41f6fb612858">229,205</ix:nonFraction> shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants.  On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $<ix:nonFraction unitRef="usd" contextRef="i5a16259aa7064665beb60a659a9e175f_I20181017" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NDY2NQ_431e525f-18ff-4be9-afd5-661616f85da9">20.0</ix:nonFraction> million.  Cumberland increased the maximum aggregate principal available for borrowing to support potential future acquisitions and general corporate purposes.  The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i575d0c767db6474b8c9ab64d88e752e3_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NDkzNA_72cfb03f-288b-4c03-9b54-0bb3ef7e17f4">12.0</ix:nonFraction> million with the ability to increase the principal amount available for borrowing up to $<ix:nonFraction unitRef="usd" contextRef="i575d0c767db6474b8c9ab64d88e752e3_I20190331" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NTAxNw_ab40155f-70ee-4efa-b840-6dd49875f775">20.0</ix:nonFraction> million, upon the satisfaction of certain conditions.    </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had $<ix:nonFraction unitRef="usd" contextRef="i9f348e2b52e9422cb8037060ca5972d0_I20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NTM1Mg_f21c3ae0-7d0d-4f88-959d-9c966c84cb12">20.0</ix:nonFraction> million in borrowings under the Pinnacle Agreement at March 31, 2019 and December 31, 2018, thereby using all of its available borrowing under its revolving line of credit.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="i2048c5597798442694e3f3970659f9e9_I20190331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NTcyOA_1f0ae2a6-0074-429b-bfea-7e4ab2a4c6ec">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i44a6e15c3f574e3db1922e1ad5b5b56d_I20190331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NTczNA_5544d56f-b63d-4c15-b1d9-e7dd3699cca9">2.75</ix:nonFraction>% (representing an interest rate of <ix:nonFraction unitRef="number" contextRef="i575d0c767db6474b8c9ab64d88e752e3_I20190331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMzI5ODUzNDkwNzk1NQ_14c31fd0-4ec3-4e40-b30d-0bbbc112cd37">5.2</ix:nonFraction>% at March 31, 2019).  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="i2182d9e6420b4100b344f9c6cc077aa0_D20190101-20190331" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NTgwNQ_2fc16af0-c6a0-409c-b31d-0331aac9fbe4">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  As a result of the Third Amendment, the Company was in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2019.</span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_55"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(8) <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NS9mcmFnOjM4ZjAwYzYzYWNlZTRjMzM4NzhjNjZjOGViMjRjMzkxL3RleHRyZWdpb246MzhmMDBjNjNhY2VlNGMzMzg3OGM2NmM4ZWIyNGMzOTFfMTk4MA_89906b96-e97c-440c-a792-c5203ae809d8" continuedAt="ieca48fef42ec4cc88f99b57eaa17cebf" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="ieca48fef42ec4cc88f99b57eaa17cebf" continuedAt="if2db683115404766aade15596036a59f">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;the Tax Act&#8221;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.</ix:continuation></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="if2db683115404766aade15596036a59f">The SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118, providing guidance on applying the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements.  If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.  The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</ix:continuation></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_58"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(9) <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81OC9mcmFnOjVhZDZjZTBmYWU0ODQxZjJhNDI5ZGRkYTNiMWE0ZTJiL3RleHRyZWdpb246NWFkNmNlMGZhZTQ4NDFmMmE0MjlkZGRhM2IxYTRlMmJfOTc5_09ea9280-4801-4230-8783-ef354e056fd0" continuedAt="ie7b3e69167e343298e6ec48d20606d13" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><ix:continuation id="ie7b3e69167e343298e6ec48d20606d13"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).</span></ix:continuation></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_61"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">(10) <ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY1OA_d577e7b9-2860-4a98-aed4-9e98a5440844" continuedAt="i7bbbd54d16a748e1895b9e5188562ffd" escape="true">RECENT PRODUCT ADDITIONS</ix:nonNumeric></span></div><ix:continuation id="i7bbbd54d16a748e1895b9e5188562ffd" continuedAt="ie6885718c10a4236bd501db39271c40d"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Omeclamox-Pak</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak, including the product&#8217;s FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $<ix:nonFraction unitRef="usd" contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="cpix:PaymentsForAssetAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMTY0OTI2NzQ0MzM3Mw_e46ae5c4-6111-4659-8589-6b0994bc637c">2.3</ix:nonFraction> million during 2018 and ended Cumberland&#8217;s payments of royalties and manufacturing fees to GEL.  The Company has now assumed responsibility for the maintenance of the product&#8217;s FDA approval and for the oversight of the product&#8217;s manufacturing and packaging.</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Vibativ</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  While Cumberland is still evaluating the tax deductibility of the goodwill acquired in the acquisition, it expects those amounts to be deductible for tax purposes.    </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company paid an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie2424f11376147c9af04e9c63133c333_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMTY0OTI2NzQ0OTQxMA_cba99dd0-2906-4f97-ac34-ce921a05f1a9">20.0</ix:nonFraction> million with a $<ix:nonFraction unitRef="usd" contextRef="if1788a3b19df415c95d49112f2d872f8_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMTY0OTI2NzQ0OTQyMA_ee89461f-7201-48c2-a8e1-2b01584549e5">5.0</ix:nonFraction> million cash payment that was provided in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="ie2424f11376147c9af04e9c63133c333_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMTY0OTI2NzQ0OTUxNg_6a415c01-436f-4cf7-a09d-4c9de808d16c">20</ix:nonFraction>% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div></ix:continuation><div style="margin-top:8pt;"><span><br/></span></div><div style="margin-top:8pt;"><span><br/></span></div><div style="margin-top:8pt;"><span><br/></span></div><div style="margin-top:8pt;"><span><br/></span></div><div style="margin-top:8pt;"><span><br/></span></div><div style="margin-top:8pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:54pt;width:100%;"><div><span><br/></span></div></div><ix:continuation id="ie6885718c10a4236bd501db39271c40d" continuedAt="iaa3e38f445c847f49a6c66d74edf87d7"><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY1OQ_5a0fd7ba-a5d2-41a8-86f0-74e1e469af39" escape="true"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:75.631579%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.368421%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjQzZTcyN2NlZjRiNjQzZDM5OGYyYzM0N2QwYTZjOWM5L3RhYmxlcmFuZ2U6NDNlNzI3Y2VmNGI2NDNkMzk4ZjJjMzQ3ZDBhNmM5YzlfMi0xLTEtMS0zNzM3_1ecdd589-24e9-4d8c-97d9-54c169989f97">20,000,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during early 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjQzZTcyN2NlZjRiNjQzZDM5OGYyYzM0N2QwYTZjOWM5L3RhYmxlcmFuZ2U6NDNlNzI3Y2VmNGI2NDNkMzk4ZjJjMzQ3ZDBhNmM5YzlfMy0xLTEtMS0zNzM5_3ecbb306-3f20-4f66-8184-474659f11722">5,000,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="cpix:PaymentsForContingentConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjQzZTcyN2NlZjRiNjQzZDM5OGYyYzM0N2QwYTZjOWM5L3RhYmxlcmFuZ2U6NDNlNzI3Y2VmNGI2NDNkMzk4ZjJjMzQ3ZDBhNmM5YzlfNC0xLTEtMS0zNzQx_0fbf8878-a992-49ed-afc7-f91a91dddae9">9,182,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjQzZTcyN2NlZjRiNjQzZDM5OGYyYzM0N2QwYTZjOWM5L3RhYmxlcmFuZ2U6NDNlNzI3Y2VmNGI2NDNkMzk4ZjJjMzQ3ZDBhNmM5YzlfNS0xLTEtMS0zNzQz_54ffea73-6cd4-4302-ae4b-a3f24406d6ab">34,182,000</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements.  The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. </span></div><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY2MA_723ef2db-45bd-4d80-8b21-62fbf2cc4b20" escape="true"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:75.923977%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.076023%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at November 12, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifda35f731b37450782fc5c338eb2a4a8_I20181112" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfMS0xLTEtMS0zNzUz_81a5d605-a6ca-4afe-b130-788c2a830e6b">9,034,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i31c62ad8b23f4059be803e962f97748f_D20181113-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfMi0xLTEtMS0xMTM3_d9fc0602-5bd6-4dc5-9cb5-1aeedbc5b57b">40,000</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a9204f2031142428a1963d884e11716_D20181112-20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfMy0xLTEtMS0xMTM3_3536fcef-de16-4fa0-b2bb-dc077cbbf33e">508,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1f6ebe33ae304eed860a6b42f65a094e_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfNC0xLTEtMS0zNzU5_fea5d8a1-4283-403c-957f-8d75073398ca">9,502,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfNS0xLTEtMS0zNzYx_760baf03-15ae-4155-b6f1-73017c352aa0">148,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfNi0xLTEtMS0zNzYz_6b920b3b-be9c-46ec-9a3b-54c75f5e06d8">507,505</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfNy0xLTEtMS0zNzY1_60e84f8b-b2b0-440f-966a-5b3aab2d60ed">269,422</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfOC0xLTEtMS0zNzY3_1b4648f4-b9b6-4b44-a4a7-868fe420beea">199,432</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i370fbb3a09b94f55b491f2c991a0a56a_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfOS0xLTEtMS0zNzY5_1163e487-7435-479e-a603-2532f3a48009">9,072,505</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;"><span><br/></span></div><ix:nonNumeric contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY2MQ_6f2dc7ed-f377-48b5-b8c5-e5e29ef17696" escape="true"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:8pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:75.923977%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.076023%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfMC0xLTEtMS0zNzc1_1f92e4a8-f9a0-44c0-8cf9-f8594938da23">6,624,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfMS0xLTEtMS0zNzc3_04e9cddb-6f84-4eb3-a2e6-e5b3fda12040">3,970,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfMi0xLTEtMS0zNzc5_2b8cfb72-a02e-41d0-9516-ededeb569371">1,827,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfMy0xLTEtMS0zNzgx_0eb89c77-dfa4-4c41-93dc-0989984437ad">9,129,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfNC0xLTEtMS0zNzgz_5ac748e9-bf0f-4a98-9e59-9e30b071a09d">21,550,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfNi0xLTEtMS0zNzg1_e9bc3c3a-f10b-4e5c-beb9-16ee87371dfa">11,750,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfNy0xLTEtMS0zNzg3_fc152256-4f6f-46ff-8d04-251db26e1a00">882,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfOC0xLTEtMS0zNzg5_491c2cac-6349-4107-b812-ad423cf52bba">12,632,000</ix:nonFraction>&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfOS0xLTEtMS0zNzkx_833afe85-be9d-4841-ad85-c3cf21dbd64b">34,182,000</ix:nonFraction>&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"><ix:continuation id="iaa3e38f445c847f49a6c66d74edf87d7">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $<ix:nonFraction unitRef="usd" contextRef="if53f00afbc0c44d78276b75547af3d20_I20190331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY2Nw_721ee587-97d2-4700-9397-90af4c41a4e6">2.2</ix:nonFraction> million and the non-current portion is $<ix:nonFraction unitRef="usd" contextRef="if53f00afbc0c44d78276b75547af3d20_I20190331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY3Mw_a5092d89-b3d8-43a9-baaa-93549c8f9d6d">6.9</ix:nonFraction> million.</ix:continuation>   </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i_0_64"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Disclosure regarding forward-looking statements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that our actual results may differ significantly from the results we discuss in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital required to finance the business model; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; and management of our growth and integration of our acquisitions. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2018 (&#8220;2018 Annual Report on Form 10-K&#8221;).  We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div id="i_0_67"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">OVERVIEW</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Our Business</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription products. Our primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve the quality of care for patients and address unmet or poorly met medical needs.  We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to bring our medicines to patients in their countries.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our portfolio of FDA approved brands includes:</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Acetadote</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">acetylcysteine</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Caldolor</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">ibuprofen</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">) Injection, for the treatment of pain and fever;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Kristalose</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">lactulose</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Omeclamox</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">-Pak</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">, (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">omeprazole, clarithromycin, amoxicillin</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">) for the treatment of Helicobacter pylori (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">H. pylori</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">) infection and related duodenal ulcer disease;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Vaprisol</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">conivaptan</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Ethyol</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;"> (amifostine) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Injection, for the reduction of xerostomia (dry mouth) in patients undergoing post-operative radiation treatment for head and neck cancer and the renal toxicity associated with the administration of cisplatin in patients with advanced ovarian cancer;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;padding-left:14.5pt;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;">Totect</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">(dexrazoxane hydrochloride) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy in case of extravasation (drug leakage from the bloodstream into the tissues); and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Vibativ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">telavancin</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</span></div><div><span><br/></span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Our pipeline of product candidates includes:</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Hepatoren</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">ifetroban</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">) Injection, a Phase II candidate for the treatment of critically ill patients suffering from liver and kidney failure associated with hepatorenal syndrome ("HRS"); </span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Boxaban</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">(ifetroban) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Oral Capsules, a Phase II candidate for the treatment of asthma patients with aspirin-exacerbated respiratory disease ("AERD");</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Vasculan</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">(ifetroban) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Oral Capsules, a Phase II candidate for the treatment of patients with the systemic sclerosis ("SSc") form of autoimmune disease;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">Portaban</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">(ifetroban) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Injection and Oral Capsules, a Phase II candidate for the treatment of patients with portal hypertension associated with liver disease; and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">RediTrex</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;line-height:115%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:115%;">methotrexate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">) Injection, an approval submission candidate for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as severe disabling psoriasis.</span></div><div><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We have both product development and commercial capabilities and believe we can leverage our existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing, and finance. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion opportunities. Our product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions and manages our medical call center. Our quality and manufacturing professionals oversee the manufacture, release, and shipment of our products. Our marketing and sales professionals are responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Growth Strategy</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our growth strategy involves maximizing the potential of our existing brands, while continuing to build a portfolio of differentiated products. We currently market eight FDA approved products for sale in the United States. Through our international partners, we are working to bring our products to patients in their countries. We also look for opportunities to expand our products into additional patient populations through clinical trials, new indications, and select investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products, as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates to address unmet medical needs. Further, we are supplementing these activities with the early stage drug development activities at Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary. Specifically, we are seeking long term sustainable growth by executing the following plans:        </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Support and expand the use of our marketed products.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use.  We will continue to explore opportunities for label expansion to bring our products to new patient populations.  We have secured pediatric approval, expanding the labeling for both our Acetadote and Caldolor brands. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Selectively add complementary brands.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA approved drugs, as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure.  Our acquisition of Vibativ represents our largest product acquisition.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Progress clinical pipeline and incubate future product opportunities at CET.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> We believe it is important to build a pipeline of innovative new product opportunities. Our ifetroban Phase II development programs represent the implementation of this strategy. At CET, we are supplementing our acquisition and late-stage development activities with the early-stage drug development activities. CET partners with universities and other research organizations to develop promising, early-stage product candidates, which Cumberland has the opportunity to further develop and commercialize. We expanded our network of university collaborations with the addition of Louisiana State University and the Medical University of South Carolina.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Leverage our infrastructure through co-promotion partnerships.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance the opportunity for our brands. Our recent co-promotion partnerships with Poly Pharmaceuticals, Inc. and Foxland Pharmaceuticals, Inc allow us to expand current promotional support for Kristalose across the United States.     </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Build an international contribution to our business.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> We have established our own commercial capabilities, including two sales divisions to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We will continue to develop and expand our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Manage our operations with financial discipline.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> We continually work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. We remain in a strong financial position, with favorable gross margins, and a strong balance sheet. We use excess cash flow for our ongoing share repurchase program. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is www.cumberlandpharma.com. We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all material press releases and other reports as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission, (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;">www.sec.gov</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">RECENT DEVELOPMENTS</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Methotrexate</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On January 18, 2019, the Company received notification from the U.S Food and Drug Administration (&#8220;FDA&#8221;) that the new drug application (&#8220;NDA&#8221;) for our new line of methotrexate products is complete and acceptable for filing. Furthermore, the FDA has set September 2019 as the Prescription Drug User Fee (&#8220;PDUFA&#8221;) action date for an approval decision.  In November 2018, we submitted the NDA for approval from the FDA.  In conjunction with this submission, we remitted payment of $1.3 million to the FDA for the PDUFA Application Fee associated with this methotrexate product line application.  These products are designed to treat adult and pediatric patients with rheumatoid arthritis, as well as adults with psoriasis.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Caldolor</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On January 28, 2019, the FDA approved the application of our next generation Caldolor (ibuprofen) injection product. In February 2018, Cumberland completed and filed with the FDA an application for approval. The product features a new, patented formulation in a more convenient to use package.  In April 2018, the FDA determined that the application was complete and notified us of their acceptance for review. On August 2, 2018, we received a complete response from the FDA outlining additional quality and nonclinical data needed for the application&#8217;s approval.  On September 26, 2018, the Company submitted an amendment to our application containing additional quality and nonclinical data.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">New CET Collaboration Agreement</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At CET, we are working with a select group of academic research institutions located in the mid-south region of the U.S. These relationships enable CET to identify therapeutic compounds addressing poorly met medical needs and partner with university-based researchers to advance their scientific discoveries through pre-clinical development.  CET contributes product design and development support services to help our collaborators bridge the gap between discovery and clinical investigation. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In February 2019, CET and the technology transfer organization for the Medical University of South Carolina ("MUSC") entered into an agreement, adding to CET&#8217;s roster of academic collaborations which also includes Vanderbilt University, the University of Mississippi, Louisiana State University and the University of Tennessee Research Foundation. Under the agreement, CET will evaluate MUSC discoveries, license intellectual property rights to promising technologies, and partner with MUSC research scientists to advance product development toward commercialization. </span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">New Hospital Product Candidate Study</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol reducing agent for use in the hospital setting. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During 2017, we completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA and, as a result, in 2018 a Phase II study was initiated.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Strategic Review</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On March 29, 2019, we announced that we had initiated a strategic review of our brands, capabilities and international partners. This review followed our accelerated business development initiative, which delivered a series of transactions over the last thirty-six months. Because of that progress, we felt that it was prudent to take a fresh look at our portfolio, partners, and organization to ensure we have the proper focus and capabilities. As a result: </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">In China, the largest market for pharmaceutical products outside the U.S., we have reached an agreement with Hong Kong WinHealth Pharmaceuticals (&#8220;WinHealth&#8221;) to assume responsibility for our Acetadote and Caldolor brands in that market.  WinHealth will provide $2 million in milestone payments and up to an estimated $290 million in revenue contribution over a ten - year period for supplies following the registration of both products in China.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">Meanwhile, we have reached an agreement with Clinigen Group plc to return the U.S. rights to their Ethyol and Totect brands to them later this year in exchange for $5 million in financial consideration paid over a two year period.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">As a result, our hospital product efforts will now be focused on our three key acute care products. We are expanding our hospital sales division as well as our field-based medical science team in order to ensure coverage and support for the majority of our acute care business in the U.S.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:14.5pt;">We have also been meeting with our other key international partners and expect to announce addition</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">al improvements to that network over the remainder of the year.</span></div><div id="i_0_70"></div><div style="margin-top:8pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2018 Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Accounting Estimates and Judgments</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, fair value of marketable securities, inventories, provision for income taxes, share-based compensation, research and development expenses and intangible assets.</span></div><div id="i_0_73"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Three months ended March 31, 2019 compared to the three months ended March 31, 2018 </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents the unaudited interim statements of operations for the three months ended March 31, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:47.707602%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643275%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.228070%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.228070%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="18" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,902,747&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,587,605&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,315,142&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,999,736&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,527,961&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">471,775&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,120,505&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,670,511&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">449,994&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,267,601&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,874,939&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(607,338)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,670,056&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,330,281&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">339,775&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,021,645&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">636,135&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">385,510&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,079,543&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,039,827&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,039,716&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(176,796)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,452,222)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,275,426&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">115,861&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">82,494&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">33,367&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(60,911)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(18,302)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(42,609)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(121,846)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,388,030)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,266,184&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">81,428&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,159)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">85,587&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,418)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,392,189)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,351,771&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes net revenues by product for the periods presented: </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853801%;"><tr><td style="width:1.0%;"></td><td style="width:47.780381%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.251830%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.251830%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532064%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.251830%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">849,502&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,273,764&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(424,262)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">199,537&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">141,392&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">58,145&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,307,658&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,269,901&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">37,757&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">286,676&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,890&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">192,786&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,317,074&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,039,747&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">277,327&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,091,991&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,256,073&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">835,918&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Totect</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,896&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">412,774&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(331,878)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060,195&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060,195&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">709,218&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">100,064&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">609,154&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,902,747&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,587,605&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,315,142&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Net revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Net revenues for the three months ended March 31, 2019 were $11.9 million compared to $8.6 million for the three months ended March 31, 2018, representing an increase of $3.3 million, or 39%.  The increase is due primarily to net revenues associated with our newest product, Vibativ and as detailed in the table above, five of our eight marketed products experienced increases in net revenue during the quarter: Omeclamox-Pak, Kristalose, Vaprisol, Caldolor, and Ethyol.  This increase was partially offset by a decrease in Totect and Acetadote net revenue compared to the prior year period.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Vaprisol revenue experienced an increase of $0.2 million during the first quarter of 2019 when compared to the prior year period due to higher sales volumes.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Ethyol revenue increased by $0.8 million for the three months ended March 31, 2019 compared to three months ended March 31, 2018 as a result of higher sales volume.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Kristalose revenue increased by 1.2% during the first quarter of 2019 when compared to the prior year period.  The product's net revenue experienced an improvement in net pricing for the product. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Omeclamox-Pak revenue increased $0.1 million for the first quarter of 2019 compared to the first quarter of 2018 primarily due to higher sales volumes and improved net pricing during the period.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a $0.4 million decrease in revenue from our Acetadote brand when compared to the prior year period as a result of generic competition.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Caldolor revenue increased $0.3 million for the three months ended March 31, 2019 primarily due to increased domestic and international sales revenue in the first quarter of 2019 compared to the first quarter of 2018.  The product also experienced an improvement in net pricing.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Cost of products sold</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. </span><span style="background-color:#ffffff;color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Co</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">st of products sold for the first quarter of 2019 increased $0.5 million compared to the prior year period as a result of increased sales. Cost of products sold, as a percentage of net revenues, improved to 16.8% during the three months ended March 31, 2019 compared to 17.8% during the three months ended March 31, 2018.  This improvement in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, including the decrease in Totect sales, during the quarter compared to the prior year period. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Selling and marketing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. Selling and marketing expense for the first quarter of 2019 increased $0.4 million compared to the prior year period.  This increase is primarily attributable to higher royalties related to the increased product sales during the first quarter of 2019. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Research and development</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. Research and development costs for the first quarter of 2019 were $1.3 million, compared to $1.9 million for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, cost of the per patient study protocol and patients involved in the development of our new product candidates. The $0.6 million decrease was the result of a lower amount of variable spending required during the period compared to the prior year period for our ongoing clinical initiatives associated with our pipeline products.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">General and administrative</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">.  General and administrative expense for the first quarter of 2019 increased to $2.7 million from  $2.3 million during the first quarter of 2018 as a result of increases in advisory, legal and professional fees during the period.  A portion of these increased costs were related to our acquisition of Vibativ. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Amortization.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended March 31, 2019 and the three months ended March 31, 2018  totaled approximately $1.0 million and $0.6 million, respectively.  This increase was driven primarily by the amortization of the intangible assets acquired in the Vibativ transaction.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Income taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. Income tax benefit for the three months ended March 31, 2019 was $0.1&#160;million. As a percentage of income (loss) before income taxes, the income tax benefit was 66.8% for the three months ended March 31, 2019 compared to income tax expense of 0.2% for the three months ended March 31, 2018.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of March 31, 2019, we have approximately $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options in 2009 that have historically been used to significantly offset future income tax obligations.  Since they were generated during 2009, we have utilized these net operating loss carryforwards to pay minimal income taxes.  We will continue to pay minimal income taxes during 2019 and beyond, through the continued utilization of these net operating loss carryforwards, as we are able to achieve taxable income through our operations. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div id="i_0_79"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Working Capital</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Our primary sources of liquidity are cash flows provided by our operations, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows, existing working capital and our line of credit, including its recent expansion to $20 million, will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We invest a portion of our cash reserves in marketable securities including short-term cash investments, U.S. Treasury notes and bonds, corporate bonds, commercial paper and other marketable securities.&#160; At March 31, 2019 and December 31, 2018, we had approximately $9.7 million and $8.3 million, respectively, invested in marketable securities.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes our liquidity and working capital as of March 31, 2019 and December 31, 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:57.852941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.558824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.829412%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.558824%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">24,609,415&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,938,960&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,667,073&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,290,679&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">34,276,488&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">36,229,639&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Working capital (current assets less current liabilities)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29,967,524&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31,311,813&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolving line of credit availability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr></table></div><div style="margin-top:11pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes our net changes in cash and cash equivalents for the three months ended March 31, 2019 and March 31, 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:57.852941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.558824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.829412%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.558824%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:16pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:16pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(385,733)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">235,589&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,723,388)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,522,126)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,220,424)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,136,645&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,329,545)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,149,892)</span></td></tr></table></div><div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The net $3.3 million decrease in cash and cash equivalents for the three months ended March 31, 2019 was attributable to cash used in investing, financing and operating activities.  Cash used in operating activities of $0.4 million was primarily impacted by the increase in accounts receivable of  $2.1 million. The use of operating cash was partially offset by the add back of non-cash expenses of depreciation and amortization and share-based compensation expense totaling $1.4 million.  Cash used in investing activities included net cash invested in marketable securities of $1.3 million and additions to intangibles of $0.4 million.  Our financing activities reflected the $0.7 million in cash used to repurchase shares of our common stock. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The net $10.1 million decrease in cash and cash equivalents for the three months ended March&#160;31, 2018 was attributable to cash used in investing activities partially offset by cash provided by financing and operating activities.  Cash provided by operating activities of $0.2 million was primarily impacted by changes in our working capital which provided net cash of $1.6 million, including net collections of accounts receivable of $2.1 million and non-cash expenses of depreciation and amortization and share-based compensation expense totaling $1.0 million. The generation of operating cash was offset by a net loss for the period of $2.4 million. Cash used in investing activities included net cash investment in marketable securities of $10.9 million and additions to intangibles of $0.5 million.  Our financing activities included $2.2 million in net cash provided by borrowings under our line of credit offset by $1.0 million in cash used to repurchase shares of our common stock. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On May 10, 2019, we entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants.  On October 17, 2018, we entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  For a summary of the material terms of the Pinnacle Agreement, as amended, see Note 7 to the accompanying unaudited condensed consolidated financial statements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the Pinnacle Agreement, we were initially subject to one financial covenant, the maintenance of a Funded Debt Ratio. On August 14, 2018 we amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  As a result of the Third Amendment, we were in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2019 and expect to maintain compliance with this covenant in future periods. </span></div><div id="i_0_82"></div><div style="margin-top:12pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the three months ended March 31, 2019 and 2018, we did not engage in any off-balance sheet arrangements.</span></div><div id="i_0_85"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Interest Rate Risk</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts. Based on the $9.7 million in marketable securities outstanding at March 31, 2019, a 1% decrease in the fair value of the securities would result in a reduction in pretax net income (loss) of $0.1 million.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Based on current interest rates, we do not believe we are exposed to significant downside risk related to change in interest on our investment accounts.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 5.2% at March 31, 2019). As of March 31, 2019, we had $20 million in borrowings outstanding under our revolving credit facility. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Exchange Rate Risk</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the three months ended March 31, 2019 and 2018.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="i_0_88"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4. Controls and Procedures</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15-15(e) of the Exchange Act, as of March 31, 2019. Based on that evaluation, our CEO and CFO concluded that, as of March 31, 2019, our disclosure controls and procedures are considered effective to ensure that the information required to be disclosed by the Company in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's CEO and CFO, as appropriate, to allow for timely decisions regarding required disclosure.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the three months ended March 31, 2019, there has not been any change in our internal control over financial reporting that has materially affected, or is likely to materially affect, our internal control over financial reporting. </span></div><div id="i_0_91"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PART II &#8211; OTHER INFORMATION</span></div><div id="i_0_94"></div><div style="margin-top:14pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1. Legal Proceedings</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">None.</span></div><div id="i_0_97"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1A. Risk Factors</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">There have been no material changes to the information regarding risk factors that appears in the 2018 Annual Report on Form 10-K under the section titled "Risk Factors." </span></div><div id="i_0_100"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Purchases of Equity Securities</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the activity, by month, during the three months ended March 31, 2019:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.654971%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.105263%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530994%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.444444%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Total</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Number&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Shares (or</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Purchased (1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Price&#160;Paid</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">per&#160;Share</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">(or Unit)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Total&#160;Number&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Shares (or Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Purchased&#160;as&#160;Part</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">of Publicly</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Announced Plans</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">or Programs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Maximum&#160;Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">(or Approximate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Dollar Value) of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Shares&#160;(or&#160;Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">that May Yet Be</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">Purchased&#160;Under</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">the Plans or</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:700;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Programs </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">January</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,018&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6.00&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,018&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,247,180&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">February</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,436&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.70&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,436&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,929,124&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">88,012&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5.76&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">88,012&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,422,065&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">121,466&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">121,466&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">(1) Of this amount, 67,391 shares were repurchased directly through private purchases at the then-current fair market value of common stock.</span></div><div id="i_0_103"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;5. Other Information</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following information is included for the purpose of providing the disclosures required under "Item 1.01 - Entry into a Material Definitive Agreement" of Form 8-K.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified the definitions and terms of the existing financial covenants.  </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio.  Note that the description is qualified by its entirety by the amendment which is incorporated by reference as Exhibit 10.2.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:12pt;"><span><br/></span></div><div id="i_0_106"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;6. Exhibits</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415205%;"><tr><td style="width:1.0%;"></td><td style="width:8.000000%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.970588%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:84.029412%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit101.htm">First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement, dated as of October 17, 2018, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on October 19, 2018.</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit102.htm">Second</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit102.htm"> Amendment to Revolving Credit Note and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit102.htm">T</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit102.htm">hird</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit102.htm"> Amendment to Revolving Credit Loan Agreement, dated as of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit102.htm">May 10</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit102.htm">,</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit102.htm"> 2019</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit102.htm"> by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit102.htm">.</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000FF;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="cpixq12019-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith.</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Furnished herewith.</span></td></tr></table></div><div><span><br/></span></div><div id="i_0_109"></div><div style="text-align:center;-sec-extract:summary;"></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"></hr><div style="height:45pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099415%;"><tr><td style="width:1.0%;"></td><td style="width:7.388972%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.080477%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.184501%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.769001%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.307004%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.172876%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.184501%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:34.512668%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumberland Pharmaceuticals Inc.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Michael Bonner</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">25</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>cpixq12019-exhibit101.htm
<DESCRIPTION>EXHIBIT-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:18pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;text-decoration: underline;">FIRST AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">THIS FIRST AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#8221;) is entered into as of August 14, 2018, by and between CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Borrower</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#8221;), and PINNACLE BANK, a Tennessee banking corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Lender</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#8221;).</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">RECITALS&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">A.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;padding-left:25.31pt;">The Borrower and the Lender entered into that certain Revolving Credit Loan Agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Loan Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#8221;) dated as of July&#160;31, 2017. Capitalized terms not otherwise defined therein have the same meaning as set forth in the Loan Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">B.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">The Borrower and the Lender desire to amend the Loan Agreement as provided herein.</font></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;text-decoration: underline;">Section 6.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"> of the Loan Agreement is hereby amended and restated as follows&#58; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">6.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;text-decoration: underline;">Funded Debt Ratio and Tangible Capital Ratio</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">. Permit both (i) the Funded Debt Ratio of the Borrower as calculated for the Borrower and its Subsidiaries at the end of each fiscal quarter on a rolling four quarter basis to exceed 2.50 to 1.00, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;text-decoration: underline;">and</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"> (ii) the Funded Debt to Tangible Capital Ratio of the Borrower as calculated for the Borrower and its Subsidiaries to exceed forty percent (40%).  For clarification, if the Borrower maintains compliance with either of the above required calculations, then the Borrower shall be in compliance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;text-decoration: underline;">Section 6.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"> for the applicable period.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">The following new definitions are hereby added to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;text-decoration: underline;">Section 9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"> of the Loan Agreement&#58; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Funded Debt to Tangible Capital Ratio</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#8221; means the ratio, expressed as a percentage, of Funded Debt divided by Tangible Capital. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Tangible Capital</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#8221; means the amount equal to total shareholders&#8217; equity, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-style:italic;line-height:120%;">plus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"> Funded Debt, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-style:italic;line-height:120%;">less</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"> the value of intangible assets, all of the foregoing to be determined in accordance with the financial statements and reports provided to Lender, which are to be prepared in accordance with GAAP. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">The Loan Agreement is not amended in any other respect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">The Borrower reaffirms the terms and provisions of the Loan Agreement, along with the other Loan Documents, and the Borrower agrees that such terms and provisions are valid and binding, enforceable in accordance with its terms and provisions, subject to no defense, counterclaim, or objection.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#91;signatures commence on following page&#93;</font></div><div><font><br></font></div><div id="i_0_4"></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">ENTERED INTO as of the date first written above.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:53.846154%;"><tr><td style="width:1.0%;"></td><td style="width:12.285714%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.714286%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:55pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:100%;text-decoration: underline;">BORROWER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:100%;">&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:100%;">CUMBERLAND PHARMACEUTICALS INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:100%;">By&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;">&#47;s&#47; A.J. Kazimi</font></div></td></tr></table></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">A.J. Kazimi, </font></div><div style="padding-left:252pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">Chairman and Chief Executive Officer</font></div><div style="padding-left:216pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#160;</font></div><div style="padding-left:216pt;text-align:justify;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:53.846154%;"><tr><td style="width:1.0%;"></td><td style="width:12.285714%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.714286%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:55pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:100%;text-decoration: underline;">LENDER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:100%;">&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:100%;">PINNACLE BANK</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:100%;">By&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;">&#47;s&#47; Tim Bewley</font></div></td></tr></table></div><div style="padding-left:252pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">Tim Bewley,</font></div><div style="text-indent:126pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">Senior Vice President</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;">&#91;Signature Page to First Amendment to Revolving Credit Loan Agreement&#93;</font></div><div style="text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>cpixq12019-exhibit102.htm
<DESCRIPTION>EXHIBIT-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;text-decoration: underline;">SECOND AMENDMENT TO REVOLVING CREDIT NOTE AND</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;text-decoration: underline;">THIRD AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT </font></div><div style="text-align:center;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">THIS SECOND AMENDMENT TO REVOLVING CREDIT NOTE AND THIRD AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8221;) is entered into as of May</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"> 10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">, 2019, by and between CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Borrower</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), and PINNACLE BANK, a Tennessee banking corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Lender</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">RECITALS&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">A.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.31pt;">Borrower issued to the order of Lender that certain $12,000,000.00 Revolving Credit Note dated July 31, 2017, as amended by that certain First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement dated October 17, 2018, whereby, among other things, the principal amount was increased to $20,000,000.00 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Note</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8221;).  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">B.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">Borrower and the Lender entered into that certain Revolving Credit Loan Agreement dated as of July&#160;31, 2017, as amended by that certain First Amendment to Revolving Credit Loan Agreement dated August 14, 2018, as amended by that certain First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement dated October 17, 2018 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Loan Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8221;). Capitalized terms not otherwise defined therein have the same meaning as set forth in the Loan Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">C.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">Borrower and the Lender desire to amend the Note and Loan Agreement as provided herein.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">The fifth paragraph of the Note, regarding repayment, is hereby amended and restated as follows&#58; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">This Note shall be payable as follows&#58; (a) commencing on May 1, 2019 and continuing on the 1</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:7.15pt;font-weight:400;line-height:120%;vertical-align:top;">st</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> day of each consecutive month thereafter through and including July&#160;1, 2021, Borrower shall pay to the Lender all accrued and unpaid interest&#59; and (b) this Note shall mature on July 31, 2021 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Maturity Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8221;), at which time Borrower shall pay to the Lender an amount equal to all outstanding principal, plus all accrued and unpaid interest and any other outstanding fees and expenses due and payable under the Loan Documents. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> of the Loan Agreement is hereby amended and restated as follows&#58; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">6.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Funded Debt Ratio and Tangible Capital Ratio</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">. Permit both (i) the Funded Debt Ratio of Borrower as calculated for Borrower and its Subsidiaries at the end of each fiscal quarter on a rolling four quarter basis to exceed 2.50 to 1.00, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">and</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> (ii) the Funded Debt to Tangible Capital Ratio of Borrower as calculated for Borrower and its Subsidiaries to exceed fifty percent (50.0%).  For clarification, if Borrower maintains compliance with either of the above required calculations, then Borrower shall be in compliance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> for the applicable period.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 7.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> of the Loan Agreement is hereby amended and restated as follows&#58; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:8pt;font-weight:400;line-height:120%;">105639-301010</font></div><div style="margin-top:6pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">7.6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Liquidity Cure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">. For a fifteen (15) day period after the occurrence of an Event of Default under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 6.7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> hereof (such Event of Default being deemed to have occurred on the date on which the Compliance Certificate for such period is required to be delivered pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5.1(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> hereof), Borrower may cure such Event of Default by depositing and maintaining on account with Lender a cash amount equal to all outstanding Indebtedness hereunder. Borrower may only exercise the liquidity cure described herein twice during the period beginning May 1, 2019 and ending July 31, 2021. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">The following definitions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> of the Loan Agreement are hereby amended and restated as follows&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">EBITDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8221; means (a) Net Income Attributable to Borrowers Shareholders, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;">plus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> (b) to the extent deducted in determining Net Income Attributable to Borrowers Shareholders, and without duplication, the sum of (i) Interest Expense, (ii) income tax expense, (iii) depreciation expense, (iv) amortization expense, (v) Non-Cash Compensation Expense, and (vi) cost of products sold associated with the Vibativ Acquisition provided that (x) the inventory was acquired on the acquisition date, and (y) the aggregate amount of such cost of products sold shall not exceed 30% of EBITDA in any measurement period, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;">minus or plus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">, as applicable (c) gains or losses resulting from adjustments to the fair value of the contingent consideration liability, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;">minus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> (d) contingent consideration liability payments, as determined at each fiscal quarter end on a rolling four (4) quarter basis.</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Maturity Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8221; mean July 31, 2021.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">The following definition of &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Vibativ Acquisition</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8221; is hereby added to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 9.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;"> of the Loan Agreement&#58; </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:120%;">Vibativ Acquisition</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#8221; means Borrower&#8217;s purchase of certain assets related to the manufacture, marketing and sale of the proprietary antibiotic, Vibativ from Theravance Biopharma Ireland Limited and Theravance Biopharma US, Inc. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">As a condition to the effectiveness of this Amendment, Borrower agrees to pay all fees and expenses set forth in the Closing Statement executed in connection with this Amendment. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">The Note and Loan Agreement are not amended in any other respect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">Borrower reaffirms the terms and provisions of the Note and Loan Agreement, as amended hereby, along with the other Loan Documents, and Borrower agrees that such terms and provisions are valid and binding, enforceable in accordance with its terms and provisions, subject to no defense, counterclaim, or objection.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#91;signatures commence on following page&#93;</font></div><div><font><br></font></div><div id="i_0_4"></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:6pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">ENTERED INTO as of the date first written above.</font></div><div style="padding-left:216pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:53.846154%;"><tr><td style="width:1.0%;"></td><td style="width:12.285714%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.714286%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:56pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:100%;text-decoration: underline;">BORROWER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:100%;">&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:100%;">CUMBERLAND PHARMACEUTICALS INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:100%;">A.J. Kazimi, Chief Executive Officer</font></div><div><font><br></font></div></td></tr></table></div><div style="padding-left:252pt;"><font><br></font></div><div style="padding-left:216pt;text-align:justify;"><font><br></font></div><div style="padding-left:216pt;text-align:justify;"><font><br></font></div><div style="padding-left:216pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:53.846154%;"><tr><td style="width:1.0%;"></td><td style="width:12.285714%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.714286%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;height:56pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:100%;text-decoration: underline;">LENDER</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:700;line-height:100%;">&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:100%;">PINNACLE BANK</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">&#160;</font></div><div><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Tim Bewley</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Tim Bewley, Senior Vice Presiden</font></td></tr></table></div><div style="padding-left:252pt;text-align:justify;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">&#91;Signature Page to Second Amendment to Revolving Credit Loan Note and</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:400;line-height:120%;">Third Amendment to Revolving Credit Loan Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>cpixq12019-exhibit311.htm
<DESCRIPTION>EXHIBIT-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I, A.J. Kazimi, certify that&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:30pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:49.395007%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.698972%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.443172%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.262849%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2019</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>cpixq12019-exhibit312.htm
<DESCRIPTION>EXHIBIT-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">I, Michael Bonner, certify that&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:30pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"></td><td style="width:49.835536%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.258443%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.443172%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.262849%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2019</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>cpixq12019-exhibit321.htm
<DESCRIPTION>EXHIBIT-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2019 Workiva -->
<title>Document</title></head><body><div id="i_0_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:700;line-height:120%;">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">March 31, 2019</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and Michael Bonner, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"></td><td style="width:3.865103%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.134897%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:400;line-height:100%;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;">&#160;</font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:38.888889%;"><tr><td style="width:1.0%;"></td><td style="width:98.000000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2019</font></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2019</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:9pt;line-height:120%;">&#160;</font></div><div style="text-align:right;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;width:100%;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cpix-20190331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:031f68bb-a3b6-4ac5-91de-52b2b78765c7,g:bb439603-ef46-4aac-8075-326b08cd6501-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:cpix="http://www.cumberlandpharma.com/20190331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:link="http://www.xbrl.org/2003/linkbase" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20190331">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
  <xs:element id="cpix_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_PaymentsForAssetAcquisitions" abstract="false" name="PaymentsForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EthyolMember" abstract="true" name="EthyolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SecondAmendmentMember" abstract="true" name="SecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_LeaseAsset" abstract="false" name="LeaseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" abstract="true" name="UsTreasuryNotesAndBondsSecuritiesMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_PaymentsForContingentConsideration" abstract="false" name="PaymentsForContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TotectMember" abstract="true" name="TotectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20190331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20190331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20190331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20190331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.cumberlandpharma.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities">
        <link:definition>2104102 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails">
        <link:definition>2406402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2107103 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2308302 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2409403 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2111104 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2312303 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2413405 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2114105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2315304 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2416406 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2118106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2319305 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2420408 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2421409 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>2123107 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2126108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2427413 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2128109 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentProductAdditions" roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditions">
        <link:definition>2129110 - Disclosure - Recent Product Additions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentProductAdditionsTables" roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsTables">
        <link:definition>2330306 - Disclosure - Recent Product Additions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentProductAdditionsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails">
        <link:definition>2431414 - Disclosure - Recent Product Additions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails">
        <link:definition>2432415 - Disclosure - Recent Product Additions - Schedule of Initial Payments and Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentProductAdditionsChangeinConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails">
        <link:definition>2433416 - Disclosure - Recent Product Additions - Change in Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails" roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails">
        <link:definition>2434417 - Disclosure - Recent Product Additions - Schedule of Preliminary Purchase Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cpix-20190331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:031f68bb-a3b6-4ac5-91de-52b2b78765c7,g:bb439603-ef46-4aac-8075-326b08cd6501-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="cpix-20190331.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e5f0057d-2968-4300-b8a2-53cbeee4fe9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_df3f6ea7-6a03-4d72-aa06-41a54e63221b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5f0057d-2968-4300-b8a2-53cbeee4fe9f" xlink:to="loc_us-gaap_LiabilitiesCurrent_df3f6ea7-6a03-4d72-aa06-41a54e63221b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_f7a8c7da-a7da-4a5a-95e4-ce39826e3dac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5f0057d-2968-4300-b8a2-53cbeee4fe9f" xlink:to="loc_us-gaap_LongTermLineOfCredit_f7a8c7da-a7da-4a5a-95e4-ce39826e3dac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_cf1eaabd-3604-4439-9263-09e25f875a25" xlink:href="cpix-20190331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5f0057d-2968-4300-b8a2-53cbeee4fe9f" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_cf1eaabd-3604-4439-9263-09e25f875a25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d09d202-a62e-4cca-a6a1-edb5da8b8257" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cf829f48-18d8-4702-8fb9-783b135134af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d09d202-a62e-4cca-a6a1-edb5da8b8257" xlink:to="loc_us-gaap_Liabilities_cf829f48-18d8-4702-8fb9-783b135134af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8cf18793-2b45-4da4-b39d-df0defae823f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d09d202-a62e-4cca-a6a1-edb5da8b8257" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8cf18793-2b45-4da4-b39d-df0defae823f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ac4b301d-3cb2-4fb5-b61c-e165b1acc2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d09d202-a62e-4cca-a6a1-edb5da8b8257" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ac4b301d-3cb2-4fb5-b61c-e165b1acc2e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cefe6-159e-4dc2-ba7c-f4f0c9e80bac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f7179b09-3cb2-4ee7-a1bf-385db31fbc24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cefe6-159e-4dc2-ba7c-f4f0c9e80bac" xlink:to="loc_us-gaap_AccountsPayableCurrent_f7179b09-3cb2-4ee7-a1bf-385db31fbc24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_63e4925e-321f-40e4-b459-fbba8f5cea78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cefe6-159e-4dc2-ba7c-f4f0c9e80bac" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_63e4925e-321f-40e4-b459-fbba8f5cea78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_66d8d1b5-60e0-41b3-b8ad-a0f50fd33687" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e2d2664f-629d-41f5-b352-462330c8f0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66d8d1b5-60e0-41b3-b8ad-a0f50fd33687" xlink:to="loc_us-gaap_AssetsCurrent_e2d2664f-629d-41f5-b352-462330c8f0c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4426680f-4191-47f7-9fa1-dfe6066cc19f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66d8d1b5-60e0-41b3-b8ad-a0f50fd33687" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4426680f-4191-47f7-9fa1-dfe6066cc19f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66be4591-507b-4b09-87a2-52bda3e0262b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66d8d1b5-60e0-41b3-b8ad-a0f50fd33687" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66be4591-507b-4b09-87a2-52bda3e0262b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d34e89a4-0736-4b2d-9ceb-d1dd29b31423" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66d8d1b5-60e0-41b3-b8ad-a0f50fd33687" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d34e89a4-0736-4b2d-9ceb-d1dd29b31423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_34591d12-7eda-492e-b1ea-e46480524762" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66d8d1b5-60e0-41b3-b8ad-a0f50fd33687" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_34591d12-7eda-492e-b1ea-e46480524762" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_25005229-8a37-480a-a729-41573a247ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66d8d1b5-60e0-41b3-b8ad-a0f50fd33687" xlink:to="loc_us-gaap_InventoryNoncurrent_25005229-8a37-480a-a729-41573a247ca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1ef1a2ba-956f-430d-972e-427b28a2c324" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_66d8d1b5-60e0-41b3-b8ad-a0f50fd33687" xlink:to="loc_us-gaap_Goodwill_1ef1a2ba-956f-430d-972e-427b28a2c324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6432f945-bf2d-4ae6-b091-eaa14d666e19" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d7d0b397-623d-4cb4-90f4-026727a7dc81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6432f945-bf2d-4ae6-b091-eaa14d666e19" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d7d0b397-623d-4cb4-90f4-026727a7dc81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_fa373573-a9ac-4f12-8c84-52aa0e6bec8b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6432f945-bf2d-4ae6-b091-eaa14d666e19" xlink:to="loc_us-gaap_MarketableSecurities_fa373573-a9ac-4f12-8c84-52aa0e6bec8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f026bbb4-38c9-47fd-8664-d12638be01d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6432f945-bf2d-4ae6-b091-eaa14d666e19" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f026bbb4-38c9-47fd-8664-d12638be01d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5add64a5-b73b-453e-b67e-43888e16575b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6432f945-bf2d-4ae6-b091-eaa14d666e19" xlink:to="loc_us-gaap_InventoryNet_5add64a5-b73b-453e-b67e-43888e16575b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_82556468-d977-49eb-8c1f-1965892982e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6432f945-bf2d-4ae6-b091-eaa14d666e19" xlink:to="loc_us-gaap_OtherAssetsCurrent_82556468-d977-49eb-8c1f-1965892982e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a4051ec0-311b-458c-b0cc-39fe67700728" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_29d413d7-241a-4d04-941f-12cfb38502ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4051ec0-311b-458c-b0cc-39fe67700728" xlink:to="loc_us-gaap_CommonStockValue_29d413d7-241a-4d04-941f-12cfb38502ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_86e5f451-0706-47da-89ff-35e650efc75c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a4051ec0-311b-458c-b0cc-39fe67700728" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_86e5f451-0706-47da-89ff-35e650efc75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_775f0e9e-9524-45ef-af20-f61de3d4d544" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_02a46aaa-c2f4-41c0-9d24-d858131d623e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_775f0e9e-9524-45ef-af20-f61de3d4d544" xlink:to="loc_us-gaap_StockholdersEquity_02a46aaa-c2f4-41c0-9d24-d858131d623e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_129cc2a4-157a-4ad1-837d-7a669e951ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_775f0e9e-9524-45ef-af20-f61de3d4d544" xlink:to="loc_us-gaap_MinorityInterest_129cc2a4-157a-4ad1-837d-7a669e951ea6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_acd6d7d6-9b10-4ccf-8883-a6ae564f0d87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7db08a5c-ce69-4dc9-af10-9ad0a3eaa23e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_acd6d7d6-9b10-4ccf-8883-a6ae564f0d87" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7db08a5c-ce69-4dc9-af10-9ad0a3eaa23e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_584b45d1-781a-436b-9c7e-3b8c64144946" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_acd6d7d6-9b10-4ccf-8883-a6ae564f0d87" xlink:to="loc_us-gaap_SellingAndMarketingExpense_584b45d1-781a-436b-9c7e-3b8c64144946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6dae29cb-f1e4-44ae-a2e1-65957e2405d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_acd6d7d6-9b10-4ccf-8883-a6ae564f0d87" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6dae29cb-f1e4-44ae-a2e1-65957e2405d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_95033005-d813-48ec-8882-485794a7ad32" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_acd6d7d6-9b10-4ccf-8883-a6ae564f0d87" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_95033005-d813-48ec-8882-485794a7ad32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_051cad6a-11f8-4c79-a0f7-73d691ae8913" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_acd6d7d6-9b10-4ccf-8883-a6ae564f0d87" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_051cad6a-11f8-4c79-a0f7-73d691ae8913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7dc29101-acf4-41a7-b951-d54f837de2eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_01c0f148-d69c-4267-8946-12a822771643" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7dc29101-acf4-41a7-b951-d54f837de2eb" xlink:to="loc_us-gaap_ProfitLoss_01c0f148-d69c-4267-8946-12a822771643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_28bbf6cd-8136-4bd7-a3a5-a241e90fdc72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7dc29101-acf4-41a7-b951-d54f837de2eb" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_28bbf6cd-8136-4bd7-a3a5-a241e90fdc72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8e124f46-4335-4d7f-99ea-f57c9e669e15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_abe4c202-fa0c-44bf-936e-3ad864c740f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8e124f46-4335-4d7f-99ea-f57c9e669e15" xlink:to="loc_us-gaap_OperatingIncomeLoss_abe4c202-fa0c-44bf-936e-3ad864c740f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_20b151aa-3fd9-42e2-b8e2-8bee8e55fe27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8e124f46-4335-4d7f-99ea-f57c9e669e15" xlink:to="loc_us-gaap_InvestmentIncomeInterest_20b151aa-3fd9-42e2-b8e2-8bee8e55fe27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_065b6724-1345-436e-910b-9cb9b966fcb2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8e124f46-4335-4d7f-99ea-f57c9e669e15" xlink:to="loc_us-gaap_InterestExpense_065b6724-1345-436e-910b-9cb9b966fcb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4d55b112-ca2c-465a-8711-8639bab6602a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aace52ea-2e58-45b0-84bc-17fe5b903024" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_4d55b112-ca2c-465a-8711-8639bab6602a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aace52ea-2e58-45b0-84bc-17fe5b903024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_adf78673-3790-43b7-b2cd-42e02bac361f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_4d55b112-ca2c-465a-8711-8639bab6602a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_adf78673-3790-43b7-b2cd-42e02bac361f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d48298b8-2afe-4c55-8668-2d14f416d00e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_968d62d9-b747-429f-b02f-843913c54bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d48298b8-2afe-4c55-8668-2d14f416d00e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_968d62d9-b747-429f-b02f-843913c54bd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f752cb01-8949-4ba7-821f-affe195e07e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d48298b8-2afe-4c55-8668-2d14f416d00e" xlink:to="loc_us-gaap_CostsAndExpenses_f752cb01-8949-4ba7-821f-affe195e07e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b35706e7-9324-4be9-aa24-92287eac5a87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd7b5d7f-4a6a-4ed8-8aa2-361b3ea6631a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b35706e7-9324-4be9-aa24-92287eac5a87" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd7b5d7f-4a6a-4ed8-8aa2-361b3ea6631a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f0cc3e5c-5f15-4585-bb69-180c62499d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b35706e7-9324-4be9-aa24-92287eac5a87" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_f0cc3e5c-5f15-4585-bb69-180c62499d2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98c2ded4-bfeb-4adc-ab04-c5559ff06664" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7f7909dd-dafa-41c9-9192-610dab273169" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98c2ded4-bfeb-4adc-ab04-c5559ff06664" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7f7909dd-dafa-41c9-9192-610dab273169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_06f403c5-d3d7-43f7-afb9-342cf7d6d0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98c2ded4-bfeb-4adc-ab04-c5559ff06664" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_06f403c5-d3d7-43f7-afb9-342cf7d6d0ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6f6d843a-8fb2-43b7-96ce-dd190d1ba20e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98c2ded4-bfeb-4adc-ab04-c5559ff06664" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6f6d843a-8fb2-43b7-96ce-dd190d1ba20e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_9b1e77de-1b4d-405c-9bd5-454fb5250c37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98c2ded4-bfeb-4adc-ab04-c5559ff06664" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_9b1e77de-1b4d-405c-9bd5-454fb5250c37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e0b3c981-ae9c-4bef-abc2-27ad6fead6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_ProfitLoss_e0b3c981-ae9c-4bef-abc2-27ad6fead6ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_701586b2-cd73-4c44-ba7f-685d598454f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_701586b2-cd73-4c44-ba7f-685d598454f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5846f74f-3461-4179-9fdf-1d518f27e3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5846f74f-3461-4179-9fdf-1d518f27e3d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0d75482d-aa03-4513-91bb-076164841df3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_ShareBasedCompensation_0d75482d-aa03-4513-91bb-076164841df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_fbafcfb3-70ad-4f02-a5c3-c27a7c7c0ccd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_fbafcfb3-70ad-4f02-a5c3-c27a7c7c0ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_e162f047-103c-4953-bdd2-7420dbd65e79" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_e162f047-103c-4953-bdd2-7420dbd65e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_1bbc740b-10fa-46b1-9905-4595eab62cee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_1bbc740b-10fa-46b1-9905-4595eab62cee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d5b6c32e-c457-440b-8709-5400d7dff540" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d5b6c32e-c457-440b-8709-5400d7dff540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5caf077b-59e1-452e-8929-58c428c1edd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5caf077b-59e1-452e-8929-58c428c1edd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c3c63e87-b93c-4491-9d50-4d627b4bb67d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c3c63e87-b93c-4491-9d50-4d627b4bb67d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_116807f3-dcd2-4c25-9ae5-cdc2ca164758" xlink:href="cpix-20190331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_116807f3-dcd2-4c25-9ae5-cdc2ca164758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_567c0d89-58c7-4954-8b63-64f5a1b1732f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8a9eaa-346d-469c-ab67-6ada49e2fe57" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_567c0d89-58c7-4954-8b63-64f5a1b1732f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_78dbb4f6-a6ae-48ad-a7ed-aa0aeb311e73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a059a8b7-f5c1-459c-b078-9f256fa32638" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_78dbb4f6-a6ae-48ad-a7ed-aa0aeb311e73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a059a8b7-f5c1-459c-b078-9f256fa32638" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a3ce7e48-043e-48a7-a7ec-a99c92b70b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_78dbb4f6-a6ae-48ad-a7ed-aa0aeb311e73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a3ce7e48-043e-48a7-a7ec-a99c92b70b4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_afba18f4-e5a4-45a9-af23-b7b20759f7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_78dbb4f6-a6ae-48ad-a7ed-aa0aeb311e73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_afba18f4-e5a4-45a9-af23-b7b20759f7cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f2ffebc-1755-457a-b0dc-0e9997610d44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_b541ede2-8fee-4fdd-8601-1c93c70369ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f2ffebc-1755-457a-b0dc-0e9997610d44" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_b541ede2-8fee-4fdd-8601-1c93c70369ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_c69f613a-1514-49f9-b43d-6ccd66fe65fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f2ffebc-1755-457a-b0dc-0e9997610d44" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_c69f613a-1514-49f9-b43d-6ccd66fe65fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_31a3c54d-d30f-4524-bcca-25cc9e667cce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f2ffebc-1755-457a-b0dc-0e9997610d44" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_31a3c54d-d30f-4524-bcca-25cc9e667cce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_dc468741-6623-46f7-8919-0feb34777c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f2ffebc-1755-457a-b0dc-0e9997610d44" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_dc468741-6623-46f7-8919-0feb34777c6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4fe668f5-b2b5-4ac1-8f4d-f602ffa2564f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f2ffebc-1755-457a-b0dc-0e9997610d44" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4fe668f5-b2b5-4ac1-8f4d-f602ffa2564f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ea97b195-fe92-43d7-878d-e035de0d65a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f2ffebc-1755-457a-b0dc-0e9997610d44" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ea97b195-fe92-43d7-878d-e035de0d65a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20190331.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20190331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="simple" xlink:href="cpix-20190331.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20190331.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_191012b9-1e4a-45b0-b0c0-7629bcca4fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fcac942e-8ca0-46f1-a644-c4357b8f7832" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_191012b9-1e4a-45b0-b0c0-7629bcca4fbe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fcac942e-8ca0-46f1-a644-c4357b8f7832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fcbba5b2-1d7e-450c-8297-381f019aaa8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_191012b9-1e4a-45b0-b0c0-7629bcca4fbe" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fcbba5b2-1d7e-450c-8297-381f019aaa8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20190331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20190331.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20190331.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_7856609d-e614-4cb3-9314-0e065db4d0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d264eb1d-60bc-494b-a687-ccfc61057a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7856609d-e614-4cb3-9314-0e065db4d0a6" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d264eb1d-60bc-494b-a687-ccfc61057a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_2505e556-3557-4e69-9622-898b68258e02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7856609d-e614-4cb3-9314-0e065db4d0a6" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_2505e556-3557-4e69-9622-898b68258e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ccd9bbb3-1af8-4a2d-acaf-2e3908946b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7856609d-e614-4cb3-9314-0e065db4d0a6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ccd9bbb3-1af8-4a2d-acaf-2e3908946b3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_08735b64-86f5-419d-9c7c-3252c576d912" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_f1018152-5816-49b9-adf1-98909c0446b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_08735b64-86f5-419d-9c7c-3252c576d912" xlink:to="loc_us-gaap_InventoryNoncurrent_f1018152-5816-49b9-adf1-98909c0446b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_347f1ae4-c254-4db1-93dc-17cc9bf812c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_08735b64-86f5-419d-9c7c-3252c576d912" xlink:to="loc_us-gaap_InventoryGross_347f1ae4-c254-4db1-93dc-17cc9bf812c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20190331.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a1437224-52af-46c5-aa64-99457e2072f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_47f5608c-99af-45bf-bb30-d1782b32f804" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a1437224-52af-46c5-aa64-99457e2072f9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_47f5608c-99af-45bf-bb30-d1782b32f804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_6f5bd9af-4d2a-4996-b3bd-47c03463925d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a1437224-52af-46c5-aa64-99457e2072f9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_6f5bd9af-4d2a-4996-b3bd-47c03463925d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_4d66beec-689b-425f-9596-03bd3ebcf344" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a1437224-52af-46c5-aa64-99457e2072f9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_4d66beec-689b-425f-9596-03bd3ebcf344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8b0dfcff-0b1a-41a3-93d2-a4806df78713" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a1437224-52af-46c5-aa64-99457e2072f9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_8b0dfcff-0b1a-41a3-93d2-a4806df78713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d988cb40-ac7d-41ae-92bb-2b5296ff448a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a1437224-52af-46c5-aa64-99457e2072f9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d988cb40-ac7d-41ae-92bb-2b5296ff448a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09106e23-d3bd-431b-90ad-e9ac3992ff6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_a1437224-52af-46c5-aa64-99457e2072f9" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09106e23-d3bd-431b-90ad-e9ac3992ff6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_74e6fcc6-16f6-4eb8-beec-8d488747b5b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ee52094f-e078-4ef2-8836-bd2c6f0c9918" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_74e6fcc6-16f6-4eb8-beec-8d488747b5b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ee52094f-e078-4ef2-8836-bd2c6f0c9918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_98e0c804-9cea-4f12-a56a-ea35fa136229" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_74e6fcc6-16f6-4eb8-beec-8d488747b5b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_98e0c804-9cea-4f12-a56a-ea35fa136229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63828feb-5306-45d5-a79f-6443a3b25d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_74e6fcc6-16f6-4eb8-beec-8d488747b5b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63828feb-5306-45d5-a79f-6443a3b25d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dbfd9580-34fd-43ac-a187-ec1f1928bbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_74e6fcc6-16f6-4eb8-beec-8d488747b5b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dbfd9580-34fd-43ac-a187-ec1f1928bbfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_038bd61b-4e02-47f2-980f-fa7ec3aa20f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_74e6fcc6-16f6-4eb8-beec-8d488747b5b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_038bd61b-4e02-47f2-980f-fa7ec3aa20f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_10b40bfd-605a-405e-a13b-b7be8d6e6556" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_74e6fcc6-16f6-4eb8-beec-8d488747b5b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_10b40bfd-605a-405e-a13b-b7be8d6e6556" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20190331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6dd6946a-39a6-4e1e-9200-59f16c325514" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bed90db2-abe6-4b46-92f7-bc7809908e14" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6dd6946a-39a6-4e1e-9200-59f16c325514" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bed90db2-abe6-4b46-92f7-bc7809908e14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_47ca28df-9dc2-4ae7-9517-8f0b39b78d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6dd6946a-39a6-4e1e-9200-59f16c325514" xlink:to="loc_us-gaap_OperatingLeaseLiability_47ca28df-9dc2-4ae7-9517-8f0b39b78d4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20190331.xsd#ShareholdersEquityandDebt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20190331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20190331.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20190331.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditions" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditions"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_106483c4-2e1d-4225-97c5-ccf746ee8af0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_d6e3c1a0-1156-45f3-9d2f-c6d0417cd050" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_106483c4-2e1d-4225-97c5-ccf746ee8af0" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_d6e3c1a0-1156-45f3-9d2f-c6d0417cd050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ac9ddfea-98b4-408f-97a2-6a2c5fee5180" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_106483c4-2e1d-4225-97c5-ccf746ee8af0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ac9ddfea-98b4-408f-97a2-6a2c5fee5180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_4b56e8f2-cf11-4339-bacb-fd0f6ce65223" xlink:href="cpix-20190331.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_106483c4-2e1d-4225-97c5-ccf746ee8af0" xlink:to="loc_cpix_PaymentsForContingentConsideration_4b56e8f2-cf11-4339-bacb-fd0f6ce65223" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsChangeinConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cpix-20190331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:031f68bb-a3b6-4ac5-91de-52b2b78765c7,g:bb439603-ef46-4aac-8075-326b08cd6501-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="i6bd1d82e900449c7bfdffe584621d4cd_58255dfa-fe3d-4fec-b077-5049edab88b9">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1f7fc55d-35de-4b75-bb7c-29694da9c9da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f7fc55d-35de-4b75-bb7c-29694da9c9da" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff4fb30c-456c-4209-9bfa-63480c3ffa5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff4fb30c-456c-4209-9bfa-63480c3ffa5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_70913487-90ff-4982-85ff-5bc618d46248" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_70913487-90ff-4982-85ff-5bc618d46248" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5d94a763-19dd-4340-9489-a0e888dea6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5d94a763-19dd-4340-9489-a0e888dea6c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76327771-8d41-4682-8fee-2b8c2ae3aace" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76327771-8d41-4682-8fee-2b8c2ae3aace" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8ab95128-3ae1-4a1a-a7ef-6a2496ba277c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8ab95128-3ae1-4a1a-a7ef-6a2496ba277c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6647cba5-e268-47d4-8ada-960b9f298c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6647cba5-e268-47d4-8ada-960b9f298c9b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f8231aea-6798-45a4-8701-8b32f98c0f99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f8231aea-6798-45a4-8701-8b32f98c0f99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_151894f3-944c-4cd5-9237-838e1e2653bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_151894f3-944c-4cd5-9237-838e1e2653bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c362f4e9-b321-4a33-8e51-3aea17e37d96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_ProfitLoss_c362f4e9-b321-4a33-8e51-3aea17e37d96" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6db6bb9a-45a7-4bc2-99a1-60b4c4777226" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9f1c0f02-8f34-46ff-b3a6-0f6b955d5dda" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e968383c-5f5a-4c77-ac92-7ca3e911a196" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1f7fc55d-35de-4b75-bb7c-29694da9c9da" xlink:to="loc_us-gaap_StatementTable_e968383c-5f5a-4c77-ac92-7ca3e911a196" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a14e8257-c855-43f4-9459-cd4a47439236" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e968383c-5f5a-4c77-ac92-7ca3e911a196" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a14e8257-c855-43f4-9459-cd4a47439236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a14e8257-c855-43f4-9459-cd4a47439236_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a14e8257-c855-43f4-9459-cd4a47439236" xlink:to="loc_us-gaap_EquityComponentDomain_a14e8257-c855-43f4-9459-cd4a47439236_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_698765a8-d1c3-4536-88d5-12da9c4febb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a14e8257-c855-43f4-9459-cd4a47439236" xlink:to="loc_us-gaap_EquityComponentDomain_698765a8-d1c3-4536-88d5-12da9c4febb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1155dd0e-f9a5-424e-a069-508513784ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_698765a8-d1c3-4536-88d5-12da9c4febb4" xlink:to="loc_us-gaap_CommonStockMember_1155dd0e-f9a5-424e-a069-508513784ffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_da4359ed-9adb-4f89-ac9c-70ce962d3bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_698765a8-d1c3-4536-88d5-12da9c4febb4" xlink:to="loc_us-gaap_RetainedEarningsMember_da4359ed-9adb-4f89-ac9c-70ce962d3bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_31058a09-2acb-4a50-b699-46dfead0b948" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_698765a8-d1c3-4536-88d5-12da9c4febb4" xlink:to="loc_us-gaap_NoncontrollingInterestMember_31058a09-2acb-4a50-b699-46dfead0b948" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i9132ae4d41154d209942552a36e1fb54_67a7d74b-538c-45b7-a7dc-d518c1135c39">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bcb6668b-ea0a-4a6b-9e25-6f002b27a1c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_1ad290ae-e236-44a2-86dc-44db5d007cee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bcb6668b-ea0a-4a6b-9e25-6f002b27a1c7" xlink:to="loc_us-gaap_TradingSecurities_1ad290ae-e236-44a2-86dc-44db5d007cee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_55bcb790-4fbe-46d5-bb6a-aaa4babe887d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bcb6668b-ea0a-4a6b-9e25-6f002b27a1c7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_55bcb790-4fbe-46d5-bb6a-aaa4babe887d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37546177-e417-4ebb-92a5-6580118c5334" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_55bcb790-4fbe-46d5-bb6a-aaa4babe887d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37546177-e417-4ebb-92a5-6580118c5334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37546177-e417-4ebb-92a5-6580118c5334_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37546177-e417-4ebb-92a5-6580118c5334" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37546177-e417-4ebb-92a5-6580118c5334_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9900a21-efb4-476d-a97d-c5f1c326ea64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37546177-e417-4ebb-92a5-6580118c5334" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9900a21-efb4-476d-a97d-c5f1c326ea64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_45947d58-4746-4c84-801f-d7bba503bc63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9900a21-efb4-476d-a97d-c5f1c326ea64" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_45947d58-4746-4c84-801f-d7bba503bc63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0d913b95-7e0b-45a6-9d43-1204b2c69b53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9900a21-efb4-476d-a97d-c5f1c326ea64" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0d913b95-7e0b-45a6-9d43-1204b2c69b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7f3e506f-2d77-4f6d-b2b2-30fe9336609a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_55bcb790-4fbe-46d5-bb6a-aaa4babe887d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7f3e506f-2d77-4f6d-b2b2-30fe9336609a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f3e506f-2d77-4f6d-b2b2-30fe9336609a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7f3e506f-2d77-4f6d-b2b2-30fe9336609a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7f3e506f-2d77-4f6d-b2b2-30fe9336609a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7f3e506f-2d77-4f6d-b2b2-30fe9336609a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_72cf4479-2fdb-4ba4-b227-414f0c356c1d" xlink:href="cpix-20190331.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:to="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_72cf4479-2fdb-4ba4-b227-414f0c356c1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_768d054c-1bb1-44e6-a7ca-2012aa0aaca3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_768d054c-1bb1-44e6-a7ca-2012aa0aaca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cd6b3a15-a01c-4416-b2b8-23f5fc7530e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:to="loc_us-gaap_CommercialPaperMember_cd6b3a15-a01c-4416-b2b8-23f5fc7530e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c4cd738a-a328-4e98-a9e7-6471cb57e742" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:to="loc_us-gaap_MunicipalBondsMember_c4cd738a-a328-4e98-a9e7-6471cb57e742" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" id="id0f9fd85ccc94e329139fffe62334773_8f492739-e28d-417e-b6bf-3e8164e80002">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3c26a009-c35b-4278-8e04-575f347614e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f76caa30-969a-4a54-b493-d2f42823ebc0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3c26a009-c35b-4278-8e04-575f347614e3" xlink:to="loc_us-gaap_RevenuesAbstract_f76caa30-969a-4a54-b493-d2f42823ebc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_fbecc698-388e-4240-8deb-8bd8b1f2a672" xlink:href="cpix-20190331.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_f76caa30-969a-4a54-b493-d2f42823ebc0" xlink:to="loc_cpix_ProductsAbstract_fbecc698-388e-4240-8deb-8bd8b1f2a672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6a2f11e-e760-4d2e-9fad-aca70f546457" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_fbecc698-388e-4240-8deb-8bd8b1f2a672" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6a2f11e-e760-4d2e-9fad-aca70f546457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b97a5708-97e6-4c9f-a5ee-991b08be8b77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3c26a009-c35b-4278-8e04-575f347614e3" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b97a5708-97e6-4c9f-a5ee-991b08be8b77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ddc3bfd9-559c-4418-9d93-faf3067c7c29" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b97a5708-97e6-4c9f-a5ee-991b08be8b77" xlink:to="loc_srt_ProductOrServiceAxis_ddc3bfd9-559c-4418-9d93-faf3067c7c29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ddc3bfd9-559c-4418-9d93-faf3067c7c29_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ddc3bfd9-559c-4418-9d93-faf3067c7c29" xlink:to="loc_srt_ProductsAndServicesDomain_ddc3bfd9-559c-4418-9d93-faf3067c7c29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ddc3bfd9-559c-4418-9d93-faf3067c7c29" xlink:to="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_b19a88d1-3793-4e56-920a-ac2a9e1ab38b" xlink:href="cpix-20190331.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_AcetadoteMember_b19a88d1-3793-4e56-920a-ac2a9e1ab38b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_68896ef2-15d9-45ce-ba80-9f7812abaefe" xlink:href="cpix-20190331.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_OmeclamoxPakMember_68896ef2-15d9-45ce-ba80-9f7812abaefe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_74a53791-e04b-4858-b24a-0f3ec71d8f53" xlink:href="cpix-20190331.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_KristaloseMember_74a53791-e04b-4858-b24a-0f3ec71d8f53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_f57b1783-56f5-4f6b-b121-b663c39accfa" xlink:href="cpix-20190331.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_VaprisolMember_f57b1783-56f5-4f6b-b121-b663c39accfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_dfb76063-0de3-475f-a00c-7f711147d52e" xlink:href="cpix-20190331.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_CaldolorMember_dfb76063-0de3-475f-a00c-7f711147d52e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EthyolMember_3630840a-f977-4f3f-bfc3-7b87c8c70ed8" xlink:href="cpix-20190331.xsd#cpix_EthyolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_EthyolMember_3630840a-f977-4f3f-bfc3-7b87c8c70ed8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TotectMember_ddd80d07-1457-461e-85ca-8a6d85ffb188" xlink:href="cpix-20190331.xsd#cpix_TotectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_TotectMember_ddd80d07-1457-461e-85ca-8a6d85ffb188" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_61f94fe6-537e-4ffc-91a5-3aa216c25ba6" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_VIBATIVMember_61f94fe6-537e-4ffc-91a5-3aa216c25ba6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_19c8da97-9989-441c-8415-e8de9c3694ba" xlink:href="cpix-20190331.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_OtherProductsMember_19c8da97-9989-441c-8415-e8de9c3694ba" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i6daf258c6ba64806be4042fe1542f042_50e5b15a-4302-4ece-9083-b1dec2e98ee7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_301a27e6-ac7b-44bf-b7c8-61fa0d9622e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_22fc4358-dd15-4505-a25f-cf14cfc333d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_301a27e6-ac7b-44bf-b7c8-61fa0d9622e8" xlink:to="loc_us-gaap_InventoryValuationReserves_22fc4358-dd15-4505-a25f-cf14cfc333d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b76d2d54-b899-4d1c-b1ad-210972e8853a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_301a27e6-ac7b-44bf-b7c8-61fa0d9622e8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b76d2d54-b899-4d1c-b1ad-210972e8853a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_39909bf3-2bed-4aa5-8880-ce67b93da017" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_301a27e6-ac7b-44bf-b7c8-61fa0d9622e8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_39909bf3-2bed-4aa5-8880-ce67b93da017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_96b3b47b-6598-40f3-b12d-9e4d228cc922" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_301a27e6-ac7b-44bf-b7c8-61fa0d9622e8" xlink:to="loc_us-gaap_InventoryCurrentTable_96b3b47b-6598-40f3-b12d-9e4d228cc922" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b7ceb51e-fc0a-4fec-9cfd-47c2dff1cde9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_96b3b47b-6598-40f3-b12d-9e4d228cc922" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b7ceb51e-fc0a-4fec-9cfd-47c2dff1cde9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7ceb51e-fc0a-4fec-9cfd-47c2dff1cde9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7ceb51e-fc0a-4fec-9cfd-47c2dff1cde9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b7ceb51e-fc0a-4fec-9cfd-47c2dff1cde9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eaba3056-ce1d-4307-bec3-6b402599befb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7ceb51e-fc0a-4fec-9cfd-47c2dff1cde9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eaba3056-ce1d-4307-bec3-6b402599befb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_c0e91b2f-ede1-43c5-801a-61dcda78c4df" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eaba3056-ce1d-4307-bec3-6b402599befb" xlink:to="loc_cpix_VIBATIVMember_c0e91b2f-ede1-43c5-801a-61dcda78c4df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="ia8949fb09f0744c1a075f772229920b5_7a530010-05f6-4a2a-be9c-c8a42da303a7">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6e3940-79e1-4471-8cfd-3aff283e32fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:href="cpix-20190331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6e3940-79e1-4471-8cfd-3aff283e32fb" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_618471fd-670c-4531-a78a-a8e28557ebb6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_618471fd-670c-4531-a78a-a8e28557ebb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_69bdb6d2-fcbd-4bb5-965f-2471258d1e38" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_69bdb6d2-fcbd-4bb5-965f-2471258d1e38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_d70c3870-2411-4fe9-aa2e-a512b21e4402" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_d70c3870-2411-4fe9-aa2e-a512b21e4402" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_7114983d-4f7a-4be0-a750-1344f871df0d" xlink:href="cpix-20190331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_7114983d-4f7a-4be0-a750-1344f871df0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_b854247f-6e91-464e-8488-6d639dfc6fc8" xlink:href="cpix-20190331.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_b854247f-6e91-464e-8488-6d639dfc6fc8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7407d50c-38a3-44cd-b417-80047c29c9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7407d50c-38a3-44cd-b417-80047c29c9ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fc18d35e-3d25-47f5-b8ad-cebb6ece39b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fc18d35e-3d25-47f5-b8ad-cebb6ece39b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6cc45944-f168-48b9-a04e-9a0f1a21231f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6cc45944-f168-48b9-a04e-9a0f1a21231f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a55ebfcb-2e3e-40db-87da-6846265b1323" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a55ebfcb-2e3e-40db-87da-6846265b1323" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6e3940-79e1-4471-8cfd-3aff283e32fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f81bf5f6-176a-4ccb-b201-0e1b0ef2c23c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f81bf5f6-176a-4ccb-b201-0e1b0ef2c23c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f81bf5f6-176a-4ccb-b201-0e1b0ef2c23c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f81bf5f6-176a-4ccb-b201-0e1b0ef2c23c" xlink:to="loc_us-gaap_EquityComponentDomain_f81bf5f6-176a-4ccb-b201-0e1b0ef2c23c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_72fd2f65-751b-4fb2-905d-7ad83fd2ac41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f81bf5f6-176a-4ccb-b201-0e1b0ef2c23c" xlink:to="loc_us-gaap_EquityComponentDomain_72fd2f65-751b-4fb2-905d-7ad83fd2ac41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3d63238d-d8de-49c0-b5e8-411d7abcff2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_72fd2f65-751b-4fb2-905d-7ad83fd2ac41" xlink:to="loc_us-gaap_CommonStockMember_3d63238d-d8de-49c0-b5e8-411d7abcff2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_544f6be9-39dc-42a9-b22e-89a568e1f9f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:to="loc_us-gaap_TitleOfIndividualAxis_544f6be9-39dc-42a9-b22e-89a568e1f9f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_544f6be9-39dc-42a9-b22e-89a568e1f9f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_544f6be9-39dc-42a9-b22e-89a568e1f9f6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_544f6be9-39dc-42a9-b22e-89a568e1f9f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1b7ac758-e14c-45b8-b219-1f1c0c7e9f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_544f6be9-39dc-42a9-b22e-89a568e1f9f6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1b7ac758-e14c-45b8-b219-1f1c0c7e9f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_1a202db2-4e11-45a2-8fcb-4296bfa8fcf1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1b7ac758-e14c-45b8-b219-1f1c0c7e9f8b" xlink:to="loc_us-gaap_DirectorMember_1a202db2-4e11-45a2-8fcb-4296bfa8fcf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6a3c0f87-2494-4c01-9593-479922100fab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:to="loc_us-gaap_AwardTypeAxis_6a3c0f87-2494-4c01-9593-479922100fab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a3c0f87-2494-4c01-9593-479922100fab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6a3c0f87-2494-4c01-9593-479922100fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a3c0f87-2494-4c01-9593-479922100fab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ed01204-1085-45c5-b9fc-b4c89bc7479d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6a3c0f87-2494-4c01-9593-479922100fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ed01204-1085-45c5-b9fc-b4c89bc7479d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_535474ac-af48-4a9c-bb44-4d12b76f33b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ed01204-1085-45c5-b9fc-b4c89bc7479d" xlink:to="loc_us-gaap_RestrictedStockMember_535474ac-af48-4a9c-bb44-4d12b76f33b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="i652932f7c42a43c39ceb880603bc6442_902cde5e-40e9-40c4-9b24-6ea0b5732424">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4579fad3-863f-4cbb-9445-6efc6c84b0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4579fad3-863f-4cbb-9445-6efc6c84b0c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_0b576677-8ec3-4a4b-87ca-8fe6fcc62d59" xlink:href="cpix-20190331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_0b576677-8ec3-4a4b-87ca-8fe6fcc62d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_1ec50071-e3e4-44a7-a258-91c9f1aa76a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_LongTermLineOfCredit_1ec50071-e3e4-44a7-a258-91c9f1aa76a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ba46ca07-0c0b-434d-b609-e25c6e11b939" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ba46ca07-0c0b-434d-b609-e25c6e11b939" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_49840887-37e7-4955-b48e-74316e520c70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_49840887-37e7-4955-b48e-74316e520c70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_d38554d0-6ef3-4d42-998c-3acd831be58c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_d38554d0-6ef3-4d42-998c-3acd831be58c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_33917baf-2147-43bd-9106-fa6c9a852e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_33917baf-2147-43bd-9106-fa6c9a852e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_33917baf-2147-43bd-9106-fa6c9a852e1d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_33917baf-2147-43bd-9106-fa6c9a852e1d" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_33917baf-2147-43bd-9106-fa6c9a852e1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_4d5cd665-4b1b-42ce-8f89-f5de83c36620" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_33917baf-2147-43bd-9106-fa6c9a852e1d" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_4d5cd665-4b1b-42ce-8f89-f5de83c36620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_204ccec0-e745-43db-9f99-05b9c26c36a7" xlink:href="cpix-20190331.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_4d5cd665-4b1b-42ce-8f89-f5de83c36620" xlink:to="loc_cpix_PinnacleBankMember_204ccec0-e745-43db-9f99-05b9c26c36a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_57c6b141-481d-4e0e-9a72-19dd649466a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:to="loc_us-gaap_DebtInstrumentAxis_57c6b141-481d-4e0e-9a72-19dd649466a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_57c6b141-481d-4e0e-9a72-19dd649466a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_57c6b141-481d-4e0e-9a72-19dd649466a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_57c6b141-481d-4e0e-9a72-19dd649466a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c5453363-d1b4-4102-be56-4b2686171ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_57c6b141-481d-4e0e-9a72-19dd649466a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c5453363-d1b4-4102-be56-4b2686171ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_3138fcfc-b273-4475-acbd-a3e862dfb811" xlink:href="cpix-20190331.xsd#cpix_SecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5453363-d1b4-4102-be56-4b2686171ff0" xlink:to="loc_cpix_SecondAmendmentMember_3138fcfc-b273-4475-acbd-a3e862dfb811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5008e804-78ca-4c3b-a579-05b746de336f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5453363-d1b4-4102-be56-4b2686171ff0" xlink:to="loc_us-gaap_LineOfCreditMember_5008e804-78ca-4c3b-a579-05b746de336f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_486fd79b-1617-46ef-b24a-6803302bd49b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:to="loc_us-gaap_CreditFacilityAxis_486fd79b-1617-46ef-b24a-6803302bd49b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_486fd79b-1617-46ef-b24a-6803302bd49b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_486fd79b-1617-46ef-b24a-6803302bd49b" xlink:to="loc_us-gaap_CreditFacilityDomain_486fd79b-1617-46ef-b24a-6803302bd49b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ee2df373-c04e-4d6d-9383-a00e16abf7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_486fd79b-1617-46ef-b24a-6803302bd49b" xlink:to="loc_us-gaap_CreditFacilityDomain_ee2df373-c04e-4d6d-9383-a00e16abf7d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_fa118156-ae23-4f83-8679-c6c584d77b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ee2df373-c04e-4d6d-9383-a00e16abf7d2" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_fa118156-ae23-4f83-8679-c6c584d77b4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7c04d1e-56b9-4af6-8e97-01d94aa8bf26" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:to="loc_srt_RangeAxis_e7c04d1e-56b9-4af6-8e97-01d94aa8bf26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7c04d1e-56b9-4af6-8e97-01d94aa8bf26_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e7c04d1e-56b9-4af6-8e97-01d94aa8bf26" xlink:to="loc_srt_RangeMember_e7c04d1e-56b9-4af6-8e97-01d94aa8bf26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d876ad8-16ec-422b-b81a-6182576f70e1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e7c04d1e-56b9-4af6-8e97-01d94aa8bf26" xlink:to="loc_srt_RangeMember_1d876ad8-16ec-422b-b81a-6182576f70e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_80aae8dd-d6c5-4b56-8606-16710433c938" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1d876ad8-16ec-422b-b81a-6182576f70e1" xlink:to="loc_srt_MinimumMember_80aae8dd-d6c5-4b56-8606-16710433c938" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f6046af-9568-4e54-8af1-1872db34b632" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1d876ad8-16ec-422b-b81a-6182576f70e1" xlink:to="loc_srt_MaximumMember_5f6046af-9568-4e54-8af1-1872db34b632" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails" xlink:type="extended" id="i87bea5750aaf4ef9a3e1622e202b2bb3_76f26078-5b68-4b1e-9c1a-81fce0014858">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForAssetAcquisitions_8eea3b03-4dca-46c6-9122-8a9914da20b8" xlink:href="cpix-20190331.xsd#cpix_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_cpix_PaymentsForAssetAcquisitions_8eea3b03-4dca-46c6-9122-8a9914da20b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_125f1d47-b6d9-4eba-b6b4-5bb05e96acf0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_125f1d47-b6d9-4eba-b6b4-5bb05e96acf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_261d8c10-8039-4f13-9441-a1408edd3f09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_261d8c10-8039-4f13-9441-a1408edd3f09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_374e130d-ec0d-489c-901c-0a1f46243d85" xlink:href="cpix-20190331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_374e130d-ec0d-489c-901c-0a1f46243d85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_31e68b64-b39c-42c9-adcb-601adeabac73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_31e68b64-b39c-42c9-adcb-601adeabac73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_953df45f-1a7b-4fe2-a638-aaee348c72e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_953df45f-1a7b-4fe2-a638-aaee348c72e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f648fd71-51e5-4f7b-81cd-6d27319081ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f648fd71-51e5-4f7b-81cd-6d27319081ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f648fd71-51e5-4f7b-81cd-6d27319081ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f648fd71-51e5-4f7b-81cd-6d27319081ff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f648fd71-51e5-4f7b-81cd-6d27319081ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4567080e-a074-4e29-ad0d-79762543b6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f648fd71-51e5-4f7b-81cd-6d27319081ff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4567080e-a074-4e29-ad0d-79762543b6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d58bf5bc-b269-48fa-97a0-f5812fb39b83" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4567080e-a074-4e29-ad0d-79762543b6dc" xlink:to="loc_cpix_VIBATIVMember_d58bf5bc-b269-48fa-97a0-f5812fb39b83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d5acba45-08f1-4057-88b8-89056f9fb670" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d5acba45-08f1-4057-88b8-89056f9fb670" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d5acba45-08f1-4057-88b8-89056f9fb670_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d5acba45-08f1-4057-88b8-89056f9fb670" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d5acba45-08f1-4057-88b8-89056f9fb670_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7648aa5d-3a2f-49f7-a388-c8de0964164b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d5acba45-08f1-4057-88b8-89056f9fb670" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7648aa5d-3a2f-49f7-a388-c8de0964164b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_211c7299-b034-48ed-8d35-dac829e34101" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7648aa5d-3a2f-49f7-a388-c8de0964164b" xlink:to="loc_us-gaap_SubsequentEventMember_211c7299-b034-48ed-8d35-dac829e34101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a0dd6f6d-8eb2-46f8-a0b2-32cd8555d67f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a0dd6f6d-8eb2-46f8-a0b2-32cd8555d67f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a0dd6f6d-8eb2-46f8-a0b2-32cd8555d67f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a0dd6f6d-8eb2-46f8-a0b2-32cd8555d67f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a0dd6f6d-8eb2-46f8-a0b2-32cd8555d67f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06300f95-cbd3-42d2-92ea-660d42b5b477" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a0dd6f6d-8eb2-46f8-a0b2-32cd8555d67f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06300f95-cbd3-42d2-92ea-660d42b5b477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1b29c25b-c239-4218-b45d-d60e96b57509" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06300f95-cbd3-42d2-92ea-660d42b5b477" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1b29c25b-c239-4218-b45d-d60e96b57509" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended" id="i98e56e3383534a68a9b19250c50f12d9_598de4da-7a7b-44a5-be04-d2a1e6b3c2c1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_360b0d64-b3cd-4527-a5ca-a4712ec17ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_360b0d64-b3cd-4527-a5ca-a4712ec17ed8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_43e844b4-ef8c-4c70-ba42-18cd8b81769a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_43e844b4-ef8c-4c70-ba42-18cd8b81769a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_69216203-06d3-4d3f-bf26-60afd13f5680" xlink:href="cpix-20190331.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:to="loc_cpix_PaymentsForContingentConsideration_69216203-06d3-4d3f-bf26-60afd13f5680" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c3a8fe73-ba2e-4380-8a32-1177e0e1498f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c3a8fe73-ba2e-4380-8a32-1177e0e1498f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f69f2157-f92a-4a74-83cd-2f41d05d411e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f69f2157-f92a-4a74-83cd-2f41d05d411e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e361cca4-a8ea-47c3-b917-639d70d1c1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f69f2157-f92a-4a74-83cd-2f41d05d411e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e361cca4-a8ea-47c3-b917-639d70d1c1c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e361cca4-a8ea-47c3-b917-639d70d1c1c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e361cca4-a8ea-47c3-b917-639d70d1c1c6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e361cca4-a8ea-47c3-b917-639d70d1c1c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d33ab-8f30-41d4-b8f2-09c6c003e396" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e361cca4-a8ea-47c3-b917-639d70d1c1c6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d33ab-8f30-41d4-b8f2-09c6c003e396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_2cbf89be-c6f1-4d3e-8ce0-03d861e7e94e" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d33ab-8f30-41d4-b8f2-09c6c003e396" xlink:to="loc_cpix_VIBATIVMember_2cbf89be-c6f1-4d3e-8ce0-03d861e7e94e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsChangeinConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails" xlink:type="extended" id="i12a759cf9ded4061ac1a3496cc4a03ae_6de4aa78-c51a-46a2-bdfa-1dc26db51361">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3f29675d-7dca-44bc-a891-f57c7f515e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f29675d-7dca-44bc-a891-f57c7f515e0d" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ac8c2bdc-b8c6-42a2-98f8-86d0c286a5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ac8c2bdc-b8c6-42a2-98f8-86d0c286a5b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_08143da5-9d5e-449c-abc6-4b792d749c42" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_08143da5-9d5e-449c-abc6-4b792d749c42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_05370d6e-fe2f-403e-88c1-cb82f4c89594" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_us-gaap_PaymentsForRoyalties_05370d6e-fe2f-403e-88c1-cb82f4c89594" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cb2afad1-a031-48a1-8aff-76b34dd9df74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cb2afad1-a031-48a1-8aff-76b34dd9df74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_6a14f996-9c7d-451b-8489-b89400b9cd87" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_6a14f996-9c7d-451b-8489-b89400b9cd87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b11efb36-ac83-412d-bd2a-fc1f7d3a51f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fc900b09-f7f6-4244-8e4a-a8d9dc93adcc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f29675d-7dca-44bc-a891-f57c7f515e0d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fc900b09-f7f6-4244-8e4a-a8d9dc93adcc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_99b5de23-69c4-469d-a871-4a041244c444" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fc900b09-f7f6-4244-8e4a-a8d9dc93adcc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_99b5de23-69c4-469d-a871-4a041244c444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99b5de23-69c4-469d-a871-4a041244c444_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_99b5de23-69c4-469d-a871-4a041244c444" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_99b5de23-69c4-469d-a871-4a041244c444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fdb6f83-f0e1-46dc-93a5-284b6a4f9db8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_99b5de23-69c4-469d-a871-4a041244c444" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fdb6f83-f0e1-46dc-93a5-284b6a4f9db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_32b1e0d6-96d0-4302-ac45-1671ce8f8c39" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fdb6f83-f0e1-46dc-93a5-284b6a4f9db8" xlink:to="loc_cpix_VIBATIVMember_32b1e0d6-96d0-4302-ac45-1671ce8f8c39" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended" id="ib0717bec04fe4d26b0ed96b42374a948_9067307e-c0b6-4856-b0ad-fdaf28e5b959">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_7f8d27ef-b3c8-4375-b508-e31fe9832cc2" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_7f8d27ef-b3c8-4375-b508-e31fe9832cc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_b61fbbfa-2258-47b1-a0e2-e0dee6fac12d" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_b61fbbfa-2258-47b1-a0e2-e0dee6fac12d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_3523f1ee-e6c4-438a-9ecc-add649921600" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_3523f1ee-e6c4-438a-9ecc-add649921600" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_8454a4ba-3d39-4575-b658-703e124bf969" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_8454a4ba-3d39-4575-b658-703e124bf969" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ade52d7b-af5a-4c60-bcd7-08691e642a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ade52d7b-af5a-4c60-bcd7-08691e642a3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_7cd19b24-60d6-46d5-aa7b-b0c181e024ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_7cd19b24-60d6-46d5-aa7b-b0c181e024ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2987d5f1-c1ef-4e86-9b9f-73b10530c336" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_us-gaap_Goodwill_2987d5f1-c1ef-4e86-9b9f-73b10530c336" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_bc1343e6-ab41-4e45-9370-4682e096ba77" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_bc1343e6-ab41-4e45-9370-4682e096ba77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_415d1220-4652-47f0-8f1e-fb9ca69582e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_415d1220-4652-47f0-8f1e-fb9ca69582e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82666c11-0d63-42aa-89eb-45ab26c6c24f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82666c11-0d63-42aa-89eb-45ab26c6c24f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d2c95eb7-6592-4668-a69d-a94c9c370b81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82666c11-0d63-42aa-89eb-45ab26c6c24f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d2c95eb7-6592-4668-a69d-a94c9c370b81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2c95eb7-6592-4668-a69d-a94c9c370b81_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d2c95eb7-6592-4668-a69d-a94c9c370b81" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d2c95eb7-6592-4668-a69d-a94c9c370b81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d99b5f2-acf0-4fef-976e-69357d1e4846" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d2c95eb7-6592-4668-a69d-a94c9c370b81" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d99b5f2-acf0-4fef-976e-69357d1e4846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_22c7915a-bd94-4ea4-a010-948f2b261a39" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d99b5f2-acf0-4fef-976e-69357d1e4846" xlink:to="loc_cpix_VIBATIVMember_22c7915a-bd94-4ea4-a010-948f2b261a39" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cpix-20190331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:031f68bb-a3b6-4ac5-91de-52b2b78765c7,g:bb439603-ef46-4aac-8075-326b08cd6501-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_90d80516-037f-4f49-8354-66bdd1933d11_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of operating lease assets and liabilities through adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b147709f-dc2b-442e-ba74-15825a557d14_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_e68914b1-5151-412d-9be7-f6727fe0cebe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_eda23df8-586f-42ac-80b4-0e57969859f2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_ac79db3f-1646-469b-81a8-5998fcc8e10e_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangibles and goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_acadf1cb-a386-4d33-892f-d5ed17e6f21d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_b6fe37c2-eb8a-4bb4-83e0-30f0c12a8bc5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b43177f9-d8b5-46b4-ae9a-b7efb8a0ae51_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c8459799-b945-4693-9791-29266819eceb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_489e0144-2553-4ba1-a20a-3359e494de05_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e24fdfae-4d55-4049-8add-c028c32653f7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_e40abe42-550d-4968-be3e-2e6786bd2ae0_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dac96d8e-ec74-40cb-bfc4-5ffdfdd2dfcc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Leases Liabilities at March 31, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fa59675b-186e-42ce-81bf-4bb76d7e4cc5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of the contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_1c063fac-f7d9-4354-8642-c9a324b05a16_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c232ee00-9682-4985-94c9-87acf87b70a8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_baba0f29-3e60-436d-8167-1318a2771c86_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1d7f0e50-8553-4793-a4d0-3f60412e891b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_448ec4de-638d-4fa4-b06b-3161b2bc3858_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c4288d48-9dbf-46fd-a1b4-01f6b1d2d259_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d5673654-f15d-44d1-af26-41dd9eeccc71_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c95661d4-9828-4782-8865-38f91a84b2d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent portion of the contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8e4770ed-afe6-4d96-bc9b-8002186facce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of marketable securities, by type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_984022b5-5222-4a8a-b1c0-584496b56d74_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investment gains</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_4d258d35-d1e7-4857-8fae-9afd2e9dff8f_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20190331.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_a5cd187d-5a88-456e-9ec7-c0a5fb51e16f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods, net of reserve</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_daa91df3-1bcc-4c35-acbe-4b3992e3f5a6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ac55e69d-3546-4a03-917d-9bee17da2bc6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c96f1619-8792-4f8d-93c8-d2bd48210a1c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d15597c5-849c-4418-9f8d-20a041fbb97a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_f71d9a4b-9057-44e9-8106-fca7e43c29ef_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20190331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_98eac3da-fa73-44aa-b315-64031e0926ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsForAssetAcquisitions_c87881bb-71d0-4808-85cb-70d30edb29b2_terseLabel_en-US" xlink:label="lab_cpix_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for asset acquisitions</link:label>
    <link:label id="lab_cpix_PaymentsForAssetAcquisitions_label_en-US" xlink:label="lab_cpix_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:label id="lab_cpix_PaymentsForAssetAcquisitions_documentation_en-US" xlink:label="lab_cpix_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForAssetAcquisitions" xlink:href="cpix-20190331.xsd#cpix_PaymentsForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsForAssetAcquisitions" xlink:to="lab_cpix_PaymentsForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e094f555-1f41-4113-9200-64ffdb3387a8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_04781f6c-78e7-460a-88e1-f0801abfac6b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_50d0257e-d97f-4a45-a782-a3cdc986785d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_903f462b-c255-44d1-8dd1-783cf8bd066c_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f9145168-9922-4c90-9c17-b9fe40dab11f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_17bb21e7-b6d7-4dce-b86a-de4978818c08_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4b071f42-07f4-465c-88df-4d0b6b4ec0b2_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0ad826df-c5ac-42f9-b88f-d696fcc6fee2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_26da8061-3400-457b-8608-5c4ccc48ff36_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_13660ae5-637e-4cec-ab10-887ab0b5269a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b1a0e51-726c-4515-8ab5-314895b49b7e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_793dea31-ee83-4b3c-ab3b-46e856e32526_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_88643141-6310-4aa0-bdfe-b8bd9396515b_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to initial fair value of the contingent consideration liability</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e2d3265f-d083-43f0-8e13-eb2a45356d0e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SecondAmendmentMember_f2f7d7d9-2cfe-448b-886e-af8e18f71ce9_terseLabel_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_label_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment [Member]</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_documentation_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember" xlink:href="cpix-20190331.xsd#cpix_SecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SecondAmendmentMember" xlink:to="lab_cpix_SecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_d2c9c02e-6cd4-4ef6-85ab-e23f6fb8126c_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_2a9a260b-eedf-41bb-a92a-547afc942b08_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20190331.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_b074ac95-bbf5-4864-ad0a-2c416b54315c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e52f6c15-7dab-442e-bf93-17fd69b0cbd9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_351d856d-817a-4e80-944b-5b2aaf0ca672_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_720fcd26-62b6-4bf8-9e0f-a9410cbc90fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f4cef4d5-7ef7-4db4-a31a-9b82052721cf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dd810828-45a5-496d-b7f5-abeb58d683bf_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_49220950-db7e-4e33-af6b-e4e3c43eb253_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_265108d3-22e7-4fee-b18b-8a42c1f5ba33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e90fdace-9491-4c84-b226-74bd25aa72d5_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseAsset_7198f644-1f9a-498b-8452-75b17b95859e_terseLabel_en-US" xlink:label="lab_cpix_LeaseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseAsset_label_en-US" xlink:label="lab_cpix_LeaseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Asset</link:label>
    <link:label id="lab_cpix_LeaseAsset_documentation_en-US" xlink:label="lab_cpix_LeaseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseAsset" xlink:href="cpix-20190331.xsd#cpix_LeaseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseAsset" xlink:to="lab_cpix_LeaseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f624d5ac-0ffe-4039-a1ed-103a09257bc1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_5139fe0e-85a8-4e4a-b29e-72ce65c65168_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_44e1e522-a55d-44b0-9ea4-063be3a709aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_c7615cba-e0d0-4f43-a9aa-e9d02aee9c72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Commitments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1c43e7fe-e6e0-4c7e-a996-3aed80a47485_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_39665fbb-3e16-4175-a673-2757dae4b0c8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3196b887-ce98-458c-b813-20093093f6a1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_93a68d05-cf08-4d57-adf2-c5e6345be77c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_176cbf61-fbeb-4e4c-9ff2-4855730e4bba_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_8622142b-f3d0-4a5d-80a1-57bb56f17897_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross, Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_136c2cac-38ac-48ca-86cf-64fc8a8c0cb4_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - validation vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_1b6e0fef-3401-4571-808c-74d45746c34e_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20190331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e0901ade-9ba0-4d6b-8118-d1bcfafb0828_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_fe0437c7-f5bb-482f-b1ff-f81ebc870645_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT PRODUCT ADDITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1c17e506-48f2-45ff-ae21-e1ccb8bf8a3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_13466fec-7f4f-4af7-a76e-54752731b78b_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_35f5a196-8f21-4549-b6a6-25a4a9ee81d4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8abda71c-7c6f-4ee0-85aa-6339c71cf412_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_746b6bbb-a710-4330-baa3-c2f74ddefe48_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_d90f9577-71e1-417c-9358-d50e0a81800a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1f6fe3aa-783e-4687-a0a3-a2bc1987e581_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6fa01538-6f56-42ce-a86f-e3c2e8f490db_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_a0b7cf70-1370-4e16-ba9d-02d8a3a3382b_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20190331.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_b3bfc3c3-c3ce-481a-841e-98528fafac0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_af0d9ff4-fa80-4d0f-8270-9cda2bd42c49_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_cfbe2176-599f-4969-a781-f77871dbdf9e_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20190331.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2e80c4f4-b50d-46a9-a936-6b3bfbf297db_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_d7e66f44-3d11-4ed0-8014-57a4105082e3_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_8efba3da-eea5-4838-9be3-f719b65b75e2_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_2f714bc3-122c-440b-8188-1dcfce11cbef_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20190331.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_b4955207-727a-48be-8ec6-6843bf085b9b_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20190331.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dbe99b0-702e-405f-953f-a6eb3cef6a5b_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_89517783-4760-4a95-870c-4a772e1b9db1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment during early 2019</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_bcafe0ef-964b-4c1e-9b23-ec6a68b50891_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_e36bf89d-421a-4bd2-a6e2-8544602824be_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20190331.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_82d6d503-e51d-48ca-a8d6-bb1e46b6e8a2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_68ab2ac9-ed71-4139-ad27-1ccf374dbb64_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0c3f31fb-c1d8-4567-a85c-6dcb3c9221db_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_952caa0b-68e8-422b-9389-65d41ce80081_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_31f3fc5e-e47f-43ba-8d1a-42eb82f04c92_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b35d29f0-0448-4545-b01f-3ed6787a8f1a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_84266f2c-8569-4f94-942e-2f1e079c2650_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a3d32bd-c88a-4120-8faf-2509cb65d4c2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_23d4087e-96c4-4c59-a516-1115bdc05486_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfa86a96-d95c-4a44-a193-f3d086e8b40b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_9ca6574b-a2ab-420c-8723-182fab2fef7b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_85fdb489-b9f7-4382-87f8-43c9a94c7a1d_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectorMember_c16f9739-4b5f-43ef-be0b-cadd651d9c8d_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_us-gaap_DirectorMember_label_en-US" xlink:label="lab_us-gaap_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember" xlink:to="lab_us-gaap_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_086ff40a-e89d-4863-bf41-0f77324ad739_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fb1a1fd3-2a18-4cf2-a932-799f728b1c02_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_31c35355-178e-4902-8da0-1c6c5a5b1e7f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_dd831700-1881-4ad7-b1e6-5aa62714a5da_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_70181657-f2d4-424b-96c9-e308ae4934b3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_7eba8fa5-9da5-43e8-a0ef-b5bdfe27dc8b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_07d4e38b-48e8-43c8-8f4a-249133da148b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_56d5151d-f0f5-4b22-b3e4-762d67ca8cf8_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_d4ffc150-4977-499b-9490-516681c16b94_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_c38816c9-be4c-46c9-93f4-f4707ff22f45_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7b51d917-1f67-440c-a76b-28cc86dead61_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_d520ea4b-4055-4cc5-8136-bc3d9bf4ab8c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e5e1738e-0eb1-43ea-8e0a-839a9ac37c8c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6412794c-340f-462d-add9-ac4ceac6bcb2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_5f66ac31-a0ac-4321-9026-d44c5a38f6a1_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_43036def-8e82-415e-a2a9-8940669d4e41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2ddcefcc-33a5-4a6a-abe8-2435a49c9239_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_429b0a62-da45-4dcb-ae55-9528a06d7a3d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7977cacb-cbb7-42d1-86a3-913b591bd189_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_22366519-6fe6-4b40-a822-e65b3fcb52c9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_98b09a6e-bc36-4fcf-812f-338d1ef61045_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d221f4a7-93e9-47bc-be3c-03ebbe0c96b9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_05c7d781-78bd-4fdd-8083-98f5d133b780_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_403d4117-eca0-4ae4-9035-6311e00f7ed7_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_8434202b-cf89-4ab8-ae72-6dcc6b1f348f_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_6c25ebee-2352-432f-aa44-e5218feb3d1a_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_876ecb50-dff1-4e00-a093-56db925065aa_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_443ce8fa-a7ca-4586-b13c-0b11cc030c76_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_7123e3f7-d46d-49ba-8ced-26f0cb7adf9a_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6e8fc163-a821-4cc7-a0ff-825df4bce66e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_8d180b21-9466-460d-b2b4-98319834290d_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:href="cpix-20190331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_9dc45f89-53d5-46b1-8791-01cfe109de1b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_cfbe57ed-bd54-4795-aa9e-5cf7d37cd34f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_b3f09a45-6ad6-490a-86dc-5359fd0ad805_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_79dcb150-aa86-406a-bc27-bd9872a1fb3d_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ff71962d-bf53-48f2-9d0a-22eb49e054d7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e0ad78f8-27de-4795-96e5-274b3095c5a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_5b59d80b-a5c5-4fd6-a513-ecf132babfea_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_13edcbd1-fae8-4450-9458-b88e55294e3d_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0d67caa3-652c-4eed-be25-c14a0361a218_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_698a5102-cf04-431c-84f0-6b93f435b827_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3cc5ea4b-4877-4c11-b9e7-22bf8e08ec3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_eb638ac9-d9a4-43c7-abcc-54feed928741_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_53acf2af-7972-4c14-9251-dac0dfa955ef_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5b6535d3-738b-4444-a5bb-bb89f8b350be_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_8b95f51a-ed90-4bdc-84ee-3d573d5895c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03be21fa-e632-4b93-ada0-22fffc665b26_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7f37fbb5-bc96-462f-a6dd-f3da9e1bab89_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c9547fe-0376-4764-826e-ad63bb1b6c53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6d690f0c-ec71-4d12-a238-1cbc338fcc96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8188e591-150d-4073-8599-e8d6ec2df9ed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_e5c650f1-0c1d-4440-ba9d-77725a49b432_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_160360f0-9425-4c4d-a8ca-ff81576456d0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c5ff491a-58bf-4e6e-b747-91fc58abd993_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b2851d9a-3fdd-40f7-bb78-4ccdc97124c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b92d3ec2-c2da-4a8e-b7d7-0a74f28cf8c0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ce67be58-c930-4d9d-81df-ca1b9d6d6195_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a4322a5f-8dd9-4fbc-900b-fc5914f24b28_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_2cfea3ff-55cd-4b31-ad85-f026b5c13cf5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ade392c5-284f-49a5-9956-3c24c2768d4c_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_9fc37dd8-f2af-4e10-b219-8cb33b5dea92_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d749ce13-5cf0-44a6-b044-6008a8a71f5f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_569a5370-2855-47e2-a438-b3a12b4635bf_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_8549e5cd-9e4d-4b12-956b-826666c90b4d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_daa37493-0807-489b-b6a5-8bb33642d0f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b211dec2-efe6-4d94-a712-27a2e7277e15_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_94008578-f55e-4d43-b465-97c5df8f6994_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3ea7af93-23f0-442f-aab8-11d0b0678aa1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_21e1054d-337b-4b7c-9f33-39605a427dd8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_1d69e999-91ca-403f-9ac4-f3f774429591_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20190331.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_da024274-464c-49bf-acc0-31d682b491cf_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0ec27559-d1cc-40ba-b78b-4f3e22399b74_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8b5ee1b7-4423-469b-9328-fbaded4d3415_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_829f2c6a-bc0c-403a-a0a5-6e0b23ac7d1e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e9a43da0-1241-4919-a015-e398045f8533_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3890103b-9fd2-4880-b8c3-bc5f3a07c150_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_c5ef6868-2a40-4010-9da3-5ed5edf004d4_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term cash investments</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_02ec3d0f-d6d7-4d51-b778-3a26e90fd184_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b0a266d7-c9e9-4d34-b834-dd3338acc92e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5b5dacbe-22c4-45e4-9215-4378f7857fb5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_28ac6cbd-a8d2-49c3-9a34-0337deec6f74_terseLabel_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration - net sales royalty</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_label_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_documentation_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration" xlink:href="cpix-20190331.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsForContingentConsideration" xlink:to="lab_cpix_PaymentsForContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_87984002-6ccc-4ba7-b7d5-d64c0ed1a792_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_cf34b163-003b-4e48-a1d6-318a60f7b881_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInCurrentOperatingLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20190331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_11cd725f-dac8-4013-ad97-596ca904677d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_abdb8a2f-90a4-41ac-8af7-863dddd0810b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for potential obsolescence of products</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_3006f1b5-e9ce-431f-8077-19a180faa4e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_78dfc976-6228-4cd1-b581-87ec8de5ea9d_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20190331.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_a89a9eb0-8a81-428c-99c7-ee5977d09b53_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20190331.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a03d6840-ae17-4803-9a02-bbca23333b95_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_49819b96-877e-48df-8fbf-4dedbbb29778_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_b96dc420-02dc-41e9-95e5-227aabbb5098_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2c4cc084-ebc3-4599-a4f3-418e3c0158d7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_77ff023c-67de-4f9d-9e5b-c5ca0ebba597_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e9c1e3a5-5c10-4afd-a7a3-c00e473d88e3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_113ac5fb-15c7-4240-ae34-7c726bd52ac5_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d9b136cc-2a52-4b41-8f28-ff50712d13c3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_251ff300-ee40-4f54-bc2b-d7a822e58397_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ba9c49e9-a21a-4022-b02d-c2c7e69c3205_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_995f86b3-5c04-442c-b088-d676b82c5d07_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_18b778a1-f23a-488d-88ca-4121667e7964_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36d71d0e-9194-487a-937e-b05ec49812eb_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EthyolMember_bc3ef085-a90a-4999-b504-022b019b9e7c_terseLabel_en-US" xlink:label="lab_cpix_EthyolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethyol</link:label>
    <link:label id="lab_cpix_EthyolMember_label_en-US" xlink:label="lab_cpix_EthyolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethyol [Member]</link:label>
    <link:label id="lab_cpix_EthyolMember_documentation_en-US" xlink:label="lab_cpix_EthyolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethyol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EthyolMember" xlink:href="cpix-20190331.xsd#cpix_EthyolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EthyolMember" xlink:to="lab_cpix_EthyolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3053df98-d2cf-4ad9-a2b4-16139995719d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_88656a64-b092-4c38-873e-f61f103dae95_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_68d7d126-b932-48ca-9513-4c35e318bea1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_73d0e46f-56ca-478a-b266-e1604a5b75fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_70be7fe0-2a9b-4da4-9a37-9f0230954492_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_4548b096-7c7b-4806-a73c-6427282e52fa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_42d8a532-72b3-451d-8289-cbc0b4e83709_terseLabel_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes and bonds</link:label>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_label_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Us Treasury Notes And Bonds Securities Member [Member]</link:label>
    <link:label id="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_documentation_en-US" xlink:label="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Us Treasury Notes And Bonds Securities Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:href="cpix-20190331.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:to="lab_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_49a2512d-bc55-45fa-b6a7-001922dd7c64_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_79a8fad8-2114-4532-ba73-389ea185a50e_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_91f93c61-17df-45f3-b113-f3154c7415eb_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_0ecea46d-489d-4dd2-8a05-0eafd96c4621_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7b1ceaf9-a259-49f1-a970-03fd0cd360be_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_5e2ea628-505c-4a89-a628-b9c967eb40e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_35dcc8ce-6b2b-4fcd-9d05-adebc7129968_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_57035759-d6dc-4cf3-8f6d-f0d8a1293f0d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_89d85522-f8f4-4baa-999d-1ccec4876d67_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - unlabeled vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_03da78f6-be16-4c95-9346-d87fa07a816f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_77dc8ece-6724-4039-a444-a42794dfb928_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cdbc880b-8e8f-4af5-a856-c7e8b02bf692_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_529fa472-2b90-4246-9439-f599ab40257a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_df0e528f-b07b-4dff-b39b-f0e4003c8e5c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7d6cdd38-45ef-473d-89b1-dd7f3b684a9e_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_1ad4b5b0-013e-47c5-b998-7824a00f507f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_01e82380-e0d2-49e4-97cf-4a20415133e8_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2b44e90d-df08-45da-b54b-38d3be5cd167_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e8c65340-c876-4099-b2f3-946799baf8b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_67c701bc-fa3a-4b55-88fc-f03bb29136b8_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3909e578-04cb-4f14-bf52-dd1b9a7fd1fb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20190331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_2702c3a5-8532-42b2-8a9f-eee3cccfb190_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_666a7466-c95e-4c7b-b28c-4d0ad19a554b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_328ea8ea-05c2-4190-91f3-e8ccea241e4a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5e757374-d8d9-4ec6-a686-7947a3d83e63_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_9200f744-ec8d-4273-9a3b-e3267a2b24e9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_deeb4bee-f777-4ca7-85aa-418459b648b3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_47180e51-a3fe-49b1-b7dd-28c898b97bbc_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20190331.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2aef160c-beff-4ce2-a48d-7fc1dd559285_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f50c1a62-7182-4de7-b16f-c613464d3005_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9dde7411-59c9-428f-aabe-f43c77d90a86_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_72d20286-fd7f-47fd-ac49-75ba2889f583_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_c1b761bc-fe7f-411d-b5f6-f78a9afd6913_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12091829-1ead-413c-a5f6-ea26c501fb91_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24acb1ea-ea00-4261-bfc5-8446b147b9ba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_4e3e3fe2-556f-42bc-ac6d-7ce7447a1344_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_2626653a-42a8-4893-a44d-072dacfa3c32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_6f32c27f-4704-4a50-8719-59f60f20a70e_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20190331.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_f427d556-2c74-44a8-b0c1-aae53a580378_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fbf870c1-b46c-419b-a0b8-e87f98a605bb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0fd58c34-b74f-4c55-ba8e-0b13c9c5de90_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_4b9604ce-f684-46af-85c5-da35845ed343_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ea6a69b1-d57d-44b7-bdae-9ceac70ef75d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_625c7f1c-e2b0-4b51-8698-acc801ae036d_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_8fd25927-6725-4e79-b913-1da57212f7be_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20190331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d88e8bc5-653b-48b1-92ea-d2a77671e8c0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6ad23988-dfdf-45b3-ad52-8ccf512730c6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3900f875-ef42-4f8f-8ad9-3be051a102f1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b1b55d9e-82f7-4696-88c3-5f3418a0de9d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e59e4d7b-07b7-4bfe-a32e-1b054d96d56f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_19feccc2-36b7-4931-a7fc-cef2e8a1ea6a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_76e1a855-0802-4a63-8038-999c74862dcc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d93f6153-fc42-4740-a0ca-437b567a2afb_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_bbe4282c-2053-4a06-9fa5-4647ed2377fb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fbcecc12-ea2c-413d-9dcb-962380266317_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_536cf4ac-1129-49fd-ba08-9fe58de0ab17_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4d8a4934-5ebf-4c1f-8921-34658ecc27ba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_38974650-8a05-4082-8264-38527c95746a_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20190331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_49aeceaa-e878-4e07-b7b6-dc0ac126643d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4778b97d-d3d9-4b0e-9325-062213631e42_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2d506594-6bc0-423e-b818-ea86ade1d459_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ce0eb676-871a-46c2-b290-7b8a61350b65_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_04e19c78-8cb7-44c3-85cf-a7e00e12d5df_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:href="cpix-20190331.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_052c97a9-c33e-45b9-bf48-0a9bb5379226_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_cpix_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_cpix_DocumentAndEntityInformationAbstract_documentation_en-US" xlink:label="lab_cpix_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DocumentAndEntityInformationAbstract" xlink:href="cpix-20190331.xsd#cpix_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract" xlink:to="lab_cpix_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_7a9dc911-5ab3-4e78-a2d2-2a479d64da74_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_711ee45c-f673-4ddb-9e5d-7aa9b8775f55_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_d9e6c77c-05b3-47a1-b249-2727262c137d_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_9b1529c5-4c24-466c-965c-019697725872_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_aca46fad-d81c-4084-8a52-aeeef3e9aa3e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bf2d08c6-4f77-4ab9-99a2-8cff39fe90cb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TotectMember_513b5c62-545e-4e24-9d2d-da0bc0902d52_terseLabel_en-US" xlink:label="lab_cpix_TotectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Totect</link:label>
    <link:label id="lab_cpix_TotectMember_label_en-US" xlink:label="lab_cpix_TotectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Totect [Member]</link:label>
    <link:label id="lab_cpix_TotectMember_documentation_en-US" xlink:label="lab_cpix_TotectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Totect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TotectMember" xlink:href="cpix-20190331.xsd#cpix_TotectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TotectMember" xlink:to="lab_cpix_TotectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_09f5a913-951a-4685-a271-b18f63daf603_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cpix-20190331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2017 Workiva-->
<!--r:031f68bb-a3b6-4ac5-91de-52b2b78765c7,g:bb439603-ef46-4aac-8075-326b08cd6501-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="cpix-20190331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:href="cpix-20190331.xsd#cpix_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7f051b22-d99b-4af7-8ac5-58672514eb63" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_EntityRegistrantName_7f051b22-d99b-4af7-8ac5-58672514eb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5c1151dd-07d6-4b20-bf7b-6bebdc70178d" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_EntityCentralIndexKey_5c1151dd-07d6-4b20-bf7b-6bebdc70178d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_84bbfbb3-9d11-486c-800b-64df159012af" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_CurrentFiscalYearEndDate_84bbfbb3-9d11-486c-800b-64df159012af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_8da4e365-acf0-45cc-84ba-d96083af1402" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_EntityFilerCategory_8da4e365-acf0-45cc-84ba-d96083af1402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b32e767d-fed0-45a6-91d1-135180423975" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_DocumentType_b32e767d-fed0-45a6-91d1-135180423975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1b2146e8-9930-422e-9aa9-c6c10d192ed5" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_DocumentPeriodEndDate_1b2146e8-9930-422e-9aa9-c6c10d192ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_297fdff3-2d4f-4188-a1ef-6527fc3f8209" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_DocumentFiscalYearFocus_297fdff3-2d4f-4188-a1ef-6527fc3f8209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ab335227-bdbc-474b-90e3-f90aaa8834bb" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ab335227-bdbc-474b-90e3-f90aaa8834bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e024e42a-12c8-41ab-a350-7cd9599033a7" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_AmendmentFlag_e024e42a-12c8-41ab-a350-7cd9599033a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e34f1ba1-188f-4fe1-a3b4-234fb5ba72ea" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_EntityEmergingGrowthCompany_e34f1ba1-188f-4fe1-a3b4-234fb5ba72ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c4d2b213-6646-490c-8ec2-ba6160162083" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_EntitySmallBusiness_c4d2b213-6646-490c-8ec2-ba6160162083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_17600745-0b17-42c1-9302-55fac84f9953" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DocumentAndEntityInformationAbstract_e088dc54-670a-41e3-8a59-29291aa68aa3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_17600745-0b17-42c1-9302-55fac84f9953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_58cfa9e1-8335-4e02-aea9-de4fe53875c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b0ca7516-c7cd-4cc4-bc4c-163ce8a0942b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_58cfa9e1-8335-4e02-aea9-de4fe53875c9" xlink:to="loc_us-gaap_AssetsAbstract_b0ca7516-c7cd-4cc4-bc4c-163ce8a0942b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2ce70c06-eddd-44b4-925e-627ca44f058e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0ca7516-c7cd-4cc4-bc4c-163ce8a0942b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2ce70c06-eddd-44b4-925e-627ca44f058e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54705e52-fc43-4faf-a92a-bfd87e10cfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ce70c06-eddd-44b4-925e-627ca44f058e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54705e52-fc43-4faf-a92a-bfd87e10cfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_43331a61-889e-47bd-aff2-496964ba0ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ce70c06-eddd-44b4-925e-627ca44f058e" xlink:to="loc_us-gaap_MarketableSecurities_43331a61-889e-47bd-aff2-496964ba0ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7d1a54ce-cca9-43cd-b0c0-f5885b53d981" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ce70c06-eddd-44b4-925e-627ca44f058e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7d1a54ce-cca9-43cd-b0c0-f5885b53d981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7be79c06-c9ef-406c-85aa-412a743884ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ce70c06-eddd-44b4-925e-627ca44f058e" xlink:to="loc_us-gaap_InventoryNet_7be79c06-c9ef-406c-85aa-412a743884ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0bc74ef7-4eba-4b5d-8c73-98da74fa97cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ce70c06-eddd-44b4-925e-627ca44f058e" xlink:to="loc_us-gaap_OtherAssetsCurrent_0bc74ef7-4eba-4b5d-8c73-98da74fa97cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d1473324-1fb0-4c3e-abbd-7363e7df55dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2ce70c06-eddd-44b4-925e-627ca44f058e" xlink:to="loc_us-gaap_AssetsCurrent_d1473324-1fb0-4c3e-abbd-7363e7df55dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_393490d4-12f3-4fdc-85f6-39a2cf9872b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0ca7516-c7cd-4cc4-bc4c-163ce8a0942b" xlink:to="loc_us-gaap_InventoryNoncurrent_393490d4-12f3-4fdc-85f6-39a2cf9872b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2b78a65-fe62-46f0-8ee8-f290420fb34d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0ca7516-c7cd-4cc4-bc4c-163ce8a0942b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d2b78a65-fe62-46f0-8ee8-f290420fb34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0d6b605e-b7da-4278-9b27-9c948f379e26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0ca7516-c7cd-4cc4-bc4c-163ce8a0942b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0d6b605e-b7da-4278-9b27-9c948f379e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_54a53680-b19d-4292-996d-60408730fe50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0ca7516-c7cd-4cc4-bc4c-163ce8a0942b" xlink:to="loc_us-gaap_Goodwill_54a53680-b19d-4292-996d-60408730fe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_cba7fb94-98f4-4731-9989-5946d78761ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0ca7516-c7cd-4cc4-bc4c-163ce8a0942b" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_cba7fb94-98f4-4731-9989-5946d78761ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a992c51d-f503-4163-b7de-e3c5e73c5ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0ca7516-c7cd-4cc4-bc4c-163ce8a0942b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a992c51d-f503-4163-b7de-e3c5e73c5ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_80952512-57bf-4438-af7d-37f8689abdfa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0ca7516-c7cd-4cc4-bc4c-163ce8a0942b" xlink:to="loc_us-gaap_Assets_80952512-57bf-4438-af7d-37f8689abdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4fb36b59-99ba-47b4-9efc-dea7409111c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_58cfa9e1-8335-4e02-aea9-de4fe53875c9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4fb36b59-99ba-47b4-9efc-dea7409111c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_db726f77-6001-4f78-8e4b-738ccc029a81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4fb36b59-99ba-47b4-9efc-dea7409111c5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_db726f77-6001-4f78-8e4b-738ccc029a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_de375209-2595-4faf-82c0-4e47f4163e35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_db726f77-6001-4f78-8e4b-738ccc029a81" xlink:to="loc_us-gaap_AccountsPayableCurrent_de375209-2595-4faf-82c0-4e47f4163e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_52a2837d-0442-49c2-9e1d-360027d9e4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_db726f77-6001-4f78-8e4b-738ccc029a81" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_52a2837d-0442-49c2-9e1d-360027d9e4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f7f1e36d-a38c-479b-9a47-d6901b8753f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_db726f77-6001-4f78-8e4b-738ccc029a81" xlink:to="loc_us-gaap_LiabilitiesCurrent_f7f1e36d-a38c-479b-9a47-d6901b8753f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_e925c144-c833-4e42-985e-34f57d730e11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4fb36b59-99ba-47b4-9efc-dea7409111c5" xlink:to="loc_us-gaap_LongTermLineOfCredit_e925c144-c833-4e42-985e-34f57d730e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_1b4f9774-7eaa-42eb-b6e7-8126b467131b" xlink:href="cpix-20190331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4fb36b59-99ba-47b4-9efc-dea7409111c5" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_1b4f9774-7eaa-42eb-b6e7-8126b467131b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5f737067-7be5-4ca7-8aa4-1de45ee69a51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4fb36b59-99ba-47b4-9efc-dea7409111c5" xlink:to="loc_us-gaap_Liabilities_5f737067-7be5-4ca7-8aa4-1de45ee69a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fb73e5a8-089f-4828-b8bb-c1a0eb4eb466" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4fb36b59-99ba-47b4-9efc-dea7409111c5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fb73e5a8-089f-4828-b8bb-c1a0eb4eb466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f5c48611-9484-450c-a3f9-000c6a3d3b98" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4fb36b59-99ba-47b4-9efc-dea7409111c5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f5c48611-9484-450c-a3f9-000c6a3d3b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5473aabd-f117-4743-8168-14bfdee8125b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f5c48611-9484-450c-a3f9-000c6a3d3b98" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5473aabd-f117-4743-8168-14bfdee8125b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_565ec50a-2c49-41fe-92db-c66d5b75eb55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473aabd-f117-4743-8168-14bfdee8125b" xlink:to="loc_us-gaap_CommonStockValue_565ec50a-2c49-41fe-92db-c66d5b75eb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a75d1df5-e283-417a-a2c7-34d47d3efce3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473aabd-f117-4743-8168-14bfdee8125b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a75d1df5-e283-417a-a2c7-34d47d3efce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61004e0e-a76a-4158-a8cf-6d8262f6630c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5473aabd-f117-4743-8168-14bfdee8125b" xlink:to="loc_us-gaap_StockholdersEquity_61004e0e-a76a-4158-a8cf-6d8262f6630c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_76b751a1-bc1e-4cbf-99a3-2d8837a3c0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f5c48611-9484-450c-a3f9-000c6a3d3b98" xlink:to="loc_us-gaap_MinorityInterest_76b751a1-bc1e-4cbf-99a3-2d8837a3c0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ffc2bd18-000a-46c2-b745-a9844e3f2ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_f5c48611-9484-450c-a3f9-000c6a3d3b98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ffc2bd18-000a-46c2-b745-a9844e3f2ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_947ed356-35b3-4854-a4ce-8bf77d888a41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4fb36b59-99ba-47b4-9efc-dea7409111c5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_947ed356-35b3-4854-a4ce-8bf77d888a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_afbd17cf-4ca8-4867-8c73-e934d016e09d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_36ece2c7-42ad-4c5b-84c6-c192704604f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_afbd17cf-4ca8-4867-8c73-e934d016e09d" xlink:to="loc_us-gaap_CommonStockNoParValue_36ece2c7-42ad-4c5b-84c6-c192704604f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f189d7a9-3a5d-4209-beec-d7bee4af2d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_afbd17cf-4ca8-4867-8c73-e934d016e09d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f189d7a9-3a5d-4209-beec-d7bee4af2d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_67eb4ae8-9873-4baf-903f-b0da8bd691a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_afbd17cf-4ca8-4867-8c73-e934d016e09d" xlink:to="loc_us-gaap_CommonStockSharesIssued_67eb4ae8-9873-4baf-903f-b0da8bd691a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bf73a686-a44c-4544-8a24-14f6172cea0a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_afbd17cf-4ca8-4867-8c73-e934d016e09d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bf73a686-a44c-4544-8a24-14f6172cea0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ea7bef5c-b678-4b82-9498-8c1909abc306" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ea7bef5c-b678-4b82-9498-8c1909abc306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ab05bd03-c346-49b5-8b03-ab989bf704a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ab05bd03-c346-49b5-8b03-ab989bf704a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ffdc88a1-9023-4201-aefb-29984d29f480" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab05bd03-c346-49b5-8b03-ab989bf704a7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ffdc88a1-9023-4201-aefb-29984d29f480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_c545c930-4b9e-43dd-9dcd-1349b6f7e8c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab05bd03-c346-49b5-8b03-ab989bf704a7" xlink:to="loc_us-gaap_SellingAndMarketingExpense_c545c930-4b9e-43dd-9dcd-1349b6f7e8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9057f081-c09b-4c4f-b516-2f3d61171555" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab05bd03-c346-49b5-8b03-ab989bf704a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9057f081-c09b-4c4f-b516-2f3d61171555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fbc14ec6-090b-4f61-8c2d-184558c971e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab05bd03-c346-49b5-8b03-ab989bf704a7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fbc14ec6-090b-4f61-8c2d-184558c971e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b597c69b-47f8-420f-af9c-ecf5e7798bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab05bd03-c346-49b5-8b03-ab989bf704a7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b597c69b-47f8-420f-af9c-ecf5e7798bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_879a0937-d6d7-48e7-bfc6-1c438df77b11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab05bd03-c346-49b5-8b03-ab989bf704a7" xlink:to="loc_us-gaap_CostsAndExpenses_879a0937-d6d7-48e7-bfc6-1c438df77b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_20dcb9fe-18e4-4b90-991c-c2866f5df49f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab05bd03-c346-49b5-8b03-ab989bf704a7" xlink:to="loc_us-gaap_OperatingIncomeLoss_20dcb9fe-18e4-4b90-991c-c2866f5df49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ca59c510-03a7-4d9c-bb04-2609cd6383a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ca59c510-03a7-4d9c-bb04-2609cd6383a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_718024c6-92dd-4b1d-969b-5757e9334590" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_InterestExpense_718024c6-92dd-4b1d-969b-5757e9334590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8bc51259-22e9-4dde-bddd-3282d35da2fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8bc51259-22e9-4dde-bddd-3282d35da2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2ac44b98-b6a3-495d-b7cb-3c83dd610262" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2ac44b98-b6a3-495d-b7cb-3c83dd610262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ed7bb84e-12ce-43f9-aa09-2a1c418970e0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_ProfitLoss_ed7bb84e-12ce-43f9-aa09-2a1c418970e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6858d311-f339-498d-8631-cf427aa2e273" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6858d311-f339-498d-8631-cf427aa2e273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_63a9e45d-df95-4cc8-915e-6b65a164b2a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_NetIncomeLoss_63a9e45d-df95-4cc8-915e-6b65a164b2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3dba0157-92d6-4089-bfa3-13c47494a438" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_EarningsPerShareAbstract_3dba0157-92d6-4089-bfa3-13c47494a438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_af899836-2e17-49a0-8fe1-e328c163ac72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3dba0157-92d6-4089-bfa3-13c47494a438" xlink:to="loc_us-gaap_EarningsPerShareBasic_af899836-2e17-49a0-8fe1-e328c163ac72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4bfdb725-6d18-4f17-b408-7c63017ea786" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3dba0157-92d6-4089-bfa3-13c47494a438" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4bfdb725-6d18-4f17-b408-7c63017ea786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_45d238b8-868c-4efb-b63a-29e25b654965" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_45d238b8-868c-4efb-b63a-29e25b654965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67d6c17c-34b2-44e4-95f5-5fd6c5087848" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_45d238b8-868c-4efb-b63a-29e25b654965" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67d6c17c-34b2-44e4-95f5-5fd6c5087848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_644961dd-41fb-4be7-8615-09360ba56351" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_45d238b8-868c-4efb-b63a-29e25b654965" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_644961dd-41fb-4be7-8615-09360ba56351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bc4c9174-3062-456a-bef2-14f40662c4bc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bc4c9174-3062-456a-bef2-14f40662c4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c042ee0f-0d60-4321-aaea-1369d2000b40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c042ee0f-0d60-4321-aaea-1369d2000b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2397e87c-9652-42ad-b874-3fe0a93ac8db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aacb9865-3fe9-4e75-8a45-871901a32c1c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2397e87c-9652-42ad-b874-3fe0a93ac8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c110b610-905c-48df-87b4-9b0d230889a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b0129f97-adc3-4476-ae34-dca7869eb2fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c110b610-905c-48df-87b4-9b0d230889a4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b0129f97-adc3-4476-ae34-dca7869eb2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0a1751dd-368e-4edb-94d7-09d3e106aefd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b0129f97-adc3-4476-ae34-dca7869eb2fc" xlink:to="loc_us-gaap_ProfitLoss_0a1751dd-368e-4edb-94d7-09d3e106aefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f3426d78-5c52-4411-ba41-c20a450a9002" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b0129f97-adc3-4476-ae34-dca7869eb2fc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f3426d78-5c52-4411-ba41-c20a450a9002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e72c2aa9-c1c5-4cd6-8885-af1689cd77cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f3426d78-5c52-4411-ba41-c20a450a9002" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e72c2aa9-c1c5-4cd6-8885-af1689cd77cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e55dbad8-11dc-4bf7-be7e-bed0faea9df4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f3426d78-5c52-4411-ba41-c20a450a9002" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e55dbad8-11dc-4bf7-be7e-bed0faea9df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_30f124d4-d95a-40b7-8958-b4c06f84cc8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f3426d78-5c52-4411-ba41-c20a450a9002" xlink:to="loc_us-gaap_ShareBasedCompensation_30f124d4-d95a-40b7-8958-b4c06f84cc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_a60ee229-f956-4690-add9-88a93c862b71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f3426d78-5c52-4411-ba41-c20a450a9002" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_a60ee229-f956-4690-add9-88a93c862b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_301fb15d-97a0-4f5e-9fb8-c6bc2d75ca63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f3426d78-5c52-4411-ba41-c20a450a9002" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_301fb15d-97a0-4f5e-9fb8-c6bc2d75ca63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_8ff11b64-c482-40bd-b46c-fb044afed0bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f3426d78-5c52-4411-ba41-c20a450a9002" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_8ff11b64-c482-40bd-b46c-fb044afed0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b089e300-9021-4a53-99e7-ccc94921eee9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f3426d78-5c52-4411-ba41-c20a450a9002" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b089e300-9021-4a53-99e7-ccc94921eee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0833cd7c-3694-4b9c-bee3-87d2a6d0159b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b089e300-9021-4a53-99e7-ccc94921eee9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0833cd7c-3694-4b9c-bee3-87d2a6d0159b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_578471d3-50c4-4b5d-9399-7db8f11f22a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b089e300-9021-4a53-99e7-ccc94921eee9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_578471d3-50c4-4b5d-9399-7db8f11f22a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8a4423c9-2cb1-4f5f-90eb-ac4b1b2a5039" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b089e300-9021-4a53-99e7-ccc94921eee9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8a4423c9-2cb1-4f5f-90eb-ac4b1b2a5039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_99e08eb9-fcf6-4800-bab6-aac9885b0af2" xlink:href="cpix-20190331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b089e300-9021-4a53-99e7-ccc94921eee9" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_99e08eb9-fcf6-4800-bab6-aac9885b0af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_91c3b7d8-8a93-492d-a680-e6925dfac751" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b089e300-9021-4a53-99e7-ccc94921eee9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_91c3b7d8-8a93-492d-a680-e6925dfac751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd5770de-0c59-4d78-85c9-2e9f31eb31e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b0129f97-adc3-4476-ae34-dca7869eb2fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd5770de-0c59-4d78-85c9-2e9f31eb31e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2636ff44-9dfc-485f-997b-3def665bc7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c110b610-905c-48df-87b4-9b0d230889a4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2636ff44-9dfc-485f-997b-3def665bc7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4dc02fbb-7e17-404f-b60c-bdd962c2dc20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2636ff44-9dfc-485f-997b-3def665bc7d9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4dc02fbb-7e17-404f-b60c-bdd962c2dc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1df07978-3287-4f79-b4e4-33e45538a7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2636ff44-9dfc-485f-997b-3def665bc7d9" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1df07978-3287-4f79-b4e4-33e45538a7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_af5bdd9b-cccf-4f99-b52c-6d7c3fbe51b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2636ff44-9dfc-485f-997b-3def665bc7d9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_af5bdd9b-cccf-4f99-b52c-6d7c3fbe51b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a2f511af-6410-448d-b753-beabf224b5fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2636ff44-9dfc-485f-997b-3def665bc7d9" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a2f511af-6410-448d-b753-beabf224b5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4be54c9-edf0-43c3-99ce-db7769495f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2636ff44-9dfc-485f-997b-3def665bc7d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4be54c9-edf0-43c3-99ce-db7769495f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c110b610-905c-48df-87b4-9b0d230889a4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_e1985b79-219b-446e-92ae-f5c83f890607" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_e1985b79-219b-446e-92ae-f5c83f890607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_1afcd6d2-8efd-45a0-b174-0e7d0cb0b91f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_1afcd6d2-8efd-45a0-b174-0e7d0cb0b91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_496fe5c3-d395-4509-98c7-85e4efa81019" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_496fe5c3-d395-4509-98c7-85e4efa81019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e3a821f0-e11e-437c-b521-70e6b8a86f34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e3a821f0-e11e-437c-b521-70e6b8a86f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_840a3ad6-76bb-4b60-9722-3d13a4066a44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_840a3ad6-76bb-4b60-9722-3d13a4066a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_07d6b000-2408-4563-88be-2387b4058bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_07d6b000-2408-4563-88be-2387b4058bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a4b50e5-1528-44af-a439-f1b950607890" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a4b50e5-1528-44af-a439-f1b950607890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8652eb66-c0b4-46c7-9ec9-68ef2f9ca25a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_8652eb66-c0b4-46c7-9ec9-68ef2f9ca25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cfc02906-a9d9-45a9-bba4-b078310b16b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cfc02906-a9d9-45a9-bba4-b078310b16b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d1b180a-e0d0-4db7-9074-9acca837e694" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d1b180a-e0d0-4db7-9074-9acca837e694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_419f87bb-c3ed-4f08-8448-0829a0b1ae91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28d02812-c1d4-4277-adce-4a284cb87bff" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_419f87bb-c3ed-4f08-8448-0829a0b1ae91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20190331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c24d4d38-bac7-404e-be41-6badccfc860f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e968383c-5f5a-4c77-ac92-7ca3e911a196" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c24d4d38-bac7-404e-be41-6badccfc860f" xlink:to="loc_us-gaap_StatementTable_e968383c-5f5a-4c77-ac92-7ca3e911a196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a14e8257-c855-43f4-9459-cd4a47439236" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e968383c-5f5a-4c77-ac92-7ca3e911a196" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a14e8257-c855-43f4-9459-cd4a47439236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_698765a8-d1c3-4536-88d5-12da9c4febb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a14e8257-c855-43f4-9459-cd4a47439236" xlink:to="loc_us-gaap_EquityComponentDomain_698765a8-d1c3-4536-88d5-12da9c4febb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1155dd0e-f9a5-424e-a069-508513784ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_698765a8-d1c3-4536-88d5-12da9c4febb4" xlink:to="loc_us-gaap_CommonStockMember_1155dd0e-f9a5-424e-a069-508513784ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_da4359ed-9adb-4f89-ac9c-70ce962d3bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_698765a8-d1c3-4536-88d5-12da9c4febb4" xlink:to="loc_us-gaap_RetainedEarningsMember_da4359ed-9adb-4f89-ac9c-70ce962d3bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_31058a09-2acb-4a50-b699-46dfead0b948" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_698765a8-d1c3-4536-88d5-12da9c4febb4" xlink:to="loc_us-gaap_NoncontrollingInterestMember_31058a09-2acb-4a50-b699-46dfead0b948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1f7fc55d-35de-4b75-bb7c-29694da9c9da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e968383c-5f5a-4c77-ac92-7ca3e911a196" xlink:to="loc_us-gaap_StatementLineItems_1f7fc55d-35de-4b75-bb7c-29694da9c9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f7fc55d-35de-4b75-bb7c-29694da9c9da" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff4fb30c-456c-4209-9bfa-63480c3ffa5e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff4fb30c-456c-4209-9bfa-63480c3ffa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_70913487-90ff-4982-85ff-5bc618d46248" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_70913487-90ff-4982-85ff-5bc618d46248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5d94a763-19dd-4340-9489-a0e888dea6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5d94a763-19dd-4340-9489-a0e888dea6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76327771-8d41-4682-8fee-2b8c2ae3aace" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_76327771-8d41-4682-8fee-2b8c2ae3aace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8ab95128-3ae1-4a1a-a7ef-6a2496ba277c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8ab95128-3ae1-4a1a-a7ef-6a2496ba277c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6647cba5-e268-47d4-8ada-960b9f298c9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6647cba5-e268-47d4-8ada-960b9f298c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f8231aea-6798-45a4-8701-8b32f98c0f99" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f8231aea-6798-45a4-8701-8b32f98c0f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_151894f3-944c-4cd5-9237-838e1e2653bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_151894f3-944c-4cd5-9237-838e1e2653bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c362f4e9-b321-4a33-8e51-3aea17e37d96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_ProfitLoss_c362f4e9-b321-4a33-8e51-3aea17e37d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6db6bb9a-45a7-4bc2-99a1-60b4c4777226" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6db6bb9a-45a7-4bc2-99a1-60b4c4777226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9f1c0f02-8f34-46ff-b3a6-0f6b955d5dda" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_520e4ac8-1621-416b-b5d8-ae5544d1e473" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9f1c0f02-8f34-46ff-b3a6-0f6b955d5dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20190331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66ed5470-16d7-4d12-8ed6-84fbc3a0164b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1fa692b5-b6f1-4472-9698-dc449b29c9b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66ed5470-16d7-4d12-8ed6-84fbc3a0164b" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1fa692b5-b6f1-4472-9698-dc449b29c9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20190331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a3646bc-51d7-4abf-8a31-168e9b9adb20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5b136bb3-0ef6-4685-aefe-d0300f1051c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a3646bc-51d7-4abf-8a31-168e9b9adb20" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5b136bb3-0ef6-4685-aefe-d0300f1051c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_8f800e89-728a-4ffa-8dc9-6fcda31b9bce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a3646bc-51d7-4abf-8a31-168e9b9adb20" xlink:to="loc_us-gaap_UseOfEstimates_8f800e89-728a-4ffa-8dc9-6fcda31b9bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ba11bb90-3be4-4bac-96cb-1b07e45cc2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a3646bc-51d7-4abf-8a31-168e9b9adb20" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ba11bb90-3be4-4bac-96cb-1b07e45cc2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aa653b6e-5faf-49c9-b338-8e531db7ce2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_babd4958-22c6-4bcd-8f63-fb7cfe7a3316" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aa653b6e-5faf-49c9-b338-8e531db7ce2b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_babd4958-22c6-4bcd-8f63-fb7cfe7a3316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="simple" xlink:href="cpix-20190331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a28986f3-452e-4466-ab27-d995628ae9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1077f56c-6752-4c0a-a65c-4c17b1fb98f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a28986f3-452e-4466-ab27-d995628ae9d6" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1077f56c-6752-4c0a-a65c-4c17b1fb98f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3bbdcf08-5170-4cc5-9851-475331cf8cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4ee64aee-7747-49a9-b05c-302b7b2715e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3bbdcf08-5170-4cc5-9851-475331cf8cf6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4ee64aee-7747-49a9-b05c-302b7b2715e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eaf779ad-5fc3-427b-ae33-b6a97067f427" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_55bcb790-4fbe-46d5-bb6a-aaa4babe887d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eaf779ad-5fc3-427b-ae33-b6a97067f427" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_55bcb790-4fbe-46d5-bb6a-aaa4babe887d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37546177-e417-4ebb-92a5-6580118c5334" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_55bcb790-4fbe-46d5-bb6a-aaa4babe887d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37546177-e417-4ebb-92a5-6580118c5334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9900a21-efb4-476d-a97d-c5f1c326ea64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37546177-e417-4ebb-92a5-6580118c5334" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9900a21-efb4-476d-a97d-c5f1c326ea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_45947d58-4746-4c84-801f-d7bba503bc63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9900a21-efb4-476d-a97d-c5f1c326ea64" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_45947d58-4746-4c84-801f-d7bba503bc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0d913b95-7e0b-45a6-9d43-1204b2c69b53" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9900a21-efb4-476d-a97d-c5f1c326ea64" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0d913b95-7e0b-45a6-9d43-1204b2c69b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7f3e506f-2d77-4f6d-b2b2-30fe9336609a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_55bcb790-4fbe-46d5-bb6a-aaa4babe887d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7f3e506f-2d77-4f6d-b2b2-30fe9336609a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7f3e506f-2d77-4f6d-b2b2-30fe9336609a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_72cf4479-2fdb-4ba4-b227-414f0c356c1d" xlink:href="cpix-20190331.xsd#cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:to="loc_cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember_72cf4479-2fdb-4ba4-b227-414f0c356c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_768d054c-1bb1-44e6-a7ca-2012aa0aaca3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_768d054c-1bb1-44e6-a7ca-2012aa0aaca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cd6b3a15-a01c-4416-b2b8-23f5fc7530e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:to="loc_us-gaap_CommercialPaperMember_cd6b3a15-a01c-4416-b2b8-23f5fc7530e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_c4cd738a-a328-4e98-a9e7-6471cb57e742" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e5ce713-1092-4921-8923-d1f9b5315a54" xlink:to="loc_us-gaap_MunicipalBondsMember_c4cd738a-a328-4e98-a9e7-6471cb57e742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bcb6668b-ea0a-4a6b-9e25-6f002b27a1c7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_55bcb790-4fbe-46d5-bb6a-aaa4babe887d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bcb6668b-ea0a-4a6b-9e25-6f002b27a1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_1ad290ae-e236-44a2-86dc-44db5d007cee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bcb6668b-ea0a-4a6b-9e25-6f002b27a1c7" xlink:to="loc_us-gaap_TradingSecurities_1ad290ae-e236-44a2-86dc-44db5d007cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20190331.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_969f20ba-7d3b-47ae-9947-88dad433555a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_15eb9817-76a0-429b-8f44-3dd26cbb4b62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_969f20ba-7d3b-47ae-9947-88dad433555a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_15eb9817-76a0-429b-8f44-3dd26cbb4b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0d5ae47b-f869-4658-977f-21dc3bb03954" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f4697cc1-51bb-4df6-944f-d40758d69630" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d5ae47b-f869-4658-977f-21dc3bb03954" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f4697cc1-51bb-4df6-944f-d40758d69630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7aec9c99-21a7-4861-ba4e-18746b5c1d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_2aac6555-1c05-4347-b4b0-a720a37efaae" xlink:href="cpix-20190331.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7aec9c99-21a7-4861-ba4e-18746b5c1d3f" xlink:to="loc_cpix_NumeratorAbstract_2aac6555-1c05-4347-b4b0-a720a37efaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_36f264b6-574f-459b-a023-6068ec52e691" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_2aac6555-1c05-4347-b4b0-a720a37efaae" xlink:to="loc_us-gaap_NetIncomeLoss_36f264b6-574f-459b-a023-6068ec52e691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_ec359566-d121-42b9-9c24-9692ed34f97e" xlink:href="cpix-20190331.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7aec9c99-21a7-4861-ba4e-18746b5c1d3f" xlink:to="loc_cpix_DenominatorAbstract_ec359566-d121-42b9-9c24-9692ed34f97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9d022864-163c-4022-ac40-6cf3131d0866" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_ec359566-d121-42b9-9c24-9692ed34f97e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9d022864-163c-4022-ac40-6cf3131d0866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c3e2bce3-63b4-4538-a5e2-8560f1f08158" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_ec359566-d121-42b9-9c24-9692ed34f97e" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c3e2bce3-63b4-4538-a5e2-8560f1f08158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_901df8f7-9799-4a0e-9969-e175210ce51a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_ec359566-d121-42b9-9c24-9692ed34f97e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_901df8f7-9799-4a0e-9969-e175210ce51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20190331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_04ef2cfe-b698-4737-b7c3-eca1fd660b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5ae40797-6f60-456a-905b-dccedce67fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_04ef2cfe-b698-4737-b7c3-eca1fd660b2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5ae40797-6f60-456a-905b-dccedce67fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20190331.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d3099d64-d07a-40e3-987b-7dacd660b488" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1efaaeef-9341-450f-8cb5-0203d5a60683" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d3099d64-d07a-40e3-987b-7dacd660b488" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1efaaeef-9341-450f-8cb5-0203d5a60683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2079cc59-9322-4b24-893e-dc1bf93c18a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_a6bfdae1-723e-4be2-8c00-72342203cc9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2079cc59-9322-4b24-893e-dc1bf93c18a7" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_a6bfdae1-723e-4be2-8c00-72342203cc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_46e695d1-dec3-4c17-8dbf-6f3a10b6f105" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b97a5708-97e6-4c9f-a5ee-991b08be8b77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_46e695d1-dec3-4c17-8dbf-6f3a10b6f105" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b97a5708-97e6-4c9f-a5ee-991b08be8b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ddc3bfd9-559c-4418-9d93-faf3067c7c29" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b97a5708-97e6-4c9f-a5ee-991b08be8b77" xlink:to="loc_srt_ProductOrServiceAxis_ddc3bfd9-559c-4418-9d93-faf3067c7c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ddc3bfd9-559c-4418-9d93-faf3067c7c29" xlink:to="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_b19a88d1-3793-4e56-920a-ac2a9e1ab38b" xlink:href="cpix-20190331.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_AcetadoteMember_b19a88d1-3793-4e56-920a-ac2a9e1ab38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_68896ef2-15d9-45ce-ba80-9f7812abaefe" xlink:href="cpix-20190331.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_OmeclamoxPakMember_68896ef2-15d9-45ce-ba80-9f7812abaefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_74a53791-e04b-4858-b24a-0f3ec71d8f53" xlink:href="cpix-20190331.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_KristaloseMember_74a53791-e04b-4858-b24a-0f3ec71d8f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_f57b1783-56f5-4f6b-b121-b663c39accfa" xlink:href="cpix-20190331.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_VaprisolMember_f57b1783-56f5-4f6b-b121-b663c39accfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_dfb76063-0de3-475f-a00c-7f711147d52e" xlink:href="cpix-20190331.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_CaldolorMember_dfb76063-0de3-475f-a00c-7f711147d52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EthyolMember_3630840a-f977-4f3f-bfc3-7b87c8c70ed8" xlink:href="cpix-20190331.xsd#cpix_EthyolMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_EthyolMember_3630840a-f977-4f3f-bfc3-7b87c8c70ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TotectMember_ddd80d07-1457-461e-85ca-8a6d85ffb188" xlink:href="cpix-20190331.xsd#cpix_TotectMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_TotectMember_ddd80d07-1457-461e-85ca-8a6d85ffb188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_61f94fe6-537e-4ffc-91a5-3aa216c25ba6" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_VIBATIVMember_61f94fe6-537e-4ffc-91a5-3aa216c25ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_19c8da97-9989-441c-8415-e8de9c3694ba" xlink:href="cpix-20190331.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e4d25b5-955c-4cb5-b4ba-8a2e3bfc4e82" xlink:to="loc_cpix_OtherProductsMember_19c8da97-9989-441c-8415-e8de9c3694ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3c26a009-c35b-4278-8e04-575f347614e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_b97a5708-97e6-4c9f-a5ee-991b08be8b77" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3c26a009-c35b-4278-8e04-575f347614e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f76caa30-969a-4a54-b493-d2f42823ebc0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3c26a009-c35b-4278-8e04-575f347614e3" xlink:to="loc_us-gaap_RevenuesAbstract_f76caa30-969a-4a54-b493-d2f42823ebc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_fbecc698-388e-4240-8deb-8bd8b1f2a672" xlink:href="cpix-20190331.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f76caa30-969a-4a54-b493-d2f42823ebc0" xlink:to="loc_cpix_ProductsAbstract_fbecc698-388e-4240-8deb-8bd8b1f2a672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6a2f11e-e760-4d2e-9fad-aca70f546457" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_fbecc698-388e-4240-8deb-8bd8b1f2a672" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d6a2f11e-e760-4d2e-9fad-aca70f546457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20190331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_28afdfb4-3bd8-4148-b108-28abc82a86e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_77acdba3-882c-425f-be62-ba8de5d41717" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_28afdfb4-3bd8-4148-b108-28abc82a86e2" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_77acdba3-882c-425f-be62-ba8de5d41717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8cfdd751-3c31-4717-89a0-6c630da6cf4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_52e97557-7ad3-42be-a3e0-6ba4c03080b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8cfdd751-3c31-4717-89a0-6c630da6cf4c" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_52e97557-7ad3-42be-a3e0-6ba4c03080b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_db9f20b3-869b-4cf4-81ae-5fdfe1497698" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_96b3b47b-6598-40f3-b12d-9e4d228cc922" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_db9f20b3-869b-4cf4-81ae-5fdfe1497698" xlink:to="loc_us-gaap_InventoryCurrentTable_96b3b47b-6598-40f3-b12d-9e4d228cc922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b7ceb51e-fc0a-4fec-9cfd-47c2dff1cde9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_96b3b47b-6598-40f3-b12d-9e4d228cc922" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b7ceb51e-fc0a-4fec-9cfd-47c2dff1cde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eaba3056-ce1d-4307-bec3-6b402599befb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b7ceb51e-fc0a-4fec-9cfd-47c2dff1cde9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eaba3056-ce1d-4307-bec3-6b402599befb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_c0e91b2f-ede1-43c5-801a-61dcda78c4df" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eaba3056-ce1d-4307-bec3-6b402599befb" xlink:to="loc_cpix_VIBATIVMember_c0e91b2f-ede1-43c5-801a-61dcda78c4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_301a27e6-ac7b-44bf-b7c8-61fa0d9622e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_96b3b47b-6598-40f3-b12d-9e4d228cc922" xlink:to="loc_us-gaap_InventoryLineItems_301a27e6-ac7b-44bf-b7c8-61fa0d9622e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_22fc4358-dd15-4505-a25f-cf14cfc333d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_301a27e6-ac7b-44bf-b7c8-61fa0d9622e8" xlink:to="loc_us-gaap_InventoryValuationReserves_22fc4358-dd15-4505-a25f-cf14cfc333d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b76d2d54-b899-4d1c-b1ad-210972e8853a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_301a27e6-ac7b-44bf-b7c8-61fa0d9622e8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b76d2d54-b899-4d1c-b1ad-210972e8853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_39909bf3-2bed-4aa5-8880-ce67b93da017" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_301a27e6-ac7b-44bf-b7c8-61fa0d9622e8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_39909bf3-2bed-4aa5-8880-ce67b93da017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_da97c77c-dd3d-4f9f-8fcd-a0cb93b11f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_fd8fdaf9-e4e5-4c55-a4a9-9cfe9d69ef94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_da97c77c-dd3d-4f9f-8fcd-a0cb93b11f9d" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_fd8fdaf9-e4e5-4c55-a4a9-9cfe9d69ef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_08173c76-6fd8-4925-9a65-e1d251612b63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_fd8fdaf9-e4e5-4c55-a4a9-9cfe9d69ef94" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_08173c76-6fd8-4925-9a65-e1d251612b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_d1eb11ab-4ada-4992-9752-4c4000ffc335" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_fd8fdaf9-e4e5-4c55-a4a9-9cfe9d69ef94" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_d1eb11ab-4ada-4992-9752-4c4000ffc335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_15545e9c-33d4-40aa-872e-0f0ba5859dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_fd8fdaf9-e4e5-4c55-a4a9-9cfe9d69ef94" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_15545e9c-33d4-40aa-872e-0f0ba5859dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_38c35157-443b-4b24-93c9-014a01d046f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_fd8fdaf9-e4e5-4c55-a4a9-9cfe9d69ef94" xlink:to="loc_us-gaap_InventoryGross_38c35157-443b-4b24-93c9-014a01d046f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_4f085738-9591-422d-97bc-2c392b3c2c39" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_fd8fdaf9-e4e5-4c55-a4a9-9cfe9d69ef94" xlink:to="loc_us-gaap_InventoryNoncurrent_4f085738-9591-422d-97bc-2c392b3c2c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_586301eb-4c3f-468e-9c13-4ca2db973dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_fd8fdaf9-e4e5-4c55-a4a9-9cfe9d69ef94" xlink:to="loc_us-gaap_InventoryNet_586301eb-4c3f-468e-9c13-4ca2db973dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20190331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_45a8cbcb-ff16-4c4c-a9b9-82b56d251b08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_65862986-03d6-4f46-8606-f0e1f6dcb7c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45a8cbcb-ff16-4c4c-a9b9-82b56d251b08" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_65862986-03d6-4f46-8606-f0e1f6dcb7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_783119d3-fce1-4b9c-b34a-45883b9a7b75" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_2d8f9d8b-a87f-4354-8271-a150f708f866" xlink:href="cpix-20190331.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_783119d3-fce1-4b9c-b34a-45883b9a7b75" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_2d8f9d8b-a87f-4354-8271-a150f708f866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_02bc6833-9ffe-4391-9330-c5b4c5c63749" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_783119d3-fce1-4b9c-b34a-45883b9a7b75" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_02bc6833-9ffe-4391-9330-c5b4c5c63749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_fb5a128f-1d75-4cac-a37b-ffa4b0e8bb1d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_783119d3-fce1-4b9c-b34a-45883b9a7b75" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_fb5a128f-1d75-4cac-a37b-ffa4b0e8bb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_80ad4c6a-62a4-471f-b575-659471698cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cd5007d2-1eb3-44ae-9a9f-8066d4daea2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80ad4c6a-62a4-471f-b575-659471698cf2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cd5007d2-1eb3-44ae-9a9f-8066d4daea2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c0895f05-f7e4-491d-9194-03f9a15c6c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80ad4c6a-62a4-471f-b575-659471698cf2" xlink:to="loc_us-gaap_OperatingLeaseLiability_c0895f05-f7e4-491d-9194-03f9a15c6c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_717ca717-08f2-4e60-b730-aa8b8cfc823e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80ad4c6a-62a4-471f-b575-659471698cf2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_717ca717-08f2-4e60-b730-aa8b8cfc823e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_177e0ac8-992a-45ff-b077-09fb0b39ec91" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80ad4c6a-62a4-471f-b575-659471698cf2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_177e0ac8-992a-45ff-b077-09fb0b39ec91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6397fcdd-6a0b-4118-9191-7cc40d3b1898" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e8f8bd4-227e-43c3-a3eb-dc372ce15294" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6397fcdd-6a0b-4118-9191-7cc40d3b1898" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e8f8bd4-227e-43c3-a3eb-dc372ce15294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseAsset_1b768e7a-dab1-4182-9c48-c8a803d8bfb8" xlink:href="cpix-20190331.xsd#cpix_LeaseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6397fcdd-6a0b-4118-9191-7cc40d3b1898" xlink:to="loc_cpix_LeaseAsset_1b768e7a-dab1-4182-9c48-c8a803d8bfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae321f70-ea59-4629-a3c5-646151bd4bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6397fcdd-6a0b-4118-9191-7cc40d3b1898" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ae321f70-ea59-4629-a3c5-646151bd4bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_37427afb-2a24-46d6-aa5d-8b3ba9fad0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6397fcdd-6a0b-4118-9191-7cc40d3b1898" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_37427afb-2a24-46d6-aa5d-8b3ba9fad0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_1d67d0fb-53ed-4b53-a080-3201d6fb2f26" xlink:href="cpix-20190331.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6397fcdd-6a0b-4118-9191-7cc40d3b1898" xlink:to="loc_cpix_LeaseLiability_1d67d0fb-53ed-4b53-a080-3201d6fb2f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3714f93f-1753-44fe-9475-f17c74313013" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3714f93f-1753-44fe-9475-f17c74313013" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d59b6aca-3150-4c33-bbbb-2d30517cba2f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d59b6aca-3150-4c33-bbbb-2d30517cba2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c7fe2282-eb37-4320-a8d0-8069f400a2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c7fe2282-eb37-4320-a8d0-8069f400a2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a4bcd7f4-ba0b-42e6-ba6d-4420e428b64f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a4bcd7f4-ba0b-42e6-ba6d-4420e428b64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16e11a1e-aafd-41b5-949d-f9d29e436efe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16e11a1e-aafd-41b5-949d-f9d29e436efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_18e7b3ef-209a-4216-be5d-089df2461220" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_18e7b3ef-209a-4216-be5d-089df2461220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5eaa8d14-07cd-4096-b394-db9ff628cab4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5eaa8d14-07cd-4096-b394-db9ff628cab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_02567250-7ebe-43fe-802f-756a0ce53da9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_02567250-7ebe-43fe-802f-756a0ce53da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f73daf57-0760-45a1-a206-e0837a720a97" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f73daf57-0760-45a1-a206-e0837a720a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e57ca9a0-f692-4008-9d97-e9fd0fc61bac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_27ad01d9-eb9d-48e2-9ae3-019548bca191" xlink:to="loc_us-gaap_OperatingLeaseLiability_e57ca9a0-f692-4008-9d97-e9fd0fc61bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3a7c6698-52b9-47f6-af52-03924659d11f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3714f93f-1753-44fe-9475-f17c74313013" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3a7c6698-52b9-47f6-af52-03924659d11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_07318c44-7902-4649-8f77-6044baa59215" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3a7c6698-52b9-47f6-af52-03924659d11f" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_07318c44-7902-4649-8f77-6044baa59215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_be240de9-0421-4167-aed6-486367fe7b35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3a7c6698-52b9-47f6-af52-03924659d11f" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_be240de9-0421-4167-aed6-486367fe7b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_ab05fb7a-46c1-44b0-80cd-dbd71dfb43ec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3a7c6698-52b9-47f6-af52-03924659d11f" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_ab05fb7a-46c1-44b0-80cd-dbd71dfb43ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_a005c252-98ae-4bd8-b317-685eb53a9e33" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3a7c6698-52b9-47f6-af52-03924659d11f" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_a005c252-98ae-4bd8-b317-685eb53a9e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_92f1e1f9-3f8d-47c9-8731-a6e99e7e0568" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3a7c6698-52b9-47f6-af52-03924659d11f" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_92f1e1f9-3f8d-47c9-8731-a6e99e7e0568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_5a13cc3f-dd89-4d31-815e-84d505d3f1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3a7c6698-52b9-47f6-af52-03924659d11f" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_5a13cc3f-dd89-4d31-815e-84d505d3f1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_00d46fd7-9354-490a-a077-e3d41365564f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_3a7c6698-52b9-47f6-af52-03924659d11f" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_00d46fd7-9354-490a-a077-e3d41365564f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20190331.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_e3bd8840-8103-4629-bdf7-c15c3b3dfaa8" xlink:href="cpix-20190331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22a2bcc1-a98d-4093-8de6-7825a96f65a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_e3bd8840-8103-4629-bdf7-c15c3b3dfaa8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22a2bcc1-a98d-4093-8de6-7825a96f65a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_7dbc0da9-4d5d-40ad-addb-849f645eced4" xlink:href="cpix-20190331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_7dbc0da9-4d5d-40ad-addb-849f645eced4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f81bf5f6-176a-4ccb-b201-0e1b0ef2c23c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f81bf5f6-176a-4ccb-b201-0e1b0ef2c23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_72fd2f65-751b-4fb2-905d-7ad83fd2ac41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f81bf5f6-176a-4ccb-b201-0e1b0ef2c23c" xlink:to="loc_us-gaap_EquityComponentDomain_72fd2f65-751b-4fb2-905d-7ad83fd2ac41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3d63238d-d8de-49c0-b5e8-411d7abcff2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_72fd2f65-751b-4fb2-905d-7ad83fd2ac41" xlink:to="loc_us-gaap_CommonStockMember_3d63238d-d8de-49c0-b5e8-411d7abcff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_544f6be9-39dc-42a9-b22e-89a568e1f9f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:to="loc_us-gaap_TitleOfIndividualAxis_544f6be9-39dc-42a9-b22e-89a568e1f9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1b7ac758-e14c-45b8-b219-1f1c0c7e9f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_544f6be9-39dc-42a9-b22e-89a568e1f9f6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1b7ac758-e14c-45b8-b219-1f1c0c7e9f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_1a202db2-4e11-45a2-8fcb-4296bfa8fcf1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1b7ac758-e14c-45b8-b219-1f1c0c7e9f8b" xlink:to="loc_us-gaap_DirectorMember_1a202db2-4e11-45a2-8fcb-4296bfa8fcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6a3c0f87-2494-4c01-9593-479922100fab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:to="loc_us-gaap_AwardTypeAxis_6a3c0f87-2494-4c01-9593-479922100fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ed01204-1085-45c5-b9fc-b4c89bc7479d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6a3c0f87-2494-4c01-9593-479922100fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ed01204-1085-45c5-b9fc-b4c89bc7479d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_535474ac-af48-4a9c-bb44-4d12b76f33b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ed01204-1085-45c5-b9fc-b4c89bc7479d" xlink:to="loc_us-gaap_RestrictedStockMember_535474ac-af48-4a9c-bb44-4d12b76f33b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6e3940-79e1-4471-8cfd-3aff283e32fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4473421-9cff-4c41-b296-6d29afd1bd01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6e3940-79e1-4471-8cfd-3aff283e32fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:href="cpix-20190331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c6e3940-79e1-4471-8cfd-3aff283e32fb" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_618471fd-670c-4531-a78a-a8e28557ebb6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_618471fd-670c-4531-a78a-a8e28557ebb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_69bdb6d2-fcbd-4bb5-965f-2471258d1e38" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_69bdb6d2-fcbd-4bb5-965f-2471258d1e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_d70c3870-2411-4fe9-aa2e-a512b21e4402" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_d70c3870-2411-4fe9-aa2e-a512b21e4402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_7114983d-4f7a-4be0-a750-1344f871df0d" xlink:href="cpix-20190331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_7114983d-4f7a-4be0-a750-1344f871df0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_b854247f-6e91-464e-8488-6d639dfc6fc8" xlink:href="cpix-20190331.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding_b854247f-6e91-464e-8488-6d639dfc6fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7407d50c-38a3-44cd-b417-80047c29c9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7407d50c-38a3-44cd-b417-80047c29c9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fc18d35e-3d25-47f5-b8ad-cebb6ece39b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fc18d35e-3d25-47f5-b8ad-cebb6ece39b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6cc45944-f168-48b9-a04e-9a0f1a21231f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6cc45944-f168-48b9-a04e-9a0f1a21231f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a55ebfcb-2e3e-40db-87da-6846265b1323" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_6b69c233-6605-4c9c-a42c-678be779062d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a55ebfcb-2e3e-40db-87da-6846265b1323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_dbe763bb-761a-49f6-b6a3-f78deb05e224" xlink:href="cpix-20190331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_dbe763bb-761a-49f6-b6a3-f78deb05e224" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_33917baf-2147-43bd-9106-fa6c9a852e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_33917baf-2147-43bd-9106-fa6c9a852e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_4d5cd665-4b1b-42ce-8f89-f5de83c36620" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_33917baf-2147-43bd-9106-fa6c9a852e1d" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_4d5cd665-4b1b-42ce-8f89-f5de83c36620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_204ccec0-e745-43db-9f99-05b9c26c36a7" xlink:href="cpix-20190331.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_4d5cd665-4b1b-42ce-8f89-f5de83c36620" xlink:to="loc_cpix_PinnacleBankMember_204ccec0-e745-43db-9f99-05b9c26c36a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_57c6b141-481d-4e0e-9a72-19dd649466a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:to="loc_us-gaap_DebtInstrumentAxis_57c6b141-481d-4e0e-9a72-19dd649466a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c5453363-d1b4-4102-be56-4b2686171ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_57c6b141-481d-4e0e-9a72-19dd649466a1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c5453363-d1b4-4102-be56-4b2686171ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_3138fcfc-b273-4475-acbd-a3e862dfb811" xlink:href="cpix-20190331.xsd#cpix_SecondAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5453363-d1b4-4102-be56-4b2686171ff0" xlink:to="loc_cpix_SecondAmendmentMember_3138fcfc-b273-4475-acbd-a3e862dfb811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_5008e804-78ca-4c3b-a579-05b746de336f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5453363-d1b4-4102-be56-4b2686171ff0" xlink:to="loc_us-gaap_LineOfCreditMember_5008e804-78ca-4c3b-a579-05b746de336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_486fd79b-1617-46ef-b24a-6803302bd49b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:to="loc_us-gaap_CreditFacilityAxis_486fd79b-1617-46ef-b24a-6803302bd49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ee2df373-c04e-4d6d-9383-a00e16abf7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_486fd79b-1617-46ef-b24a-6803302bd49b" xlink:to="loc_us-gaap_CreditFacilityDomain_ee2df373-c04e-4d6d-9383-a00e16abf7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_fa118156-ae23-4f83-8679-c6c584d77b4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ee2df373-c04e-4d6d-9383-a00e16abf7d2" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_fa118156-ae23-4f83-8679-c6c584d77b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7c04d1e-56b9-4af6-8e97-01d94aa8bf26" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:to="loc_srt_RangeAxis_e7c04d1e-56b9-4af6-8e97-01d94aa8bf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d876ad8-16ec-422b-b81a-6182576f70e1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e7c04d1e-56b9-4af6-8e97-01d94aa8bf26" xlink:to="loc_srt_RangeMember_1d876ad8-16ec-422b-b81a-6182576f70e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_80aae8dd-d6c5-4b56-8606-16710433c938" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1d876ad8-16ec-422b-b81a-6182576f70e1" xlink:to="loc_srt_MinimumMember_80aae8dd-d6c5-4b56-8606-16710433c938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5f6046af-9568-4e54-8af1-1872db34b632" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1d876ad8-16ec-422b-b81a-6182576f70e1" xlink:to="loc_srt_MaximumMember_5f6046af-9568-4e54-8af1-1872db34b632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7217e461-b735-45d6-ae41-a9213418f257" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4579fad3-863f-4cbb-9445-6efc6c84b0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4579fad3-863f-4cbb-9445-6efc6c84b0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_0b576677-8ec3-4a4b-87ca-8fe6fcc62d59" xlink:href="cpix-20190331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_0b576677-8ec3-4a4b-87ca-8fe6fcc62d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_1ec50071-e3e4-44a7-a258-91c9f1aa76a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_LongTermLineOfCredit_1ec50071-e3e4-44a7-a258-91c9f1aa76a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ba46ca07-0c0b-434d-b609-e25c6e11b939" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ba46ca07-0c0b-434d-b609-e25c6e11b939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_49840887-37e7-4955-b48e-74316e520c70" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_49840887-37e7-4955-b48e-74316e520c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_d38554d0-6ef3-4d42-998c-3acd831be58c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e3c1cd4a-3d10-41ed-b719-93969a10240a" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_d38554d0-6ef3-4d42-998c-3acd831be58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20190331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_771f93b0-cdca-433f-8e7a-74a8c1284808" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ebe8a5af-86fd-4939-ba9d-2d85d5ef360e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_771f93b0-cdca-433f-8e7a-74a8c1284808" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_ebe8a5af-86fd-4939-ba9d-2d85d5ef360e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20190331.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_34c08a93-cc73-4b18-9fdd-89000749de65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_d649ce50-01f1-4ec7-9991-4fb78f872879" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_34c08a93-cc73-4b18-9fdd-89000749de65" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_d649ce50-01f1-4ec7-9991-4fb78f872879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20190331.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84a19f21-bc46-4f63-804a-6f33f3ead1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_bd91b6da-340e-4ee9-a1cb-e9e8842f4cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84a19f21-bc46-4f63-804a-6f33f3ead1bd" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_bd91b6da-340e-4ee9-a1cb-e9e8842f4cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditions" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditions"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_95493ade-0e4b-44be-ba10-552a5049602c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_003d4bfe-156a-46ed-9553-1acbc4f0bf44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_95493ade-0e4b-44be-ba10-552a5049602c" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_003d4bfe-156a-46ed-9553-1acbc4f0bf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsTables" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f3badcc0-7e58-4f3a-8a7a-026eddec6fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_70bcb950-e61a-4528-8dd9-e2a9d29eee4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f3badcc0-7e58-4f3a-8a7a-026eddec6fbf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_70bcb950-e61a-4528-8dd9-e2a9d29eee4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_8a6059f8-4e89-4522-90cb-35ed4dcc851c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f3badcc0-7e58-4f3a-8a7a-026eddec6fbf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_8a6059f8-4e89-4522-90cb-35ed4dcc851c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_56ec8a13-3860-4902-924f-33021ff562f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f3badcc0-7e58-4f3a-8a7a-026eddec6fbf" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_56ec8a13-3860-4902-924f-33021ff562f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f9e27eb6-b77b-4455-96e1-f1ef93c32267" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f9e27eb6-b77b-4455-96e1-f1ef93c32267" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f648fd71-51e5-4f7b-81cd-6d27319081ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f648fd71-51e5-4f7b-81cd-6d27319081ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4567080e-a074-4e29-ad0d-79762543b6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f648fd71-51e5-4f7b-81cd-6d27319081ff" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4567080e-a074-4e29-ad0d-79762543b6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d58bf5bc-b269-48fa-97a0-f5812fb39b83" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4567080e-a074-4e29-ad0d-79762543b6dc" xlink:to="loc_cpix_VIBATIVMember_d58bf5bc-b269-48fa-97a0-f5812fb39b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d5acba45-08f1-4057-88b8-89056f9fb670" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d5acba45-08f1-4057-88b8-89056f9fb670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7648aa5d-3a2f-49f7-a388-c8de0964164b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d5acba45-08f1-4057-88b8-89056f9fb670" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7648aa5d-3a2f-49f7-a388-c8de0964164b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_211c7299-b034-48ed-8d35-dac829e34101" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7648aa5d-3a2f-49f7-a388-c8de0964164b" xlink:to="loc_us-gaap_SubsequentEventMember_211c7299-b034-48ed-8d35-dac829e34101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a0dd6f6d-8eb2-46f8-a0b2-32cd8555d67f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a0dd6f6d-8eb2-46f8-a0b2-32cd8555d67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06300f95-cbd3-42d2-92ea-660d42b5b477" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a0dd6f6d-8eb2-46f8-a0b2-32cd8555d67f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06300f95-cbd3-42d2-92ea-660d42b5b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1b29c25b-c239-4218-b45d-d60e96b57509" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_06300f95-cbd3-42d2-92ea-660d42b5b477" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1b29c25b-c239-4218-b45d-d60e96b57509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_739a75ce-fbde-4b49-9575-43cab91b708c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForAssetAcquisitions_8eea3b03-4dca-46c6-9122-8a9914da20b8" xlink:href="cpix-20190331.xsd#cpix_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_cpix_PaymentsForAssetAcquisitions_8eea3b03-4dca-46c6-9122-8a9914da20b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_125f1d47-b6d9-4eba-b6b4-5bb05e96acf0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_125f1d47-b6d9-4eba-b6b4-5bb05e96acf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_261d8c10-8039-4f13-9441-a1408edd3f09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_261d8c10-8039-4f13-9441-a1408edd3f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_374e130d-ec0d-489c-901c-0a1f46243d85" xlink:href="cpix-20190331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_374e130d-ec0d-489c-901c-0a1f46243d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_31e68b64-b39c-42c9-adcb-601adeabac73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_31e68b64-b39c-42c9-adcb-601adeabac73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_953df45f-1a7b-4fe2-a638-aaee348c72e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35621cc3-0a4a-465a-8943-4f47283e312e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_953df45f-1a7b-4fe2-a638-aaee348c72e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1dc0a555-aab4-4fa6-aa2a-579719682c77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f69f2157-f92a-4a74-83cd-2f41d05d411e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1dc0a555-aab4-4fa6-aa2a-579719682c77" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f69f2157-f92a-4a74-83cd-2f41d05d411e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e361cca4-a8ea-47c3-b917-639d70d1c1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f69f2157-f92a-4a74-83cd-2f41d05d411e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e361cca4-a8ea-47c3-b917-639d70d1c1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d33ab-8f30-41d4-b8f2-09c6c003e396" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e361cca4-a8ea-47c3-b917-639d70d1c1c6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d33ab-8f30-41d4-b8f2-09c6c003e396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_2cbf89be-c6f1-4d3e-8ce0-03d861e7e94e" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d33ab-8f30-41d4-b8f2-09c6c003e396" xlink:to="loc_cpix_VIBATIVMember_2cbf89be-c6f1-4d3e-8ce0-03d861e7e94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f69f2157-f92a-4a74-83cd-2f41d05d411e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_360b0d64-b3cd-4527-a5ca-a4712ec17ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_360b0d64-b3cd-4527-a5ca-a4712ec17ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_43e844b4-ef8c-4c70-ba42-18cd8b81769a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_43e844b4-ef8c-4c70-ba42-18cd8b81769a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_69216203-06d3-4d3f-bf26-60afd13f5680" xlink:href="cpix-20190331.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:to="loc_cpix_PaymentsForContingentConsideration_69216203-06d3-4d3f-bf26-60afd13f5680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c3a8fe73-ba2e-4380-8a32-1177e0e1498f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_69faa822-f47a-480a-85da-e8cdcd627b31" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c3a8fe73-ba2e-4380-8a32-1177e0e1498f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsChangeinConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e4aaea1f-87ef-4dab-8d6f-780c709b02c2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fc900b09-f7f6-4244-8e4a-a8d9dc93adcc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e4aaea1f-87ef-4dab-8d6f-780c709b02c2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fc900b09-f7f6-4244-8e4a-a8d9dc93adcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_99b5de23-69c4-469d-a871-4a041244c444" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fc900b09-f7f6-4244-8e4a-a8d9dc93adcc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_99b5de23-69c4-469d-a871-4a041244c444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fdb6f83-f0e1-46dc-93a5-284b6a4f9db8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_99b5de23-69c4-469d-a871-4a041244c444" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fdb6f83-f0e1-46dc-93a5-284b6a4f9db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_32b1e0d6-96d0-4302-ac45-1671ce8f8c39" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fdb6f83-f0e1-46dc-93a5-284b6a4f9db8" xlink:to="loc_cpix_VIBATIVMember_32b1e0d6-96d0-4302-ac45-1671ce8f8c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3f29675d-7dca-44bc-a891-f57c7f515e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fc900b09-f7f6-4244-8e4a-a8d9dc93adcc" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3f29675d-7dca-44bc-a891-f57c7f515e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3f29675d-7dca-44bc-a891-f57c7f515e0d" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ac8c2bdc-b8c6-42a2-98f8-86d0c286a5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ac8c2bdc-b8c6-42a2-98f8-86d0c286a5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_08143da5-9d5e-449c-abc6-4b792d749c42" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_08143da5-9d5e-449c-abc6-4b792d749c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_05370d6e-fe2f-403e-88c1-cb82f4c89594" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_us-gaap_PaymentsForRoyalties_05370d6e-fe2f-403e-88c1-cb82f4c89594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cb2afad1-a031-48a1-8aff-76b34dd9df74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cb2afad1-a031-48a1-8aff-76b34dd9df74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_6a14f996-9c7d-451b-8489-b89400b9cd87" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_6a14f996-9c7d-451b-8489-b89400b9cd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b11efb36-ac83-412d-bd2a-fc1f7d3a51f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_0a8143a6-2e7c-40b2-8d36-70acbd7e63fa" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b11efb36-ac83-412d-bd2a-fc1f7d3a51f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20190331.xsd#RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_05117f64-0b75-4f56-a3c8-c92c32b6914d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82666c11-0d63-42aa-89eb-45ab26c6c24f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_05117f64-0b75-4f56-a3c8-c92c32b6914d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82666c11-0d63-42aa-89eb-45ab26c6c24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d2c95eb7-6592-4668-a69d-a94c9c370b81" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82666c11-0d63-42aa-89eb-45ab26c6c24f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d2c95eb7-6592-4668-a69d-a94c9c370b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d99b5f2-acf0-4fef-976e-69357d1e4846" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d2c95eb7-6592-4668-a69d-a94c9c370b81" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d99b5f2-acf0-4fef-976e-69357d1e4846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_22c7915a-bd94-4ea4-a010-948f2b261a39" xlink:href="cpix-20190331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9d99b5f2-acf0-4fef-976e-69357d1e4846" xlink:to="loc_cpix_VIBATIVMember_22c7915a-bd94-4ea4-a010-948f2b261a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_82666c11-0d63-42aa-89eb-45ab26c6c24f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_7f8d27ef-b3c8-4375-b508-e31fe9832cc2" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_7f8d27ef-b3c8-4375-b508-e31fe9832cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_b61fbbfa-2258-47b1-a0e2-e0dee6fac12d" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_b61fbbfa-2258-47b1-a0e2-e0dee6fac12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_3523f1ee-e6c4-438a-9ecc-add649921600" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_3523f1ee-e6c4-438a-9ecc-add649921600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_8454a4ba-3d39-4575-b658-703e124bf969" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_8454a4ba-3d39-4575-b658-703e124bf969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ade52d7b-af5a-4c60-bcd7-08691e642a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ade52d7b-af5a-4c60-bcd7-08691e642a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_7cd19b24-60d6-46d5-aa7b-b0c181e024ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_7cd19b24-60d6-46d5-aa7b-b0c181e024ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2987d5f1-c1ef-4e86-9b9f-73b10530c336" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_us-gaap_Goodwill_2987d5f1-c1ef-4e86-9b9f-73b10530c336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_bc1343e6-ab41-4e45-9370-4682e096ba77" xlink:href="cpix-20190331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_bc1343e6-ab41-4e45-9370-4682e096ba77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_415d1220-4652-47f0-8f1e-fb9ca69582e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d0867346-38dd-43dc-950a-94f8a765ba65" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_415d1220-4652-47f0-8f1e-fb9ca69582e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>cpix-20190331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20190331"
  xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20190331.xsd" xlink:type="simple"/>
    <context id="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5158372b305c4614aa0e20e98ba862b3_I20190510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-05-10</instant>
        </period>
    </context>
    <context id="ie5d35faab61a4630ad543d1af0cc16d8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2320adaf662e4fe7b2b901c919253249_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i848ee9d3c9f34469b15767182f876fc8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i99cee5905d2948288d5318dfe9649ac8_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="idcb57fafd80b474c9f813bc964247527_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i01d3a0b7de7d4850a22eb0c312577e70_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic6cb7f2cc5dd4238b2a9d6617534f1c5_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ib8fc137f89494506ab1761e45418560b_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i7b393de430de456b88a023c44f518e62_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i1eaee2725c7b484a92409dfc296be077_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ie792e7fc787e424b892699bd22d3b60a_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="iaaf4dd1c7ae144628548a35b3f32ab80_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ief772ccce21d46749407b4179204d621_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3e5b3921e9b84154a1a03c334464f1a1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i47f13ca7b3e540f88ef7b7ea26c993de_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic77dc97e15d04aea946527778eb040f7_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic9d2de0b92954151b3696fa7f4de637a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1c9a2ee4d55b4e2cafb63a948d79be7f_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if8b31f7594ba4472a1565ad62133aa90_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if33b370a2f3346fbbcba4fad695d45d2_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i20c891e9fb7e4eae99cfa383cb0f92f7_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ib8b0db4e0d604245836d3b9282efa85b_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i765abef4a83f4226a84e14bc2ae33d8c_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2d82faed6d35438f93182aff8a5ab296_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i04d7faf7c40c47348e3a5958acb6d2bb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7e7b988036874b36afb60617609a7f43_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i133c730e71a944cc8b92b73f899eeb24_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ic1b5019d5ea04548859133f6e118e6d4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i206e669953a243e5b52cf9f148b89afe_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="idbedc37caa7c48e18842745320a00757_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifb24625818ae442c902643c2b8ef1809_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i00188b3841bf4d549fea497c3b5035bb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7b827162bfcb459c97277850d39b0195_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i3bcfe452ec854bb39d09e29c93466eb8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7ca7e00066094ffc8fc51be0ceeee303_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i786c17fe2e7b4dff8a5b3561c9d7c296_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0315ef2832504837ac981b0b26e5db25_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i931504f50ce44f4193f3ef5928d9a8ba_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia1e185405caf46dab422666fb5150a6d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i1765b684cd844ab1a94fc477dd7eca3d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ic7a0bdf9b7dc4e5c951f95a88b27da7a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9cd15aa51095453da10d48a05a1af738_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3f5f73eef27d4e28a3f1b9e8d10e3ec1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i45e179a6466142a0ad009b252e132a12_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i5ad98a5cb1834507bd141b4549bc2663_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i281bcc8e4da642aabc6d3614911c0e2b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i79fc34567df54ab59aba1ba9220cd321_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i399eff68fe09475f8d1927e1b24e18f5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8c62c25d6b474aec82dbe3df361574c8_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i78fd08901b304e87862ea793372612cc_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i243a8f22302543b491cf4c23088a5b78_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i2abb15b10ea141c0a13f38e41acbfd58_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ibf2ebe21504f48ce9df5029e04867fb4_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i992c3adfb7cf4dea8988359b85080c0e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3f711131cff84f42b7542874e5a8c211_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ia3e1587978634f259217537b16f87828_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="icd0f500556b04514907e14932d06b892_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ida8fc49ce7b346adb56f00c51bb7dbd5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i546e97edc09840048611ed807a57b0d6_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:EthyolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ia6d51fc324234a1c807f02d120cac973_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic45f1596255243a5b3a837136a21297d_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:TotectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i51174cd0c9b8448c9fdeac2a3c7adb13_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9a65212ca148417c818133e73d4e6e7e_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i187b59007ba34807a5a064a86071efa7_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib3677ad66cce4a5a86c6214572f63329_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i370fbb3a09b94f55b491f2c991a0a56a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i1f6ebe33ae304eed860a6b42f65a094e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4a7a3ae6831347ca9db4b51688a19d28_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="icec24700d0ae4b5c96e743134dc74822_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="ib7d16aac31044218bb5b9daf893c454a_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="ie1c518feb5474c11b67fefc2bfc51704_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i42d1dca0050148988cc1661e80f74884_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1a32d6eb05e04225a17c4afc1836f061_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i5a16259aa7064665beb60a659a9e175f_I20181017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-17</instant>
        </period>
    </context>
    <context id="i575d0c767db6474b8c9ab64d88e752e3_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9f348e2b52e9422cb8037060ca5972d0_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2048c5597798442694e3f3970659f9e9_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i44a6e15c3f574e3db1922e1ad5b5b56d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2182d9e6420b4100b344f9c6cc077aa0_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i73dec12684ff4570ac1aabaab6122f44_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i305b99fbf5894aaf821bf1146e80ed93_D20170731-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-31</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="ie2424f11376147c9af04e9c63133c333_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="if1788a3b19df415c95d49112f2d872f8_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ifda35f731b37450782fc5c338eb2a4a8_I20181112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-12</instant>
        </period>
    </context>
    <context id="i31c62ad8b23f4059be803e962f97748f_D20181113-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-13</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6a9204f2031142428a1963d884e11716_D20181112-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-12</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="if53f00afbc0c44d78276b75547af3d20_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityFilerCategory
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF80LTEtMS0xLTA_4900aee7-74aa-44d1-92ec-3f2fedcb8c3c">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentPeriodEndDate
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF82LTEtMS0xLTA_f85a612a-39da-4273-a2c1-d0b2b14e80d6">2019-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF83LTEtMS0xLTA_b34e029a-574a-4a4c-a8ef-85d0e3a35cad">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF84LTEtMS0xLTA_b8066440-7c6b-4e00-a5a6-9c87d483b1d9">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF85LTEtMS0xLTA_dd7c3cc1-a3fa-479f-b78b-8e0da279b5dc">false</dei:AmendmentFlag>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF8xMC0xLTEtMS0w_91299625-508c-41e5-ac41-83757536e945">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGFibGU6ZTMxNjQxYmNkZmQ4NGE2ZDg5NjIwYmU4MTU3M2VmMTQvdGFibGVyYW5nZTplMzE2NDFiY2RmZDg0YTZkODk2MjBiZTgxNTczZWYxNF8xMS0xLTEtMS0w_b9eab33b-9933-4bd4-a342-dc6ae07f9ecf">false</dei:EntitySmallBusiness>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGV4dHJlZ2lvbjplZjQxYzlkYTc1MTY0MzIxYjNhMzNlYTgyNGQzNTgzOV83OQ_b20ed109-74b3-4262-8dea-7d0d1d319a2f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80L2ZyYWc6ZWY0MWM5ZGE3NTE2NDMyMWIzYTMzZWE4MjRkMzU4MzkvdGV4dHJlZ2lvbjplZjQxYzlkYTc1MTY0MzIxYjNhMzNlYTgyNGQzNTgzOV84MA_c23d00bf-55cf-41c9-9e5e-7d803502caea">0001087294</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockNoParValue
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMS0xLTEtMS0w_f5faa35f-6352-4f9d-946d-073735174be6"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMS0yLTEtMS0w_089e5776-3150-4f21-bd1d-39a50f3df098"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMi0xLTEtMS0w_76bd57b5-5683-4af4-9e13-6c1d3621aa0b"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMi0yLTEtMS0w_49ca4bf4-1676-441c-a0a6-29e1b1c67ad4"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMy0xLTEtMS0w_6e6a50f5-1d1c-486e-a7e4-47ad05c2ce56"
      unitRef="shares">15547517</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfMy0yLTEtMS0w_094c5160-ebb9-46ba-abab-a3dd506f0b2e"
      unitRef="shares">15481497</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfNC0xLTEtMS0w_02f81989-7ff5-400d-9938-cc55bc2015a6"
      unitRef="shares">15547517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xOS9mcmFnOjcwM2I0ZmViZDUwNzRhNDFhMDUxMWUyNDEzZTg5M2Q2L3RhYmxlOmE4MTI2MjQ4ODNkYTRhOTZhZmFmNTVlOTlhZWE1ZjZiL3RhYmxlcmFuZ2U6YTgxMjYyNDg4M2RhNGE5NmFmYWY1NWU5OWFlYTVmNmJfNC0yLTEtMS0w_11f5c09f-0101-45ee-8452-28a177ab55d2"
      unitRef="shares">15481497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i1f6ebe33ae304eed860a6b42f65a094e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MDUvZnJhZzowYzkwYmM3OWQ5MzU0ZDRlYTIzYzE3YTJhM2RhMWFkNS90ZXh0cmVnaW9uOjBjOTBiYzc5ZDkzNTRkNGVhMjNjMTdhMmEzZGExYWQ1XzI3NDg3NzkwNjk2MjI_dfa4c8e1-90cf-43ed-9292-665db1b2f04e"
      unitRef="usd">14900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4a7a3ae6831347ca9db4b51688a19d28_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81OTcvZnJhZzo0YTdiZTllZDhlN2U0NzM4YTM4ODA0YzM2NGNiNjIyZC90ZXh0cmVnaW9uOjRhN2JlOWVkOGU3ZTQ3MzhhMzg4MDRjMzY0Y2I2MjJkXzI3NDg3NzkwNjk2NTA_b6e46ad4-534a-4821-9673-42cd2e2f604f"
      unitRef="usd">3800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i73dec12684ff4570ac1aabaab6122f44_D20180101-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81Mi9mcmFnOmExNGEzZWYwNDI5ZTRjNzJiNjMzZTI2ZDYyYWUwZGM3L3RhYmxlOjg3NWE1Y2ZjNGRlNTQxMDVhZmI1NzkzZGJmNDYwNTZiL3RhYmxlcmFuZ2U6ODc1YTVjZmM0ZGU1NDEwNWFmYjU3OTNkYmY0NjA1NmJfMi0xLTEtMS0w_ee6823dd-ab14-4a33-94f5-c49f2936d1f6">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i305b99fbf5894aaf821bf1146e80ed93_D20170731-20170731"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81Mi9mcmFnOmExNGEzZWYwNDI5ZTRjNzJiNjMzZTI2ZDYyYWUwZGM3L3RhYmxlOjQ4YzE1ZmI4MmYzYjRjM2Y5NDE3ODYxNTBlOTNlODE0L3RhYmxlcmFuZ2U6NDhjMTVmYjgyZjNiNGMzZjk0MTc4NjE1MGU5M2U4MTRfMS0xLTEtMS0w_93352549-7d61-4b5a-aeb7-6568c69624c8">P3Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <dei:DocumentType
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xL2ZyYWc6Mjg4ZDI3NjFjYTM1NGE1OWI1OTBlZWQ5NzNjZWQxZWQvdGV4dHJlZ2lvbjoyODhkMjc2MWNhMzU0YTU5YjU5MGVlZDk3M2NlZDFlZF8xOTQ1_6e1afdc0-8f80-45b2-b7b6-5b9f6305a5ef">10-Q</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xL2ZyYWc6Mjg4ZDI3NjFjYTM1NGE1OWI1OTBlZWQ5NzNjZWQxZWQvdGV4dHJlZ2lvbjoyODhkMjc2MWNhMzU0YTU5YjU5MGVlZDk3M2NlZDFlZF8xOTQ2_4798a91b-18f2-432c-a38b-c761094e95e8">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5158372b305c4614aa0e20e98ba862b3_I20190510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xL2ZyYWc6Mjg4ZDI3NjFjYTM1NGE1OWI1OTBlZWQ5NzNjZWQxZWQvdGFibGU6YTNkMDc0Y2U3ZDczNGQwMTllMWFhNzMwZDEwOWVkMDYvdGFibGVyYW5nZTphM2QwNzRjZTdkNzM0ZDAxOWUxYWE3MzBkMTA5ZWQwNl8xLTItMS0xLTA_56bdf145-f910-4b5f-847b-62e7cfe79978"
      unitRef="shares">15537130</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMy0xLTEtMS0w_fd18a463-a75e-40bc-bee0-b8d5bf36e3e5"
      unitRef="usd">24609415</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMy0zLTEtMS0w_967ae735-3cf9-482b-a456-3b29e13cbfb6"
      unitRef="usd">27938960</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNC0xLTEtMS0w_d09d159c-625a-4582-94d7-b20b278f26cd"
      unitRef="usd">9667073</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNC0zLTEtMS0w_878a62bd-b219-4e94-879d-0ec09f3b16d3"
      unitRef="usd">8290679</us-gaap:MarketableSecurities>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNS0xLTEtMS0w_24a39a62-0e5e-4bb3-b0ae-5d407baa230f"
      unitRef="usd">9973995</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNS0zLTEtMS0w_c27adc65-38c4-4c0a-b820-46dd8d25a824"
      unitRef="usd">7844249</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNi0xLTEtMS0w_741cf3a3-abc2-4c5e-a80d-de0de03c9e9e"
      unitRef="usd">11259233</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNi0zLTEtMS0w_aa69a738-e8c4-46d4-a157-8724e8af66b4"
      unitRef="usd">12078343</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNy0xLTEtMS0w_1eacaeac-10bf-4ffb-b2b0-ae8d49423d33"
      unitRef="usd">2456453</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfNy0zLTEtMS0w_f6c79d8c-04f1-4f0b-bd2e-1c9de4859957"
      unitRef="usd">2963806</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOC0xLTEtMS0w_38f73b82-c3da-4ca0-91f6-814d6113bf4f"
      unitRef="usd">57966169</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOC0zLTEtMS0w_13b87298-4953-46aa-b6b9-ff98538baf79"
      unitRef="usd">59116037</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOS0xLTEtMS00MDY_fd71f290-e3f7-4fc7-8669-7c64444bf25e"
      unitRef="usd">15862092</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOS0zLTEtMS0xOTgz_32cad8d0-d4f3-4688-abce-c6f806a8d6cd"
      unitRef="usd">15749000</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOS0xLTEtMS0w_1d8e9e88-1505-4696-80b7-e9c62e0708f1"
      unitRef="usd">744085</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfOS0zLTEtMS0w_9927847a-99bf-4a3a-a4b8-eb5c92cd404e"
      unitRef="usd">771213</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTAtMS0xLTEtMA_467cb10e-1f3e-48e5-9238-49b5314b166f"
      unitRef="usd">32910261</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTAtMy0xLTEtMA_aa8e189f-6738-43c4-9e5c-d83abe25ab61"
      unitRef="usd">33655099</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTEtMS0xLTEtMzk5_5249827f-fa19-49d6-9808-73340ae0e0c6"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTEtMy0xLTEtMTE_942f7c4b-a06f-4cbf-94c5-76cf3be8e477"
      unitRef="usd">784000</us-gaap:Goodwill>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTEtMS0xLTEtMA_7434345c-b36d-43a9-932b-3d3a3526bb48"
      unitRef="usd">43605</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTEtMy0xLTEtMA_b95d7d15-08e9-4053-9cb0-4a7948c1129e"
      unitRef="usd">87210</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTItMS0xLTEtMA_bcf96f24-3681-4318-ab56-f96dac1a49f7"
      unitRef="usd">6209417</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTItMy0xLTEtMA_315e863a-77ae-4523-8e51-4504304a3f3d"
      unitRef="usd">2531309</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTMtMS0xLTEtMA_bdd1a573-1f67-46f4-99c8-2dae06645ad9"
      unitRef="usd">114617629</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTMtMy0xLTEtMA_f8309603-e1f0-42f9-b0fd-43e76c8071af"
      unitRef="usd">112693868</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTYtMS0xLTEtMA_f223bbeb-4ae4-4f7f-9c0b-6adbaa366008"
      unitRef="usd">9292014</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTYtMy0xLTEtMA_bc2d29ce-e732-4bdd-864d-277ce6228bce"
      unitRef="usd">11093297</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTctMS0xLTEtMA_6354bc5e-0a30-4016-a8d6-c7677de82837"
      unitRef="usd">18706631</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTctMy0xLTEtMA_6f845629-138d-4a21-a245-a6a7757d5869"
      unitRef="usd">16710927</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTgtMS0xLTEtMA_29e1fd1f-3005-459b-8377-696becca2e01"
      unitRef="usd">27998645</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTgtMy0xLTEtMA_3253c57b-ce82-45a4-90ed-cefd99c969d1"
      unitRef="usd">27804224</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTktMS0xLTEtMA_5160c64e-98f6-44db-8940-c1f90fbfca58"
      unitRef="usd">20000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMTktMy0xLTEtMA_fd4dc959-057f-4c6f-b271-693085f3e461"
      unitRef="usd">20000000</us-gaap:LongTermLineOfCredit>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjAtMS0xLTEtMA_b1310aa2-2e91-44eb-98f8-b32ab83f5184"
      unitRef="usd">11428257</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjAtMy0xLTEtMA_326e0c82-d115-4f75-8a91-e836fb12276d"
      unitRef="usd">9319143</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjEtMS0xLTEtMA_9e9964cc-f6ac-4fa0-89f5-845636bd4f84"
      unitRef="usd">59426902</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjEtMy0xLTEtMA_bc9f72e3-644f-4622-841a-28710eb4e398"
      unitRef="usd">57123367</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjItMS0xLTEtMA_8577b57a-1c54-4c05-8d09-6e67b65b446a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjItMy0xLTEtMA_5ad7ae08-77e9-4fc1-a523-e4d7a9affff8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjUtMS0xLTEtMA_bad0ce48-bc3c-4c54-abfc-491080c1cc28"
      unitRef="usd">50759257</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjUtMy0xLTEtMA_a75f9f26-c71c-42f7-beb4-318bb00057c9"
      unitRef="usd">51098613</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjYtMS0xLTEtMA_e53069b5-fec3-402d-9de1-267695bc40e4"
      unitRef="usd">4672276</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjYtMy0xLTEtMA_11248f25-29af-45af-a560-9d3438bf8f31"
      unitRef="usd">4746154</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjctMS0xLTEtMA_51a165f2-6f84-4a58-9939-e8d6111cd5fa"
      unitRef="usd">55431533</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjctMy0xLTEtMA_d69f5988-9496-4f80-a31b-934ddc84ef49"
      unitRef="usd">55844767</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjgtMS0xLTEtMA_d043ad55-5a91-4b00-81ac-95d10247f5bd"
      unitRef="usd">-240806</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjgtMy0xLTEtMA_67c20715-5264-4ddb-b900-44b5d8a1669b"
      unitRef="usd">-274266</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjktMS0xLTEtMA_59d3e9a6-07ba-4e20-bc44-0e12d382787b"
      unitRef="usd">55190727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMjktMy0xLTEtMA_0949339c-bae2-4d03-b886-0da5018662fe"
      unitRef="usd">55570501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMzAtMS0xLTEtMA_255ff69e-f885-406b-928a-b2d965ed6f34"
      unitRef="usd">114617629</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8xNi9mcmFnOjFhNzgyOGI3ODZkZDQyMWRhZmU2NjI2ZjBiMGQ2YjRhL3RhYmxlOjhiYWRkZDczM2ExNTRhZDM5NzdjYTE3ZWQ0MDE2ZjU4L3RhYmxlcmFuZ2U6OGJhZGRkNzMzYTE1NGFkMzk3N2NhMTdlZDQwMTZmNThfMzAtMy0xLTEtMA_9227d6f6-dc70-4bac-a58b-43d84ae8a38a"
      unitRef="usd">112693868</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMi0xLTEtMS0w_20379df8-23f2-4ba6-822b-4189951145ad"
      unitRef="usd">11902747</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMi0zLTEtMS0w_11ec3a9e-95fb-41be-8e62-837a8954fe0b"
      unitRef="usd">8587605</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNC0xLTEtMS0w_22ecb181-107e-469a-89ce-1caf18598bf5"
      unitRef="usd">1999736</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNC0zLTEtMS0w_82afd672-1094-48ee-9b72-11462e1d9020"
      unitRef="usd">1527961</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNS0xLTEtMS0w_f6930b0b-62ba-4a76-aa57-cdb9b28ed95b"
      unitRef="usd">5120505</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNS0zLTEtMS0w_13f15279-15be-4c11-9473-a2b8ccc69e24"
      unitRef="usd">4670511</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNi0xLTEtMS0w_6b2daa7d-f75d-46b8-a95a-ca38cdc4e461"
      unitRef="usd">1267601</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNi0zLTEtMS0w_5587312e-0f6f-476d-9858-2d1bca90f8a5"
      unitRef="usd">1874939</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNy0xLTEtMS0w_c4defb49-33c8-4393-93ef-d8cf1bf40435"
      unitRef="usd">2670056</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfNy0zLTEtMS0w_b3903f4b-dc38-4c85-a254-bbfd34bdb75c"
      unitRef="usd">2330281</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfOC0xLTEtMS0w_bcde21ff-1bda-4e6f-9a24-b308f4b47c40"
      unitRef="usd">1021645</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfOC0zLTEtMS0w_c93d31c6-5cb8-4605-97c7-aaa2d5d22628"
      unitRef="usd">636135</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfOS0xLTEtMS0w_c215d073-9ed0-43c6-9d1f-0f9020cba7d5"
      unitRef="usd">12079543</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfOS0zLTEtMS0w_5dd020c2-b016-4d9b-80e4-2e982830a389"
      unitRef="usd">11039827</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTAtMS0xLTEtMA_9c8a7d4d-89ce-42a8-ba2c-cc174f557888"
      unitRef="usd">-176796</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTAtMy0xLTEtMA_b641687c-60d3-44bc-923d-63c39b3b2268"
      unitRef="usd">-2452222</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTEtMS0xLTEtMA_92cff2f2-798d-455b-86b9-f4be4389dc3c"
      unitRef="usd">115861</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTEtMy0xLTEtMA_4a5abb4d-1cd7-4e6a-af06-c369ef79c992"
      unitRef="usd">82494</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTItMS0xLTEtMA_fdb100c3-8158-4668-acf0-29b079968578"
      unitRef="usd">60911</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTItMy0xLTEtMA_aee32b17-5c90-4ed7-b1ae-b4f8d0a31cce"
      unitRef="usd">18302</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTMtMS0xLTEtMA_3024492f-9a2d-421f-bedd-c8d0829d9416"
      unitRef="usd">-121846</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTMtMy0xLTEtMA_435b8a76-860c-497d-bfba-6b2fd135748e"
      unitRef="usd">-2388030</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTQtMS0xLTEtMA_564d7aee-1a27-4b65-99a9-9b871543812d"
      unitRef="usd">-81428</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTQtMy0xLTEtMA_18cdb447-7bcc-4173-9abd-b16653b6ff36"
      unitRef="usd">4159</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTUtMS0xLTEtMA_8ca97719-29c0-4502-b02e-8ad01e6e6852"
      unitRef="usd">-40418</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTUtMy0xLTEtMA_3991026d-257c-4db9-aad9-562833edc792"
      unitRef="usd">-2392189</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTYtMS0xLTEtMA_ce4a3156-9ce0-47d9-9167-d0896a8c3b14"
      unitRef="usd">33460</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTYtMy0xLTEtMA_0dec5184-e0a4-48ca-a41c-05fc25d19135"
      unitRef="usd">-12950</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTctMS0xLTEtMA_a2c774aa-2585-4468-9391-4c8e4df40232"
      unitRef="usd">-73878</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTctMy0xLTEtMA_d49afcbd-8cfd-499b-8098-96260641b2f0"
      unitRef="usd">-2379239</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTktMS0xLTEtMA_d30fad80-6beb-4b45-9fb8-18cf7f2db846"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMTktMy0xLTEtMA_a28f9e57-485e-4271-9e61-836d64fa5664"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjAtMS0xLTEtMA_f783b750-1ecb-46fc-8600-c4fe7cac24f3"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjAtMy0xLTEtMA_891b50a2-b298-4f7e-8c4a-bb43ddca9243"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjItMS0xLTEtMA_c7c6e4d2-f491-4f8c-8be8-4c4e28bf1673"
      unitRef="shares">15472952</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjItMy0xLTEtMA_e103876d-d300-457a-8164-ba91713a57a3"
      unitRef="shares">15689240</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjMtMS0xLTEtMA_972fa6c1-414d-4dac-ab73-62fbb8e486e9"
      unitRef="shares">15472952</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjMtMy0xLTEtMA_9626accd-a58d-4dc8-823a-ea4399ce9c57"
      unitRef="shares">15689240</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjUtMS0xLTEtMA_f05dbbe1-9633-4e53-9f9c-7494e01768e4"
      unitRef="usd">-73878</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjUtMy0xLTEtMA_0e01c1ce-9056-49b6-8321-09a62074a150"
      unitRef="usd">-2379239</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjYtMS0xLTEtMA_ef6c6256-6cb4-44f2-837d-7822201ee8e6"
      unitRef="usd">-33460</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjYtMy0xLTEtMA_b3e0d822-1892-4367-8d8a-9d1ef8a0a410"
      unitRef="usd">12950</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjctMS0xLTEtMA_183f4502-79b8-4720-9445-ba4da91a334e"
      unitRef="usd">-40418</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yMi9mcmFnOmE4OWI0YzhhNjAzNTRmNjliZjg2YWE1N2FkNTRlMmJkL3RhYmxlOjQ2ZTc3OTM1OTRmZDRlMDY5Zjg4MmE3ZjNhZmRlNmNiL3RhYmxlcmFuZ2U6NDZlNzc5MzU5NGZkNGUwNjlmODgyYTdmM2FmZGU2Y2JfMjctMy0xLTEtMA_03c23398-f928-4a11-aadb-fd3aaea04eda"
      unitRef="usd">-2392189</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMy0xLTEtMS0w_6d4def0f-8080-4964-8632-9246038f34bc"
      unitRef="usd">-40418</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMy0zLTEtMS0w_1afe989e-2379-4404-839f-617d66c709ec"
      unitRef="usd">-2392189</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNS0xLTEtMS0w_20d2c088-89c2-450a-b393-6d1ced3ac45f"
      unitRef="usd">1076246</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNS0zLTEtMS0w_ba1d2fdf-389a-45d1-9871-ddb2615a2126"
      unitRef="usd">692991</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNi0xLTEtMS0w_4dea2f8e-f9d1-47ea-a002-3c95d80f78cc"
      unitRef="usd">43605</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNi0zLTEtMS0w_8cd5411f-fe87-447a-ac39-849e5c817f93"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNy0xLTEtMS0w_f201c7f9-608f-4275-b495-b607c935e5bd"
      unitRef="usd">364434</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNy0zLTEtMS0w_4fd8cb37-6a2b-477f-a5c1-5a374e99dc0e"
      unitRef="usd">339209</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfOC0xLTEtMS0w_67581ceb-f26f-4b40-be4d-a8af8a21769a"
      unitRef="usd">269422</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfOC0zLTEtMS0w_ce521c06-b14e-4062-bc44-0eec3e7b06dd"
      unitRef="usd">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfOS0xLTEtMS0w_08a8b88c-5e15-4f32-af70-f6334a2b06e0"
      unitRef="usd">10497</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfOS0zLTEtMS0w_1dccd48e-9486-484f-81d1-16f7feab992c"
      unitRef="usd">18303</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTAtMS0xLTEtMA_6528aa3c-8967-4fbc-82a4-f1181afcea9c"
      unitRef="usd">44191</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTAtMy0xLTEtMA_96d91590-0b77-4587-b1ef-4b8697ad4548"
      unitRef="usd">43338</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTItMS0xLTEtMA_37249ded-9e44-457a-bf92-83c764a11d07"
      unitRef="usd">2129746</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTItMy0xLTEtMA_614e6812-ff0a-45b8-8578-ceb28a9765af"
      unitRef="usd">-2093950</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTMtMS0xLTEtMA_8ce5c30b-b52c-4cde-9605-2d84e864f422"
      unitRef="usd">-819110</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTMtMy0xLTEtMA_6299c2a5-e549-4f33-8501-b852ea65233a"
      unitRef="usd">-76323</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTQtMS0xLTEtMA_aee6af7b-33d2-45b4-b727-1cc08dacb789"
      unitRef="usd">-134578</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTQtMy0xLTEtMA_76efdda9-66b4-4032-a140-f2ed4dc3b010"
      unitRef="usd">-600884</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTUtMS0xLTEtMA_17905410-622d-425a-89fc-1ec6da5ae03d"
      unitRef="usd">3499</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTUtMy0xLTEtMA_11968850-7331-4e28-a796-9bb3445556df"
      unitRef="usd">-1254535</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTYtMS0xLTEtMA_24d35a39-bd7a-45fb-8fe4-f1535aa1f1ca"
      unitRef="usd">-353925</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTYtMy0xLTEtMA_87b4a6de-a5ae-476d-8fb8-1e2a769a1af6"
      unitRef="usd">103991</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTctMS0xLTEtMA_6d3fcb16-cfc7-490e-adac-fbd54010ab60"
      unitRef="usd">-385733</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTctMy0xLTEtMA_7032356c-81e7-4e61-b0e7-1d9f81ebf8f7"
      unitRef="usd">235589</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTktMS0xLTEtMA_015eac2f-d906-48da-928c-8f0fc019d8bb"
      unitRef="usd">27474</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMTktMy0xLTEtMA_b2a998b3-64ff-4f32-9d10-9371505bd063"
      unitRef="usd">94881</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjAtMS0xLTEtMA_050f443b-8802-46a8-9173-afe389c23823"
      unitRef="usd">7816191</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjAtMy0xLTEtMA_8d678002-0034-44de-9332-04d4f0d04114"
      unitRef="usd">15151948</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjEtMS0xLTEtMA_3638dd33-fd81-473b-b127-073d482de385"
      unitRef="usd">6483988</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjEtMy0xLTEtMA_1d62442d-e45a-4181-bcc9-3d2def85528b"
      unitRef="usd">4257657</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjMtMS0xLTEtMA_61a06048-e364-4be0-8bbf-1cb7b3482899"
      unitRef="usd">363711</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjMtMy0xLTEtMA_10009b04-1f35-453f-a133-960fbc16978f"
      unitRef="usd">532954</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjQtMS0xLTEtMA_943b4640-d5c6-4488-b7cd-936b9bcc104d"
      unitRef="usd">-1723388</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjQtMy0xLTEtMA_0f3de51b-9d04-499b-a094-6de999ca9ee9"
      unitRef="usd">-11522126</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjctMS0xLTEtMA_e18842fe-ae11-4d8a-88da-294b7bb66ee6"
      unitRef="usd">19000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjctMy0xLTEtMA_e1f54621-671e-41fe-9345-a736ced472fe"
      unitRef="usd">12000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjgtMS0xLTEtMA_24cea24e-3ccb-4e55-8015-aba569c37ff2"
      unitRef="usd">19000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjgtMy0xLTEtMA_c41a9f12-32a0-4a36-8b5b-7da6af775b27"
      unitRef="usd">9800000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjktMS0xLTEtMA_25c3501b-9832-4406-b1ab-f483141e0b51"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMjktMy0xLTEtMA_0d4995da-ad08-40a1-8012-de57d78c5885"
      unitRef="usd">200909</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzAtMS0xLTEtMA_71b36207-3148-419e-b407-e0db3d8648d0"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzAtMy0xLTEtMA_69f36966-9eb2-4a78-b2b3-24ded3879107"
      unitRef="usd">248108</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzEtMS0xLTEtMjEzOQ_87af59f4-3667-4a38-a0fa-b191b006c83a"
      unitRef="usd">507505</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzEtMy0xLTEtMA_8036c5b8-5f50-4335-98aa-cef64da83ab9"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzUtMS0xLTEtMA_e93301bd-799a-4bad-bc6c-44005f761d56"
      unitRef="usd">712919</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzUtMy0xLTEtMA_c103343b-f036-4538-b909-f6e75a734f1e"
      unitRef="usd">1016156</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzYtMS0xLTEtMA_4118cfca-de7d-48c9-84be-826d4b7d93af"
      unitRef="usd">-1220424</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzYtMy0xLTEtMA_1b037671-8d4b-4582-aa17-2f29aacf43c4"
      unitRef="usd">1136645</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzctMS0xLTEtMA_9a647d0b-c195-487f-8ddf-775f4e64d01c"
      unitRef="usd">-3329545</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzctMy0xLTEtMA_14d93643-7b99-482d-8fa5-31fa4a41e93a"
      unitRef="usd">-10149892</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzgtMS0xLTEtMA_dab70f5a-fe8b-4677-aea9-377108bce4ba"
      unitRef="usd">27938960</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i848ee9d3c9f34469b15767182f876fc8_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzgtMy0xLTEtMA_4c157f44-dd62-43ed-a15a-2f25f3ca4086"
      unitRef="usd">45412868</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzktMS0xLTEtMA_946587ef-cc6d-45a8-92d1-03bf26421ca7"
      unitRef="usd">24609415</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i99cee5905d2948288d5318dfe9649ac8_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfMzktMy0xLTEtMA_eebe8f03-877d-4174-9f42-45d211c2a21b"
      unitRef="usd">35262976</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNDItMS0xLTEtMzIwNw_195d8a6b-f943-4105-8070-ea601ca38227"
      unitRef="usd">3629320</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yNS9mcmFnOjAzNGM5MDY5Yjk1ZTQ1YzhiMDJhMmEyNWY2MjI3ZTIzL3RhYmxlOjlmMWI3MjQzYjYzMjRlMjc5Y2M4MTA0OWY4MmUzMzlmL3RhYmxlcmFuZ2U6OWYxYjcyNDNiNjMyNGUyNzljYzgxMDQ5ZjgyZTMzOWZfNDItMy0xLTEtMzIwOQ_b6ab05ec-e43b-447e-a143-1b9ee5315cf8"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idcb57fafd80b474c9f813bc964247527_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMi0xLTEtMS0zMTYw_3fd8101b-1cd4-4c6c-b4be-f4daf2d37a47"
      unitRef="shares">15723075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcb57fafd80b474c9f813bc964247527_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMi0zLTEtMS0zMTYy_fa991154-fad4-45db-9083-20b2960ba685"
      unitRef="usd">52410941</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01d3a0b7de7d4850a22eb0c312577e70_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMi01LTEtMS0zMTY0_9797efb5-7b94-4efb-b90d-6a61ee808a8f"
      unitRef="usd">11709222</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6cb7f2cc5dd4238b2a9d6617534f1c5_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMi03LTEtMS0zMTY2_75fc8379-1323-4434-94aa-750dadadce91"
      unitRef="usd">-198562</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i848ee9d3c9f34469b15767182f876fc8_I20171231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMi05LTEtMS0zMTY4_83c0c328-823d-4ee6-ada5-bce545ba3712"
      unitRef="usd">63921601</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMy0xLTEtMS0zMTc0_2cc4c036-2f32-46b1-9c61-e37827a2bb3d"
      unitRef="shares">30704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMy0zLTEtMS0zMTcy_28dbfec9-5e42-423f-9fe2-54a519ebada3"
      unitRef="usd">200909</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfMy05LTEtMS0zMTcw_cd350809-c7d1-4410-8a5d-59a66108060a"
      unitRef="usd">200909</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNC0xLTEtMS0zMTc2_c77e8c99-bb4e-4c5f-a40d-e7f09a72a16d"
      unitRef="shares">145550</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNC0zLTEtMS0zMTc4_0ba7d1cd-b872-460c-9a53-e8e60039c9fd"
      unitRef="usd">339209</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNC05LTEtMS0zMTgw_47ac4265-10a4-4823-8092-be65b01be1e7"
      unitRef="usd">339209</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNS0xLTEtMS0zMTgy_abd6d4e9-02ba-4901-b11e-3a942a4e3548"
      unitRef="shares">172079</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNS0zLTEtMS0zMTg0_b5426d1c-acfb-459c-9dde-ac0fd7e89e0b"
      unitRef="usd">1195225</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNS05LTEtMS0zMTg2_63c7efcb-9cc3-47ae-8c61-b038bea589a0"
      unitRef="usd">1195225</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ib8fc137f89494506ab1761e45418560b_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNi01LTEtMS0zMTky_0aab5f47-8a62-4a92-9325-9db80650de03"
      unitRef="usd">-2379239</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7b393de430de456b88a023c44f518e62_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNi03LTEtMS0zMTk2_740054fb-d356-4f5c-b432-5792fb77bcb5"
      unitRef="usd">-12950</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNi05LTEtMS0zMjAw_795b44ad-7b23-4fe0-8384-d398b26f0ea6"
      unitRef="usd">-2392189</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1eaee2725c7b484a92409dfc296be077_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNy0xLTEtMS0zMTg4_51fd2f73-30ca-4a6e-aeed-97a6742615cb"
      unitRef="shares">15727250</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1eaee2725c7b484a92409dfc296be077_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNy0zLTEtMS0zMTkw_8ec65c4a-e532-4501-ac0f-f2adfc715759"
      unitRef="usd">51755834</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie792e7fc787e424b892699bd22d3b60a_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNy01LTEtMS0zMTk0_0766a399-6d58-4966-a010-ac8cfc33da61"
      unitRef="usd">9329983</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaaf4dd1c7ae144628548a35b3f32ab80_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNy03LTEtMS0zMTk4_74db452e-b4a1-400d-8a09-a59974904892"
      unitRef="usd">-211512</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99cee5905d2948288d5318dfe9649ac8_I20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc4ZGJiYTg4OWMwNzQzNDhhZDRiZjRiN2ViMDkyMmY5L3RhYmxlcmFuZ2U6NzhkYmJhODg5YzA3NDM0OGFkNGJmNGI3ZWIwOTIyZjlfNy05LTEtMS0zMjAy_d5c071e0-c61d-47bc-820b-d17b4a7b23f6"
      unitRef="usd">60874305</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ief772ccce21d46749407b4179204d621_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMy0xLTEtMS0w_463756db-ee55-4359-87d2-e44748b04e33"
      unitRef="shares">15481497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief772ccce21d46749407b4179204d621_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMy0zLTEtMS0w_908631cb-467a-44f3-a4e0-e6603c08eab1"
      unitRef="usd">51098613</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e5b3921e9b84154a1a03c334464f1a1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMy01LTEtMS0w_db113d11-6cc1-4194-ba9d-0a8b32c308c9"
      unitRef="usd">4746154</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47f13ca7b3e540f88ef7b7ea26c993de_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMy03LTEtMS0w_305ff98e-6b4a-42f6-ad25-ad688e0f58a7"
      unitRef="usd">-274266</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMy05LTEtMS0w_270918ca-0992-4db9-9eb8-355be89d6287"
      unitRef="usd">55570501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfNi0xLTEtMS0w_b6c58042-2b8b-4b46-ba88-32d497478af7"
      unitRef="shares">187486</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfNi0zLTEtMS0w_33f9897a-7b27-4522-b191-1bf7cfccef25"
      unitRef="usd">364434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfNi05LTEtMS0w_df0d4428-f6ec-4ecb-965e-d42a365bfd22"
      unitRef="usd">364434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfOS0xLTEtMS0w_cb2635d2-655b-4f56-972e-ae3c2873385b"
      unitRef="shares">121466</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfOS0zLTEtMS0w_75ea2dbe-6a9a-4874-af6b-8a848605685d"
      unitRef="usd">703790</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfOS05LTEtMS0w_40293af5-9d9b-4ce9-bc5d-e651f5cd0298"
      unitRef="usd">703790</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ic77dc97e15d04aea946527778eb040f7_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTAtNS0xLTEtMA_551ab4bb-48ec-4c5b-8248-6fafafe77000"
      unitRef="usd">-73878</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic9d2de0b92954151b3696fa7f4de637a_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTAtNy0xLTEtMA_38fa895d-ec4b-41e8-81e8-c088a06287d7"
      unitRef="usd">33460</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTAtOS0xLTEtMA_08cbf81c-ff52-4fb7-8506-0fad548ef981"
      unitRef="usd">-40418</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1c9a2ee4d55b4e2cafb63a948d79be7f_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTEtMS0xLTEtMA_992a00a8-57d8-4918-829f-263713bea562"
      unitRef="shares">15547517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c9a2ee4d55b4e2cafb63a948d79be7f_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTEtMy0xLTEtMA_a8dd8063-700d-42b1-9588-d3d060de82b0"
      unitRef="usd">50759257</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8b31f7594ba4472a1565ad62133aa90_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTEtNS0xLTEtMjAzOQ_f525c305-2b91-4de4-8bbc-5913a97d6d8b"
      unitRef="usd">4672276</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if33b370a2f3346fbbcba4fad695d45d2_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTEtNy0xLTEtMA_cf4b4d06-6d5d-4457-b1f0-b6a831c47a90"
      unitRef="usd">-240806</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8yOC9mcmFnOmZjZjg3YTUyYjA5MDQ5ODJiMzUzYWYxYTRkZjFiMjEyL3RhYmxlOjc0M2JlNWRkNzliYjQ2MGU4Mjk0MzQ0NGQ4ZjQ5MTIwL3RhYmxlcmFuZ2U6NzQzYmU1ZGQ3OWJiNDYwZTgyOTQzNDQ0ZDhmNDkxMjBfMTEtOS0xLTEtMjA0Nw_deee7eca-c3ea-44ba-8139-710e2941a700"
      unitRef="usd">55190727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNC9mcmFnOjAyYjhhNGE0YzIzMjRlMTU4NmEyOTE0NzZhNjMxMGE4L3RleHRyZWdpb246MDJiOGE0YTRjMjMyNGUxNTg2YTI5MTQ3NmE2MzEwYThfMTI4NjM_726ef9ef-a411-46c7-b5bf-cce95883eeb0">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2018 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 (the &#x201c;2018 Annual Report on Form 10-K&#x201d;). The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Total comprehensive income (loss) consisted solely of net income (loss) for the three months ended March 31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Recent Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#x201c;Leases.&#x201d; The new standard establishes a right-of-use (&#x201c;ROU&#x201d;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Recent Accounting Pronouncements - Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNC9mcmFnOjAyYjhhNGE0YzIzMjRlMTU4NmEyOTE0NzZhNjMxMGE4L3RleHRyZWdpb246MDJiOGE0YTRjMjMyNGUxNTg2YTI5MTQ3NmE2MzEwYThfMTI4NjQ_a9e88ae6-ff36-47ff-aa1c-26cc8b106522">&lt;div style="margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Recent Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#x201c;Leases.&#x201d; The new standard establishes a right-of-use (&#x201c;ROU&#x201d;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Recent Accounting Pronouncements - Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.&lt;/span&gt;&lt;/div&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNC9mcmFnOjAyYjhhNGE0YzIzMjRlMTU4NmEyOTE0NzZhNjMxMGE4L3RleHRyZWdpb246MDJiOGE0YTRjMjMyNGUxNTg2YTI5MTQ3NmE2MzEwYThfMTI4NjE_7997df88-82a5-42d6-a3b8-c7627be720d6">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNC9mcmFnOjAyYjhhNGE0YzIzMjRlMTU4NmEyOTE0NzZhNjMxMGE4L3RleHRyZWdpb246MDJiOGE0YTRjMjMyNGUxNTg2YTI5MTQ3NmE2MzEwYThfMTI4NjI_5b151ba5-e582-492c-a6c1-e17fd6b31aab">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNC9mcmFnOjAyYjhhNGE0YzIzMjRlMTU4NmEyOTE0NzZhNjMxMGE4L3RleHRyZWdpb246MDJiOGE0YTRjMjMyNGUxNTg2YTI5MTQ3NmE2MzEwYThfMTIwNTQ_9ca8656d-2487-4b92-bbff-6346f203f478"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RleHRyZWdpb246MzA0N2JlY2E1ZDkwNDNiMjlhOWI2NjM2MDY4YjE5OWNfMzQxMw_2d1bcdc3-ddab-4aba-851d-6ca02c3e6bf3">MARKETABLE SECURITIES&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (&#x201c;SBA&#x201d;) loan pools, corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of March 31, 2019 and December&#160;31, 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Level 3 -   Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.368576%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,088,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,088,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,256,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,256,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term cash investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,322,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,322,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of marketable  securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,088,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,578,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,667,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,255,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,290,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RleHRyZWdpb246MzA0N2JlY2E1ZDkwNDNiMjlhOWI2NjM2MDY4YjE5OWNfMzQxMA_852abe9b-256d-4cb3-a109-d2d26684efc1">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.368576%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534214%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. Treasury notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,088,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,088,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,504,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,256,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,256,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term cash investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,322,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,322,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;751,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of marketable  securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,088,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,578,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,667,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,034,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,255,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,290,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:TradingSecurities
      contextRef="i20c891e9fb7e4eae99cfa383cb0f92f7_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi0xLTEtMS0w_890ee92b-ad89-43f4-995e-e9b06c0b6f99"
      unitRef="usd">5088386</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ib8b0db4e0d604245836d3b9282efa85b_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi0zLTEtMS0w_9a6a078c-03af-4437-a5df-951f01f61ef3"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i765abef4a83f4226a84e14bc2ae33d8c_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi01LTEtMS0w_a2ed0a5a-c522-4597-b70b-7665d5a8b4ce"
      unitRef="usd">5088386</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i2d82faed6d35438f93182aff8a5ab296_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi03LTEtMS0w_72291424-a697-4516-b70c-09750d0e0d31"
      unitRef="usd">5034955</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i04d7faf7c40c47348e3a5958acb6d2bb_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi05LTEtMS0w_95094722-eabe-4bd9-a2fa-72a9309f7c5b"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i7e7b988036874b36afb60617609a7f43_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfMi0xMS0xLTEtMA_d817ec1d-1bee-4cee-9778-8c1e6e219494"
      unitRef="usd">5034955</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i133c730e71a944cc8b92b73f899eeb24_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS0xLTEtMS0w_7d72e5e7-b3ea-4c64-b161-b5ebc79435e9"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ic1b5019d5ea04548859133f6e118e6d4_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS0zLTEtMS0w_77003e95-e2c1-4bb8-857a-bde7bdb84201"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i206e669953a243e5b52cf9f148b89afe_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS01LTEtMS0w_fb0cd8d2-5a71-4982-bea8-15cfac9953f8"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="idbedc37caa7c48e18842745320a00757_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS03LTEtMS0w_90dcadfc-1f28-4303-9076-8068f1e6421d"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ifb24625818ae442c902643c2b8ef1809_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS05LTEtMS0w_8e28dd84-28b5-44c2-b39b-0339c7e7ea7b"
      unitRef="usd">2504551</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i00188b3841bf4d549fea497c3b5035bb_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNS0xMS0xLTEtMA_f864adde-e93a-4202-bbe2-d3bf4cca404e"
      unitRef="usd">2504551</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i7b827162bfcb459c97277850d39b0195_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNC0zLTEtMS02NjE_beed51c1-1cd8-41ce-aba6-36d9ea1af963"
      unitRef="usd">2256191</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i3bcfe452ec854bb39d09e29c93466eb8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNC01LTEtMS02NjE_81c6c4f5-3bc3-4509-bc3c-64251fda5980"
      unitRef="usd">2256191</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i7ca7e00066094ffc8fc51be0ceeee303_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNC03LTEtMS0zMjQ1_8976a7a1-c3f9-49a3-8c6f-40c11ef1e40c"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i786c17fe2e7b4dff8a5b3561c9d7c296_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNC05LTEtMS0zMjQ3_9d0a4512-ec47-4bee-a107-c389e9e48a51"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i0315ef2832504837ac981b0b26e5db25_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNC0xMS0xLTEtMzI0OQ_7d60dceb-46e3-443a-b6c2-8a8d843a4fb0"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i931504f50ce44f4193f3ef5928d9a8ba_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy0xLTEtMS0w_49028cfc-22b7-469c-bb0a-acb72665f82b"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ia1e185405caf46dab422666fb5150a6d_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy0zLTEtMS0w_cf83a25a-0d02-44ef-bb85-a266fd8c5e47"
      unitRef="usd">2322496</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i1765b684cd844ab1a94fc477dd7eca3d_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy01LTEtMS0w_e863332c-a6f7-470f-8e82-b8d87f018521"
      unitRef="usd">2322496</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ic7a0bdf9b7dc4e5c951f95a88b27da7a_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy03LTEtMS0w_0da62942-0896-4a52-883b-7e33308a2096"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i9cd15aa51095453da10d48a05a1af738_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy05LTEtMS0w_2294f1f0-e2d5-46cf-bd69-75f850351a61"
      unitRef="usd">751173</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i3f5f73eef27d4e28a3f1b9e8d10e3ec1_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfNy0xMS0xLTEtMA_49972c9c-2b21-4d2d-ad38-684d9a150937"
      unitRef="usd">751173</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i45e179a6466142a0ad009b252e132a12_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC0xLTEtMS0w_1becdd60-fee8-42d0-bd16-fb97c422c696"
      unitRef="usd">5088386</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i5ad98a5cb1834507bd141b4549bc2663_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC0zLTEtMS0w_2c95975c-3c1b-4353-ba5f-a5ff5b7f22cc"
      unitRef="usd">4578687</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC01LTEtMS0w_983b4d37-3f01-4c9f-89cc-5e5c75c75b8e"
      unitRef="usd">9667073</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i281bcc8e4da642aabc6d3614911c0e2b_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC03LTEtMS0w_4a7599d2-0c6f-47f0-bbed-61cc2091fc0f"
      unitRef="usd">5034955</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i79fc34567df54ab59aba1ba9220cd321_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC05LTEtMS0w_268a7a6e-c175-4221-a0fb-c4ef5a91c7f5"
      unitRef="usd">3255724</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml8zNy9mcmFnOjMwNDdiZWNhNWQ5MDQzYjI5YTliNjYzNjA2OGIxOTljL3RhYmxlOjYyMGM5Njk4MDk0YTQ2NDI4NmQxOGI3MTI4ODU0ZTgwL3RhYmxlcmFuZ2U6NjIwYzk2OTgwOTRhNDY0Mjg2ZDE4YjcxMjg4NTRlODBfOC0xMS0xLTEtMA_4e31432d-0b29-4322-a06c-8410a297861b"
      unitRef="usd">8290679</us-gaap:TradingSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RleHRyZWdpb246NGVkMGRlNDE5MzRjNDhjNWIzZmVhYWYyMzAwMjUwYzNfNDMw_b6d8bba4-3e80-4cb5-a2c6-fc306449917c">EARNINGS (LOSS) PER SHARE&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.029499%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616519%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537463%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616519%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(73,878)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,379,239)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,472,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,689,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,472,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,689,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;As of March 31, 2019 and 2018, restricted stock awards and options to purchase 263,919 and 247,530 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RleHRyZWdpb246NGVkMGRlNDE5MzRjNDhjNWIzZmVhYWYyMzAwMjUwYzNfNDI4_97c1a118-c345-49ac-ac4b-7928f213cea2">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.029499%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616519%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537463%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616519%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(73,878)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,379,239)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,472,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,689,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,472,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,689,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfMy0xLTEtMS0w_a2c774aa-2585-4468-9391-4c8e4df40232"
      unitRef="usd">-73878</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfMy0zLTEtMS0w_d49afcbd-8cfd-499b-8098-96260641b2f0"
      unitRef="usd">-2379239</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNS0xLTEtMS0w_c7c6e4d2-f491-4f8c-8be8-4c4e28bf1673"
      unitRef="shares">15472952</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNS0zLTEtMS0w_e103876d-d300-457a-8164-ba91713a57a3"
      unitRef="shares">15689240</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNi0xLTEtMS0w_3d7fcd9d-a6d6-435e-8dd6-caf62fa58dfe"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNi0zLTEtMS0w_06a92c49-21d1-49c5-9530-e9e9e23b3242"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNy0xLTEtMS0w_972fa6c1-414d-4dac-ab73-62fbb8e486e9"
      unitRef="shares">15472952</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RhYmxlOjBkMDZjNGY4YmJlOTQwOWY5MzdhNzM0Y2VlMGVhMzA2L3RhYmxlcmFuZ2U6MGQwNmM0ZjhiYmU5NDA5ZjkzN2E3MzRjZWUwZWEzMDZfNy0zLTEtMS0w_9626accd-a58d-4dc8-823a-ea4399ce9c57"
      unitRef="shares">15689240</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RleHRyZWdpb246NGVkMGRlNDE5MzRjNDhjNWIzZmVhYWYyMzAwMjUwYzNfMjUy_5b5eca14-f346-478d-b139-185d87217730"
      unitRef="shares">263919</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80MC9mcmFnOjRlZDBkZTQxOTM0YzQ4YzViM2ZlYWFmMjMwMDI1MGMzL3RleHRyZWdpb246NGVkMGRlNDE5MzRjNDhjNWIzZmVhYWYyMzAwMjUwYzNfMjU5_e3d223a6-8195-4973-b608-dc59b401a1f5"
      unitRef="shares">247530</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RleHRyZWdpb246Y2IyNzVkNWY5ZjM0NDY1NThlODI4ZTk5NjVhNTY5NTBfMTgwMA_7f720eae-5212-4a76-9aaa-c3a795b96b18">REVENUES&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. However, no cumulative effect adjustment to historical retained earnings was necessary as no revenue recognition differences were identified when comparing the revenue recognition criteria under ASC 606 to previous requirements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company&#x2019;s net revenues consisted of the following for the three months ended March 31, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.502924%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.298246%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;849,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,273,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,307,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,269,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;286,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,317,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,039,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ethyol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,091,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,256,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Totect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;412,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,060,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;709,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,902,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,587,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;The Company has agreements with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is typically entitled to receive a non-refundable, up-front payment at the time each agreement is entered into and additional payments upon the partners' achievement of defined regulatory approvals, sales milestones or both. The Company may also be entitled to receive royalties on future sales of the products under the agreements and a transfer price on supplies.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RleHRyZWdpb246Y2IyNzVkNWY5ZjM0NDY1NThlODI4ZTk5NjVhNTY5NTBfMTgwMg_f5e64e6c-ee06-447c-a162-d8e7e006b774">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company&#x2019;s net revenues consisted of the following for the three months ended March 31, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.502924%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823392%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.298246%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530994%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;849,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,273,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;141,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,307,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,269,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;286,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,317,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,039,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ethyol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,091,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,256,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Totect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;412,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,060,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;709,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,902,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,587,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i399eff68fe09475f8d1927e1b24e18f5_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMy0xLTEtMS0w_a01e2bef-f480-4b1f-9dda-91b9d716ea08"
      unitRef="usd">849502</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c62c25d6b474aec82dbe3df361574c8_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMy0zLTEtMS0w_88f32b5f-f133-44cb-a029-3db825988b70"
      unitRef="usd">1273764</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78fd08901b304e87862ea793372612cc_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNC0xLTEtMS0w_c3a8f343-71b0-42cd-8a55-dcf21601417f"
      unitRef="usd">199537</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i243a8f22302543b491cf4c23088a5b78_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNC0zLTEtMS0w_20a4e0ac-bca9-41ab-9b9d-64dafba8e2c3"
      unitRef="usd">141392</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2abb15b10ea141c0a13f38e41acbfd58_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNS0xLTEtMS0w_4d951de2-83c0-4a80-9921-f917cc3f935a"
      unitRef="usd">3307658</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf2ebe21504f48ce9df5029e04867fb4_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNS0zLTEtMS0w_3bd3808e-125b-496f-919f-550c9f1af126"
      unitRef="usd">3269901</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i992c3adfb7cf4dea8988359b85080c0e_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNi0xLTEtMS0w_2d8245f6-131c-40a0-8839-f8b28d1025c3"
      unitRef="usd">286676</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f711131cff84f42b7542874e5a8c211_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNi0zLTEtMS0w_5ff1c096-4796-4810-85ed-98e4d22e8873"
      unitRef="usd">93890</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3e1587978634f259217537b16f87828_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNy0xLTEtMS0w_4fa54a45-76c7-4978-961e-e0dc4b691b66"
      unitRef="usd">1317074</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd0f500556b04514907e14932d06b892_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfNy0zLTEtMS0w_292e5b42-a850-40be-b248-3040e245ff8f"
      unitRef="usd">1039747</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida8fc49ce7b346adb56f00c51bb7dbd5_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfOC0xLTEtMS0w_f0e00469-bffd-4b26-94ff-7638b24a66d3"
      unitRef="usd">3091991</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i546e97edc09840048611ed807a57b0d6_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfOC0zLTEtMS0w_0eb7a7d3-0c1e-48ca-a65b-1db3018435b4"
      unitRef="usd">2256073</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6d51fc324234a1c807f02d120cac973_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfOS0xLTEtMS0w_46ded999-b73b-4db7-b07b-96c054e6439c"
      unitRef="usd">80896</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic45f1596255243a5b3a837136a21297d_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfOS0zLTEtMS0w_f78aad36-91e4-45a6-9ccb-6fc096e6d558"
      unitRef="usd">412774</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51174cd0c9b8448c9fdeac2a3c7adb13_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTAtMS0xLTEtMzI1OA_81ab069b-8051-4564-973a-b6b46a74cd0c"
      unitRef="usd">2060195</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a65212ca148417c818133e73d4e6e7e_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTAtMy0xLTEtMzI2MA_e1cbfd37-5aee-4b43-a40a-253426ab32b3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i187b59007ba34807a5a064a86071efa7_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTAtMS0xLTEtMA_a5834272-660e-401f-9121-4e25936d9803"
      unitRef="usd">709218</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3677ad66cce4a5a86c6214572f63329_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTAtMy0xLTEtMA_d0778f52-67af-43e5-b8d4-6c7cc9ecc5f4"
      unitRef="usd">100064</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTEtMS0xLTEtMA_9f22830e-c0e1-4f0e-ac60-0f25f0a0910d"
      unitRef="usd">11902747</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80My9mcmFnOmNiMjc1ZDVmOWYzNDQ2NTU4ZTgyOGU5OTY1YTU2OTUwL3RhYmxlOjQxMzhmYTE1NmYzZjRjODA4OGQ0MThjZTViYzYyYTY1L3RhYmxlcmFuZ2U6NDEzOGZhMTU2ZjNmNGM4MDg4ZDQxOGNlNWJjNjJhNjVfMTEtMy0xLTEtMA_945467d5-2469-49ab-9630-853e5cfd0878"
      unitRef="usd">8587605</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfMjc0ODc3OTA3NDcyMw_ec4bf27f-8037-4c00-9295-c7150da84d40">INVENTORIES&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2019 and December 31, 2018, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.3 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total.  Consigned inventory represents Authorized Generic inventory stored until shipment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $14.9 million that are classified as non-current inventories at March 31, 2019 and December 31, 2018. Non-current inventories also include $0.9 million and $0.8 million in Vibativ finished goods at March 31, 2019 and December&#160;31, 2018, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's net inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.737151%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.681057%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,383,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,378,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;683,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;937,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,054,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,511,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,121,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,827,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,862,092)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,749,000)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,259,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,078,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfOTkz_712db7b0-370a-44c3-a71d-ff6001a3e0a2"
      unitRef="usd">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfMTAwMQ_254dd052-f5fb-47d5-8b7f-0b0133cccf12"
      unitRef="usd">300000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i370fbb3a09b94f55b491f2c991a0a56a_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfNTQ5NzU1ODE5MTg2_57b9348e-aebc-4caa-b15e-ce71327034f2"
      unitRef="usd">14900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i370fbb3a09b94f55b491f2c991a0a56a_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfNTQ5NzU1ODE5MjAw_ed1fe114-6c56-44df-89b1-0ff8203eb23c"
      unitRef="usd">900000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i1f6ebe33ae304eed860a6b42f65a094e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfNTQ5NzU1ODE5MjE0_462bf95d-4345-4fb6-8e82-025b3c0618cb"
      unitRef="usd">800000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RleHRyZWdpb246ZTljODE4ZTVhODcwNDhhMjkzM2NjYTJmOGVmYzFlZTBfMjc0ODc3OTA3NDc3MA_d812bd84-6b45-4118-8413-6ae79b876276">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's net inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.737151%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121586%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.681057%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530103%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,383,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,378,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;683,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;937,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,054,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,511,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,121,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,827,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,862,092)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,749,000)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,259,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,078,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfMi0yLTEtMS0xNzc_f8159b60-6222-47bc-93ad-e1c5f109f77f"
      unitRef="usd">18383018</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfMi00LTEtMS0xNzc_5077de3a-3868-4d72-a190-5db934ba82dd"
      unitRef="usd">18378450</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfMy0yLTEtMS0xNzc_f56512eb-8ada-440e-9717-63db6b471b7b"
      unitRef="usd">683733</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfMy00LTEtMS0xNzc_dfb08c02-7cb9-437f-9637-8145823ae767"
      unitRef="usd">937006</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNC0yLTEtMS0xNzc_f8161480-f302-4dbd-b80c-a593c10b34ea"
      unitRef="usd">8054574</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNC00LTEtMS0xNzc_e2e3d5fb-9e9d-49c9-b641-c80c72109230"
      unitRef="usd">8511887</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNS0yLTEtMS0xNzc_de6b4e13-b6b0-41bd-a322-b2998b026dc1"
      unitRef="usd">27121325</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNS00LTEtMS0xNzc_b00f6d50-56cd-4f52-a0b3-5ceb158e73a2"
      unitRef="usd">27827343</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNi0yLTEtMS0zMjcx_a54a24c5-8bea-4a0b-8a8d-23055f7c8021"
      unitRef="usd">15862092</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNi00LTEtMS0zMjc3_b9271f0b-f280-414b-8a68-83beb049197a"
      unitRef="usd">15749000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNy0yLTEtMS0zMjcz_21877af2-6848-486d-9980-55b90681d725"
      unitRef="usd">11259233</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80Ni9mcmFnOmU5YzgxOGU1YTg3MDQ4YTI5MzNjY2EyZjhlZmMxZWUwL3RhYmxlOjBlNmM0NjNmOTBiODRmYjc4YzdiZmRjYTgwOTc1NTUwL3RhYmxlcmFuZ2U6MGU2YzQ2M2Y5MGI4NGZiNzhjN2JmZGNhODA5NzU1NTBfNy00LTEtMS0zMjc5_950f64c8-6674-4f2b-b05e-4a04b2697468"
      unitRef="usd">12078343</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQzNTc_a700a015-b46a-4cc6-88de-b95e86010012">LEASES&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#x2019;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 under the alternative transition method (the effective date approach). It allowed the Company to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Prior periods have not been adjusted.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  The Company&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (&#x201c;CET&#x201d;), our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. The Company did not have any leases classified as finance leases at January 1, 2019 or March 31, 2019.  The new lease accounting standard did not have a significant impact on the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs at the adoption date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;These operating leases resulted in initial ROU assets of $3.6 million and lease liabilities of $3.8 million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is 3.7 years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;At March 31, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.036036%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.090090%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,487,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,487,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.036036%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.090090%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,023,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,605,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,629,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.078078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturity of Leases Liabilities at March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;825,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,120,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,202,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(573,139)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,629,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's future minimum lease commitments as of December 31 2018, under Accounting Standards Codification 840, predecessor to the newly adopted lease accounting guidance, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.078078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;959,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;980,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,001,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;871,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,858,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4a7a3ae6831347ca9db4b51688a19d28_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzE2NDkyNjc0NDY3MTI_9020d24c-9332-4bb1-8fe3-e69999a56915"
      unitRef="usd">3600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4a7a3ae6831347ca9db4b51688a19d28_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzE2NDkyNjc0NDY3Mzk_b6e46ad4-534a-4821-9673-42cd2e2f604f"
      unitRef="usd">3800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQ0NDA_6e0d427b-7c3b-48e6-a57c-00050a1f47c1">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQ0NDc_a4c044ac-30f2-466a-a398-09d641b5927c"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQzNTg_a51014e3-1b93-423c-9676-bfd432bf2e2e">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;At March 31, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.036036%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.090090%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,487,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,487,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.036036%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.090090%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,023,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,605,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,629,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo5NDA0ZDNhNjg5NDg0ZGRkYTM1OTI3YjgwZmY3NGNjOS90YWJsZXJhbmdlOjk0MDRkM2E2ODk0ODRkZGRhMzU5MjdiODBmZjc0Y2M5XzEtNC0xLTEtMzQ0MQ_7afa60f3-ef50-472b-9a68-d5911974ff24"
      unitRef="usd">3487977</us-gaap:OperatingLeaseRightOfUseAsset>
    <cpix:LeaseAsset
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo5NDA0ZDNhNjg5NDg0ZGRkYTM1OTI3YjgwZmY3NGNjOS90YWJsZXJhbmdlOjk0MDRkM2E2ODk0ODRkZGRhMzU5MjdiODBmZjc0Y2M5XzItNC0xLTEtMzQ0Mw_5f244461-e46f-43ca-8fc6-9f261b0c9e7e"
      unitRef="usd">3487977</cpix:LeaseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTphOWVhOWJjNzE2OWY0NzY3YmM2YjkxYjY1MzMzYjk0NS90YWJsZXJhbmdlOmE5ZWE5YmM3MTY5ZjQ3NjdiYzZiOTFiNjUzMzNiOTQ1XzItNC0xLTEtMzQ0OQ_eeba9fde-ad4a-4d44-8ae2-358e8cf24c26"
      unitRef="usd">1023603</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTphOWVhOWJjNzE2OWY0NzY3YmM2YjkxYjY1MzMzYjk0NS90YWJsZXJhbmdlOmE5ZWE5YmM3MTY5ZjQ3NjdiYzZiOTFiNjUzMzNiOTQ1XzQtNC0xLTEtMzQ1MQ_16ea01d5-5e11-42df-bf31-5dbe0d811f5b"
      unitRef="usd">2605717</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTphOWVhOWJjNzE2OWY0NzY3YmM2YjkxYjY1MzMzYjk0NS90YWJsZXJhbmdlOmE5ZWE5YmM3MTY5ZjQ3NjdiYzZiOTFiNjUzMzNiOTQ1XzUtNC0xLTEtMzQ1Mw_5f53cb68-b61d-43f8-94d3-a496b544737a"
      unitRef="usd">3629320</cpix:LeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQzNTk_243d9e35-a5d4-470f-ad5f-4726dd98b3e0">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.078078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturity of Leases Liabilities at March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;825,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,120,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,202,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(573,139)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,629,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzEtMi0xLTEtMzQ4Nw_bdd34c51-6598-4798-97e9-fa37b41e6a54"
      unitRef="usd">825712</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzItMi0xLTEtMzQ4OQ_ec48e3d4-45c0-4462-a7c6-d13990044c13"
      unitRef="usd">1120067</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzMtMi0xLTEtMzQ5MQ_062a1110-187b-4f4d-a993-328815875168"
      unitRef="usd">1144889</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzQtMi0xLTEtMzQ5NA_71c602e3-c903-4f2d-8a06-df852b84f2cd"
      unitRef="usd">1019313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzUtMi0xLTEtMzQ5Ng_72561782-3919-47db-9d91-be654f9a16e2"
      unitRef="usd">92478</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzYtMi0xLTEtMzQ5OQ_a1f7306f-28cd-4766-b88b-aedbaf29dd5a"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzctMi0xLTEtMzUwMQ_8b034f63-eede-4923-b0a8-f948072426e2"
      unitRef="usd">4202459</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzgtMi0xLTEtMzUwMw_f89f3bc9-8893-4d6e-93e5-086e3bb0141f"
      unitRef="usd">573139</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie5d35faab61a4630ad543d1af0cc16d8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo0ZDYyOTA2MWM3MWM0N2VmODkxZjI3OWQxMDZjNGI1OS90YWJsZXJhbmdlOjRkNjI5MDYxYzcxYzQ3ZWY4OTFmMjc5ZDEwNmM0YjU5XzktMi0xLTEtMzUwNQ_1ea5a555-b595-4167-ad6e-08fda0cbacdd"
      unitRef="usd">3629320</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90ZXh0cmVnaW9uOjM1YTA1OWEzNWRmYzRhYjZiNDliMTY2ZDQxOThmZDEzXzI3NDg3NzkwNzQzNjA_b5ffabdf-286a-48d6-ad42-e4b9bbbbe41c">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company's future minimum lease commitments as of December 31 2018, under Accounting Standards Codification 840, predecessor to the newly adopted lease accounting guidance, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.078078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751952%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.969970%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;959,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;980,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,001,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;871,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;44,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,858,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzEtMi0xLTEtMzUwNw_01d2156a-b349-4ea7-9b20-58a30e280fe4"
      unitRef="usd">959902</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzItMi0xLTEtMzUwOQ_6d5bcd7b-dc1c-4c36-9579-275cd0dddfe8"
      unitRef="usd">980720</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzMtMi0xLTEtMzUxMQ_b396a405-91c5-4c5f-b48b-4e592898f312"
      unitRef="usd">1001603</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzQtMi0xLTEtMzUxMw_84862e61-11ed-4cb0-84c8-aef2b5db09a3"
      unitRef="usd">871969</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzUtMi0xLTEtMzUxNQ_c8f2305a-7cb7-409b-a985-ad0225741b8a"
      unitRef="usd">44508</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzYtMi0xLTEtMzUxNw_d8373755-ffe9-4514-b3c0-3809a9510e3b"
      unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="i2320adaf662e4fe7b2b901c919253249_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NjAvZnJhZzozNWEwNTlhMzVkZmM0YWI2YjQ5YjE2NmQ0MTk4ZmQxMy90YWJsZTo3NGU4M2U5NWVkZDg0MWYwYmQ5YTA5NzlkMmNlMTUwYy90YWJsZXJhbmdlOjc0ZTgzZTk1ZWRkODQxZjBiZDlhMDk3OWQyY2UxNTBjXzctMi0xLTEtMzUxOQ_7da17104-41b4-4119-bb58-040e68094e3f"
      unitRef="usd">3858702</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMzQ4Ng_0d4bc273-de97-430e-ae99-8dc9e4235867">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2019 and March 31, 2018, the Company repurchased 121,466 shares and 172,079 shares, respectively, of common stock for approximately $0.7 million and $1.2 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;During the March 2019 trading window, several members of the the Company's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to further the amount of ownership by the Board of Directors. During the March 2019 trading window, one Board member entered into a share sale agreement, as required by a policy change by his employer, which now prohibits his ownership in the Company.  The policy did not impact his ability to serve on the Company's Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Share Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. During the three months ended March 31, 2018, the Company issued 30,704 shares of common stock for gross proceeds of $0.2 million as part of its At-The-Market (&#x201c;ATM&#x201d;) sales agreement with B. Riley FBR. The Company did not issue any shares under the ATM during the three months ended March 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Restricted Share Grants &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;During the three months ended March 31, 2019,  and March 31, 2018, the Company issued 222,269 shares and 229,205 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#x201c;Pinnacle Agreement&#x201d;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants.  On October 17, 2018, the Company entered into a second amendment (&#x201c;Second Amendment&#x201d;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  Cumberland increased the maximum aggregate principal available for borrowing to support potential future acquisitions and general corporate purposes.  The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had $20.0 million in borrowings under the Pinnacle Agreement at March 31, 2019 and December 31, 2018, thereby using all of its available borrowing under its revolving line of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 5.2% at March 31, 2019).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  As a result of the Third Amendment, the Company was in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="icec24700d0ae4b5c96e743134dc74822_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTMw_2c9e5d30-c611-4462-ad30-e6a5f6d839ff"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ib7d16aac31044218bb5b9daf893c454a_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMjkx_294b7ed1-5f09-4290-b640-9c36cb8e5805"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMzk3_80de4085-f64b-428c-a8e1-d7329e163c60"
      unitRef="shares">121466</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfNDEx_56e7eb69-c028-40ec-9064-55a08ce6da7a"
      unitRef="shares">172079</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i5abe0f84bec94e9d9c319098d61af117_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfNDcw_5ec0e313-4f87-4d06-b342-0bdc561137ea"
      unitRef="usd">700000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfNDg1_91bdb09f-ca39-4031-8281-93ce6c3083b2"
      unitRef="usd">1200000</us-gaap:StockRepurchasedDuringPeriodValue>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="ie1c518feb5474c11b67fefc2bfc51704_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfNjM5_4df810a9-7a5d-48a8-bb69-c2d7a164e92e"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding
      contextRef="ie13af4afd51e4990a0ac8e5a87d069af_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ2NDg2Mg_0925f4b3-c33c-4ba3-a5a8-20be30ba71f9"
      unitRef="shares">30704</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibcd744c2d6d842918fc6e54d499c40fb_D20180101-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfODEy_53153241-4b77-447e-8dc1-98920e44d7d0"
      unitRef="usd">200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i42d1dca0050148988cc1661e80f74884_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfOTYz_6c25fd5e-9afd-4d1f-9418-13ecd9d0ae56"
      unitRef="shares">222269</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1a32d6eb05e04225a17c4afc1836f061_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfOTc3_d6128f4c-9ba2-43c6-a309-41f6fb612858"
      unitRef="shares">229205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5a16259aa7064665beb60a659a9e175f_I20181017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NDY2NQ_431e525f-18ff-4be9-afd5-661616f85da9"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i575d0c767db6474b8c9ab64d88e752e3_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NDkzNA_72cfb03f-288b-4c03-9b54-0bb3ef7e17f4"
      unitRef="usd">12000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions
      contextRef="i575d0c767db6474b8c9ab64d88e752e3_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NTAxNw_ab40155f-70ee-4efa-b840-6dd49875f775"
      unitRef="usd">20000000.0</cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions>
    <us-gaap:LongTermLineOfCredit
      contextRef="i9f348e2b52e9422cb8037060ca5972d0_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NTM1Mg_f21c3ae0-7d0d-4f88-959d-9c966c84cb12"
      unitRef="usd">20000000.0</us-gaap:LongTermLineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2048c5597798442694e3f3970659f9e9_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NTcyOA_1f0ae2a6-0074-429b-bfea-7e4ab2a4c6ec"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i44a6e15c3f574e3db1922e1ad5b5b56d_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NTczNA_5544d56f-b63d-4c15-b1d9-e7dd3699cca9"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i575d0c767db6474b8c9ab64d88e752e3_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMzI5ODUzNDkwNzk1NQ_14c31fd0-4ec3-4e40-b30d-0bbbc112cd37"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i2182d9e6420b4100b344f9c6cc077aa0_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml80OS9mcmFnOjczN2JjNTAxYWI5NzQ5Zjc5ODRhY2Y1M2RjODE2ODZiL3RleHRyZWdpb246NzM3YmM1MDFhYjk3NDlmNzk4NGFjZjUzZGM4MTY4NmJfMTY0OTI2NzQ1NTgwNQ_2fc16af0-c6a0-409c-b31d-0331aac9fbe4"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81NS9mcmFnOjM4ZjAwYzYzYWNlZTRjMzM4NzhjNjZjOGViMjRjMzkxL3RleHRyZWdpb246MzhmMDBjNjNhY2VlNGMzMzg3OGM2NmM4ZWIyNGMzOTFfMTk4MA_89906b96-e97c-440c-a792-c5203ae809d8">INCOME TAXESOn December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#x201c;the Tax Act&#x201d;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#x201c;AMT&#x201d;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.The SEC staff issued Staff Accounting Bulletin (&#x201c;SAB&#x201d;) 118, providing guidance on applying the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements.  If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.  The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml81OC9mcmFnOjVhZDZjZTBmYWU0ODQxZjJhNDI5ZGRkYTNiMWE0ZTJiL3RleHRyZWdpb246NWFkNmNlMGZhZTQ4NDFmMmE0MjlkZGRhM2IxYTRlMmJfOTc5_09ea9280-4801-4230-8783-ef354e056fd0">COLLABORATIVE AGREEMENTS&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY1OA_d577e7b9-2860-4a98-aed4-9e98a5440844">RECENT PRODUCT ADDITIONS&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak, including the product&#x2019;s FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $2.3 million during 2018 and ended Cumberland&#x2019;s payments of royalties and manufacturing fees to GEL.  The Company has now assumed responsibility for the maintenance of the product&#x2019;s FDA approval and for the oversight of the product&#x2019;s manufacturing and packaging.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  While Cumberland is still evaluating the tax deductibility of the goodwill acquired in the acquisition, it expects those amounts to be deductible for tax purposes.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company paid an upfront payment of $20.0 million with a $5.0 million cash payment that was provided in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.631579%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.368421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment during early 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements.  The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923977%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.076023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at November 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;508,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,502,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment to initial fair value of the contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(507,505)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(269,422)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,072,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923977%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.076023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $2.2 million and the non-current portion is $6.9 million.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <cpix:PaymentsForAssetAcquisitions
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMTY0OTI2NzQ0MzM3Mw_e46ae5c4-6111-4659-8589-6b0994bc637c"
      unitRef="usd">2300000</cpix:PaymentsForAssetAcquisitions>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ie2424f11376147c9af04e9c63133c333_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMTY0OTI2NzQ0OTQxMA_cba99dd0-2906-4f97-ac34-ce921a05f1a9"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="if1788a3b19df415c95d49112f2d872f8_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMTY0OTI2NzQ0OTQyMA_ee89461f-7201-48c2-a8e1-2b01584549e5"
      unitRef="usd">5000000.0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="ie2424f11376147c9af04e9c63133c333_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMTY0OTI2NzQ0OTUxNg_6a415c01-436f-4cf7-a09d-4c9de808d16c"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY1OQ_5a0fd7ba-a5d2-41a8-86f0-74e1e469af39">&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.631579%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.368421%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment during early 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjQzZTcyN2NlZjRiNjQzZDM5OGYyYzM0N2QwYTZjOWM5L3RhYmxlcmFuZ2U6NDNlNzI3Y2VmNGI2NDNkMzk4ZjJjMzQ3ZDBhNmM5YzlfMi0xLTEtMS0zNzM3_1ecdd589-24e9-4d8c-97d9-54c169989f97"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjQzZTcyN2NlZjRiNjQzZDM5OGYyYzM0N2QwYTZjOWM5L3RhYmxlcmFuZ2U6NDNlNzI3Y2VmNGI2NDNkMzk4ZjJjMzQ3ZDBhNmM5YzlfMy0xLTEtMS0zNzM5_3ecbb306-3f20-4f66-8184-474659f11722"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:PaymentsForContingentConsideration
      contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjQzZTcyN2NlZjRiNjQzZDM5OGYyYzM0N2QwYTZjOWM5L3RhYmxlcmFuZ2U6NDNlNzI3Y2VmNGI2NDNkMzk4ZjJjMzQ3ZDBhNmM5YzlfNC0xLTEtMS0zNzQx_0fbf8878-a992-49ed-afc7-f91a91dddae9"
      unitRef="usd">9182000</cpix:PaymentsForContingentConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjQzZTcyN2NlZjRiNjQzZDM5OGYyYzM0N2QwYTZjOWM5L3RhYmxlcmFuZ2U6NDNlNzI3Y2VmNGI2NDNkMzk4ZjJjMzQ3ZDBhNmM5YzlfNS0xLTEtMS0zNzQz_54ffea73-6cd4-4302-ae4b-a3f24406d6ab"
      unitRef="usd">34182000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY2MA_723ef2db-45bd-4d80-8b21-62fbf2cc4b20">&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923977%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.076023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at November 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;508,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,502,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment to initial fair value of the contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(507,505)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(269,422)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,072,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifda35f731b37450782fc5c338eb2a4a8_I20181112"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfMS0xLTEtMS0zNzUz_81a5d605-a6ca-4afe-b130-788c2a830e6b"
      unitRef="usd">9034000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i31c62ad8b23f4059be803e962f97748f_D20181113-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfMi0xLTEtMS0xMTM3_d9fc0602-5bd6-4dc5-9cb5-1aeedbc5b57b"
      unitRef="usd">-40000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i6a9204f2031142428a1963d884e11716_D20181112-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfMy0xLTEtMS0xMTM3_3536fcef-de16-4fa0-b2bb-dc077cbbf33e"
      unitRef="usd">508000</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1f6ebe33ae304eed860a6b42f65a094e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfNC0xLTEtMS0zNzU5_fea5d8a1-4283-403c-957f-8d75073398ca"
      unitRef="usd">9502000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment
      contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfNS0xLTEtMS0zNzYx_760baf03-15ae-4155-b6f1-73017c352aa0"
      unitRef="usd">148000</cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment>
    <us-gaap:PaymentsForRoyalties
      contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfNi0xLTEtMS0zNzYz_6b920b3b-be9c-46ec-9a3b-54c75f5e06d8"
      unitRef="usd">507505</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfNy0xLTEtMS0zNzY1_60e84f8b-b2b0-440f-966a-5b3aab2d60ed"
      unitRef="usd">-269422</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfOC0xLTEtMS0zNzY3_1b4648f4-b9b6-4b44-a4a7-868fe420beea"
      unitRef="usd">199432</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i370fbb3a09b94f55b491f2c991a0a56a_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOjdjYjYwYTU3NGQ2MzQyODk5MjU5NDk0OThmZjA0M2RjL3RhYmxlcmFuZ2U6N2NiNjBhNTc0ZDYzNDI4OTkyNTk0OTQ5OGZmMDQzZGNfOS0xLTEtMS0zNzY5_1163e487-7435-479e-a603-2532f3a48009"
      unitRef="usd">9072505</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY2MQ_6f2dc7ed-f377-48b5-b8c5-e5e29ef17696">&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"&gt;The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923977%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.076023%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory
      contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfMC0xLTEtMS0zNzc1_1f92e4a8-f9a0-44c0-8cf9-f8594938da23"
      unitRef="usd">6624000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials
      contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfMS0xLTEtMS0zNzc3_04e9cddb-6f84-4eb3-a2e6-e5b3fda12040"
      unitRef="usd">3970000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials
      contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfMi0xLTEtMS0zNzc5_2b8cfb72-a02e-41d0-9516-ededeb569371"
      unitRef="usd">1827000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory
      contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfMy0xLTEtMS0zNzgx_0eb89c77-dfa4-4c41-93dc-0989984437ad"
      unitRef="usd">9129000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfNC0xLTEtMS0zNzgz_5ac748e9-bf0f-4a98-9e59-9e30b071a09d"
      unitRef="usd">21550000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfNi0xLTEtMS0zNzg1_e9bc3c3a-f10b-4e5c-beb9-16ee87371dfa"
      unitRef="usd">11750000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfNy0xLTEtMS0zNzg3_fc152256-4f6f-46ff-8d04-251db26e1a00"
      unitRef="usd">882000</us-gaap:Goodwill>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill
      contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfOC0xLTEtMS0zNzg5_491c2cac-6349-4107-b812-ad423cf52bba"
      unitRef="usd">12632000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RhYmxlOmY4NWY2Zjg3ODY1MDQzMGJhYjhjYzA5NGI2NmUzNmZjL3RhYmxlcmFuZ2U6Zjg1ZjZmODc4NjUwNDMwYmFiOGNjMDk0YjY2ZTM2ZmNfOS0xLTEtMS0zNzkx_833afe85-be9d-4841-ad85-c3cf21dbd64b"
      unitRef="usd">34182000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="if53f00afbc0c44d78276b75547af3d20_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY2Nw_721ee587-97d2-4700-9397-90af4c41a4e6"
      unitRef="usd">2200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="if53f00afbc0c44d78276b75547af3d20_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjIxYTAzMDkyY2Q0ZjQ0OTBhMWQwN2RkNWYwZGIyNTUyL3NlYzoyMWEwMzA5MmNkNGY0NDkwYTFkMDdkZDVmMGRiMjU1Ml82MS9mcmFnOjQ3ZDZjYzZhNmYyYzQ2MmI4YTlhOGIxMzQwMDhhODYxL3RleHRyZWdpb246NDdkNmNjNmE2ZjJjNDYyYjhhOWE4YjEzNDAwOGE4NjFfMjc0ODc3OTA4OTY3Mw_a5092d89-b3d8-43a9-baaa-93549c8f9d6d"
      unitRef="usd">6900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6758954384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>May 10, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,537,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759204000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,609,415<span></span>
</td>
<td class="nump">$ 27,938,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">9,667,073<span></span>
</td>
<td class="nump">8,290,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">9,973,995<span></span>
</td>
<td class="nump">7,844,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">11,259,233<span></span>
</td>
<td class="nump">12,078,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,456,453<span></span>
</td>
<td class="nump">2,963,806<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">57,966,169<span></span>
</td>
<td class="nump">59,116,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">15,862,092<span></span>
</td>
<td class="nump">15,749,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">744,085<span></span>
</td>
<td class="nump">771,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">32,910,261<span></span>
</td>
<td class="nump">33,655,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax assets, net</a></td>
<td class="nump">43,605<span></span>
</td>
<td class="nump">87,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,209,417<span></span>
</td>
<td class="nump">2,531,309<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">114,617,629<span></span>
</td>
<td class="nump">112,693,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,292,014<span></span>
</td>
<td class="nump">11,093,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">18,706,631<span></span>
</td>
<td class="nump">16,710,927<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,998,645<span></span>
</td>
<td class="nump">27,804,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">11,428,257<span></span>
</td>
<td class="nump">9,319,143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">59,426,902<span></span>
</td>
<td class="nump">57,123,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">50,759,257<span></span>
</td>
<td class="nump">51,098,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">4,672,276<span></span>
</td>
<td class="nump">4,746,154<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">55,431,533<span></span>
</td>
<td class="nump">55,844,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(240,806)<span></span>
</td>
<td class="num">(274,266)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">55,190,727<span></span>
</td>
<td class="nump">55,570,501<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 114,617,629<span></span>
</td>
<td class="nump">$ 112,693,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Obligations, Excluding Current Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6752802480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,547,517<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,547,517<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759126640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 11,902,747<span></span>
</td>
<td class="nump">$ 8,587,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">1,999,736<span></span>
</td>
<td class="nump">1,527,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">5,120,505<span></span>
</td>
<td class="nump">4,670,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,267,601<span></span>
</td>
<td class="nump">1,874,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,670,056<span></span>
</td>
<td class="nump">2,330,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,021,645<span></span>
</td>
<td class="nump">636,135<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">12,079,543<span></span>
</td>
<td class="nump">11,039,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(176,796)<span></span>
</td>
<td class="num">(2,452,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">115,861<span></span>
</td>
<td class="nump">82,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(60,911)<span></span>
</td>
<td class="num">(18,302)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="num">(121,846)<span></span>
</td>
<td class="num">(2,388,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="nump">81,428<span></span>
</td>
<td class="num">(4,159)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(40,418)<span></span>
</td>
<td class="num">(2,392,189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(33,460)<span></span>
</td>
<td class="nump">12,950<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (73,878)<span></span>
</td>
<td class="num">$ (2,379,239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">- basic (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">- diluted (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">15,472,952<span></span>
</td>
<td class="nump">15,689,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">15,472,952<span></span>
</td>
<td class="nump">15,689,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to common shareholders</a></td>
<td class="num">$ (73,878)<span></span>
</td>
<td class="num">$ (2,379,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(33,460)<span></span>
</td>
<td class="nump">12,950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss)</a></td>
<td class="num">$ (40,418)<span></span>
</td>
<td class="num">$ (2,392,189)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759360240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (40,418)<span></span>
</td>
<td class="num">$ (2,392,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,076,246<span></span>
</td>
<td class="nump">692,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">43,605<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">364,434<span></span>
</td>
<td class="nump">339,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">(Decrease) increase in non-cash contingent consideration</a></td>
<td class="num">(269,422)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">10,497<span></span>
</td>
<td class="nump">18,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Noncash investment gains</a></td>
<td class="num">(44,191)<span></span>
</td>
<td class="num">(43,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,129,746)<span></span>
</td>
<td class="nump">2,093,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">819,110<span></span>
</td>
<td class="nump">76,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">134,578<span></span>
</td>
<td class="nump">600,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="num">(1,254,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(353,925)<span></span>
</td>
<td class="nump">103,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(385,733)<span></span>
</td>
<td class="nump">235,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(27,474)<span></span>
</td>
<td class="num">(94,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(7,816,191)<span></span>
</td>
<td class="num">(15,151,948)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">6,483,988<span></span>
</td>
<td class="nump">4,257,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(363,711)<span></span>
</td>
<td class="num">(532,954)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,723,388)<span></span>
</td>
<td class="num">(11,522,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">19,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(19,000,000)<span></span>
</td>
<td class="num">(9,800,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sales of common stock, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(248,108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(507,505)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(712,919)<span></span>
</td>
<td class="num">(1,016,156)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(1,220,424)<span></span>
</td>
<td class="nump">1,136,645<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(3,329,545)<span></span>
</td>
<td class="num">(10,149,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">27,938,960<span></span>
</td>
<td class="nump">45,412,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">24,609,415<span></span>
</td>
<td class="nump">35,262,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Recognition of operating lease assets and liabilities through adoption of ASC 842</a></td>
<td class="nump">$ 3,629,320<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760767072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2017</a></td>
<td class="nump">$ 63,921,601<span></span>
</td>
<td class="nump">$ 52,410,941<span></span>
</td>
<td class="nump">$ 11,709,222<span></span>
</td>
<td class="num">$ (198,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,723,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, net of offering costs</a></td>
<td class="nump">200,909<span></span>
</td>
<td class="nump">$ 200,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">339,209<span></span>
</td>
<td class="nump">$ 339,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares</a></td>
<td class="num">(1,195,225)<span></span>
</td>
<td class="num">$ (1,195,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,392,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,379,239)<span></span>
</td>
<td class="num">(12,950)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2018</a></td>
<td class="nump">60,874,305<span></span>
</td>
<td class="nump">$ 51,755,834<span></span>
</td>
<td class="nump">9,329,983<span></span>
</td>
<td class="num">(211,512)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,727,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2018</a></td>
<td class="nump">$ 55,570,501<span></span>
</td>
<td class="nump">$ 51,098,613<span></span>
</td>
<td class="nump">4,746,154<span></span>
</td>
<td class="num">(274,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2018</a></td>
<td class="nump">15,481,497<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 364,434<span></span>
</td>
<td class="nump">$ 364,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares</a></td>
<td class="num">(703,790)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(40,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,878)<span></span>
</td>
<td class="nump">33,460<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2019</a></td>
<td class="nump">$ 55,190,727<span></span>
</td>
<td class="nump">$ 50,759,257<span></span>
</td>
<td class="nump">$ 4,672,276<span></span>
</td>
<td class="num">$ (240,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2019</a></td>
<td class="nump">15,547,517<span></span>
</td>
<td class="nump">15,547,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6750232112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2018 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 (the &#8220;2018 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Total comprehensive income (loss) consisted solely of net income (loss) for the three months ended March 31, 2019 and 2018.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 6.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Policies:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;">Operating Segments</span></div>The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6904257744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text">MARKETABLE SECURITIES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (&#8220;SBA&#8221;) loan pools, corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of March 31, 2019 and December&#160;31, 2018, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Level 3 -   Significant inputs to the valuation model are unobservable.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"> </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:27.368576%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,088,386&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,088,386&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,504,551&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,504,551&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,256,191&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,256,191&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,322,496&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,322,496&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">751,173&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">751,173&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,088,386&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,578,687&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,667,073&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,255,724&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,290,679&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6750232112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"/><td style="width:58.029499%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.616519%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537463%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.616519%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(73,878)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,379,239)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,472,952&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,689,240&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,472,952&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,689,240&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;margin-top:11pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of March 31, 2019 and 2018, restricted stock awards and options to purchase 263,919 and 247,530 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6904226928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Product Revenues</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. However, no cumulative effect adjustment to historical retained earnings was necessary as no revenue recognition differences were identified when comparing the revenue recognition criteria under ASC 606 to previous requirements.  </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:57.502924%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.444444%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.298246%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">849,502&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,273,764&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">199,537&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">141,392&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,307,658&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,269,901&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">286,676&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,890&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,317,074&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,039,747&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,091,991&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,256,073&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Totect</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,896&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">412,774&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060,195&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">709,218&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">100,064&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,902,747&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,587,605&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Other Revenues</span></div>The Company has agreements with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is typically entitled to receive a non-refundable, up-front payment at the time each agreement is entered into and additional payments upon the partners' achievement of defined regulatory approvals, sales milestones or both. The Company may also be entitled to receive royalties on future sales of the products under the agreements and a transfer price on supplies.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6744988112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2019 and December 31, 2018, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.3 million, respectively. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total.  Consigned inventory represents Authorized Generic inventory stored until shipment.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $14.9 million that are classified as non-current inventories at March 31, 2019 and December 31, 2018. Non-current inventories also include $0.9 million and $0.8 million in Vibativ finished goods at March 31, 2019 and December&#160;31, 2018, respectively.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:56.737151%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.681057%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18,383,018&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18,378,450&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">683,733&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">937,006&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,054,574&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,511,887&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,121,325&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,827,343&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,862,092)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,749,000)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,259,233&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,078,343&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6750244288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The Company adopted ASU 2016-02 under the alternative transition method (the effective date approach). It allowed the Company to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Prior periods have not been adjusted.   </span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. The Company did not have any leases classified as finance leases at January 1, 2019 or March 31, 2019.  The new lease accounting standard did not have a significant impact on the Company's Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for any period presented. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company elected the package of practical expedients offered in the transition guidance which allows management not to reassess lease identification, lease classification and initial direct costs at the adoption date. </span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">These operating leases resulted in initial ROU assets of $3.6 million and lease liabilities of $3.8 million as of January 1, 2019 for non-cancelable operating leases with original lease terms in excess of one year.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term is 3.7 years and the weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Lease Position</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At March 31, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: </span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:34.036036%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:38.090090%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,487,977&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,487,977&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:34.036036%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:38.090090%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,023,603&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,605,717&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,629,320&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:76.078078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity of Leases Liabilities at March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">825,712&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,120,067&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,144,889&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,019,313&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">92,478&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,202,459&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(573,139)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,629,320&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's future minimum lease commitments as of December 31 2018, under Accounting Standards Codification 840, predecessor to the newly adopted lease accounting guidance, are as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:76.078078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">959,902&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">980,720&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,001,603&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">871,969&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">44,508&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total future minimum lease payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,858,702&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6750831040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Share repurchases</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2019 and March 31, 2018, the Company repurchased 121,466 shares and 172,079 shares, respectively, of common stock for approximately $0.7 million and $1.2 million, respectively. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Share purchases and sales</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the March 2019 trading window, several members of the the Company's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to further the amount of ownership by the Board of Directors. During the March 2019 trading window, one Board member entered into a share sale agreement, as required by a policy change by his employer, which now prohibits his ownership in the Company.  The policy did not impact his ability to serve on the Company's Board of Directors. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Share Sale</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. During the three months ended March 31, 2018, the Company issued 30,704 shares of common stock for gross proceeds of $0.2 million as part of its At-The-Market (&#8220;ATM&#8221;) sales agreement with B. Riley FBR. The Company did not issue any shares under the ATM during the three months ended March 31, 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Restricted Share Grants </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the three months ended March 31, 2019,  and March 31, 2018, the Company issued 222,269 shares and 229,205 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants.  On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  Cumberland increased the maximum aggregate principal available for borrowing to support potential future acquisitions and general corporate purposes.  The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.    </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had $20.0 million in borrowings under the Pinnacle Agreement at March 31, 2019 and December 31, 2018, thereby using all of its available borrowing under its revolving line of credit.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 5.2% at March 31, 2019).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  As a result of the Third Amendment, the Company was in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6750207520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESOn December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;the Tax Act&#8221;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.The SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118, providing guidance on applying the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements.  If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.  The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6750220032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6904222848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Product Additions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">RECENT PRODUCT ADDITIONS</a></td>
<td class="text">RECENT PRODUCT ADDITIONS<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Omeclamox-Pak</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In December 2018, Cumberland completed an agreement with Gasto-enterlogics Inc. ("GEL") to acquire the remaining product rights associated with Omeclamox-Pak, including the product&#8217;s FDA-approved New Drug Application and the domestic and international trademarks. As part of the transaction, which was accounted for as an asset acquisition, Cumberland paid $2.3 million during 2018 and ended Cumberland&#8217;s payments of royalties and manufacturing fees to GEL.  The Company has now assumed responsibility for the maintenance of the product&#8217;s FDA approval and for the oversight of the product&#8217;s manufacturing and packaging.</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Vibativ</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  While Cumberland is still evaluating the tax deductibility of the goodwill acquired in the acquisition, it expects those amounts to be deductible for tax purposes.    </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company paid an upfront payment of $20.0 million with a $5.0 million cash payment that was provided in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.631579%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.368421%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during early 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,182,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements.  The Company will continue to evaluate the assets acquired and liabilities assumed during the measurement period. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.923977%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.076023%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at November 12, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,034,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,000)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">508,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,502,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">148,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(507,505)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(269,422)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">199,432&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,072,505&#160;</span></td></tr></table></div><div style="margin-top:8pt;"><span><br/></span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:8pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.923977%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.076023%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,624,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,970,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,827,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,129,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,550,000&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,750,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">882,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,632,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td></tr></table></div>The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. The current portion of the contingent consideration liability is $2.2 million and the non-current portion is $6.9 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6604932848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance in the form of a FASB Accounting Standards Update ("ASU") No. 2016-02, &#8220;Leases.&#8221; The new standard establishes a right-of-use (&#8220;ROU&#8221;) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance (formerly "capital leases") or operating, with classification affecting the pattern of expense recognition in the income statement. The standard provides for a modified retrospective transition approach for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients.  In July 2018, the FASB issued ASU 2018-11, "Leases: Targeted Improvements", allowing for an alternative transition method (the effective date approach). It allows an entity to initially apply the new lease guidance at the adoption date (rather than at the beginning of the earliest period presented). Cumberland adopted the lease guidance effective January 1, 2019 using the package of transition practical expedients.  This allowed the Company to retain the lease classification for any leases existing prior to adoption, in addition to other benefits. See additional discussion of the impact of adopting the lease accounting guidance in Note 6.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div>In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. The new standard will be effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its condensed consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6904249200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair value of marketable securities, by type</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:27.368576%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,088,386&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,088,386&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,504,551&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,504,551&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,256,191&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,256,191&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,322,496&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,322,496&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">751,173&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">751,173&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,088,386&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,578,687&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,667,073&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,034,955&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,255,724&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,290,679&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6749040496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122807%;"><tr><td style="width:1.0%;"/><td style="width:58.029499%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.616519%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537463%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.616519%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(73,878)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,379,239)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,472,952&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,689,240&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,472,952&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,689,240&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6904756768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2019 and 2018:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:57.502924%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.444444%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823392%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.298246%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530994%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">849,502&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,273,764&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">199,537&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">141,392&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,307,658&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,269,901&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">286,676&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">93,890&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,317,074&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,039,747&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,091,991&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,256,073&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Totect</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">80,896&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">412,774&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060,195&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">709,218&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">100,064&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,902,747&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,587,605&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6894155760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:56.737151%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121586%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.681057%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530103%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18,383,018&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">18,378,450&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">683,733&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">937,006&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,054,574&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,511,887&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,121,325&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,827,343&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,862,092)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,749,000)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,259,233&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,078,343&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6649467568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">At March 31, 2019, the Company recorded the following on the Condensed Consolidated Balance Sheet: </span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:34.036036%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:38.090090%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,487,977&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,487,977&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:34.036036%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:38.090090%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,023,603&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,605,717&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,629,320&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:76.078078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity of Leases Liabilities at March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">825,712&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,120,067&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,144,889&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,019,313&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">92,478&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,202,459&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(573,139)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,629,320&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Commitments</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's future minimum lease commitments as of December 31 2018, under Accounting Standards Codification 840, predecessor to the newly adopted lease accounting guidance, are as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368421%;"><tr><td style="width:1.0%;"/><td style="width:76.078078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751952%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.969970%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Year ending December 31:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">959,902&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">980,720&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,001,603&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">871,969&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">44,508&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2024 and thereafter</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total future minimum lease payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,858,702&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6904233296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Product Additions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.631579%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.368421%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during early 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,182,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table presents the changes in the Company's Level 3 contingent consideration liability that is measured at fair value on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.923977%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.076023%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at November 12, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,034,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,000)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">508,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,502,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">148,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(507,505)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(269,422)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">199,432&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,072,505&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:8pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.990000%;"><tr><td style="width:1.0%;"/><td style="width:75.923977%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.076023%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,624,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,970,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,827,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,129,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">21,550,000&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,750,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">882,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">12,632,000&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6750244832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759603984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 9,667,073<span></span>
</td>
<td class="nump">$ 8,290,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember', window );">U.S. Treasury notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">5,088,386<span></span>
</td>
<td class="nump">5,034,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,504,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">2,256,191<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Short-term cash investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">2,322,496<span></span>
</td>
<td class="nump">751,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">5,088,386<span></span>
</td>
<td class="nump">5,034,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">5,088,386<span></span>
</td>
<td class="nump">5,034,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term cash investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">4,578,687<span></span>
</td>
<td class="nump">3,255,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,504,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">2,256,191<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term cash investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 2,322,496<span></span>
</td>
<td class="nump">$ 751,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6749257136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (73,878)<span></span>
</td>
<td class="num">$ (2,379,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">15,472,952<span></span>
</td>
<td class="nump">15,689,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">15,472,952<span></span>
</td>
<td class="nump">15,689,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6750212496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">263,919<span></span>
</td>
<td class="nump">247,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759771216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 11,902,747<span></span>
</td>
<td class="nump">$ 8,587,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">849,502<span></span>
</td>
<td class="nump">1,273,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">199,537<span></span>
</td>
<td class="nump">141,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">3,307,658<span></span>
</td>
<td class="nump">3,269,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">286,676<span></span>
</td>
<td class="nump">93,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,317,074<span></span>
</td>
<td class="nump">1,039,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_EthyolMember', window );">Ethyol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">3,091,991<span></span>
</td>
<td class="nump">2,256,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_TotectMember', window );">Totect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">80,896<span></span>
</td>
<td class="nump">412,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">2,060,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 709,218<span></span>
</td>
<td class="nump">$ 100,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_EthyolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_EthyolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_TotectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_TotectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6752183296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for potential obsolescence of products</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">18,383,018<span></span>
</td>
<td class="nump">18,378,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">8,054,574<span></span>
</td>
<td class="nump">8,511,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">14,900,000<span></span>
</td>
<td class="nump">14,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6749291328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 18,383,018<span></span>
</td>
<td class="nump">$ 18,378,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">683,733<span></span>
</td>
<td class="nump">937,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">8,054,574<span></span>
</td>
<td class="nump">8,511,887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross, Total</a></td>
<td class="nump">27,121,325<span></span>
</td>
<td class="nump">27,827,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="num">(15,862,092)<span></span>
</td>
<td class="num">(15,749,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 11,259,233<span></span>
</td>
<td class="nump">$ 12,078,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6904253856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,487,977<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 3,629,320<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6749130960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,487,977<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseAsset', window );">Total</a></td>
<td class="nump">3,487,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,023,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,605,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 3,629,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6759418864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Leases Liabilities at March 31, 2019</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2019</a></td>
<td class="nump">$ 825,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">1,120,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">1,144,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">1,019,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">92,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">4,202,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(573,139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 3,629,320<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 959,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,001,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2024 and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,858,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760913696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="num">$ (1,195,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sales of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,269<span></span>
</td>
<td class="nump">229,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,466<span></span>
</td>
<td class="nump">172,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="num">$ (1,195,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6760490448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 17, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Second Amendment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions', window );">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Expiration period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6750345360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 43,605<span></span>
</td>
<td class="nump">$ 87,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6749595744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Product Additions - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PaymentsForAssetAcquisitions', window );">Payments for asset acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during early 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during early 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6749390640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Product Additions - Schedule of Initial Payments and Consideration (Details) - Vibativ - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during early 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PaymentsForContingentConsideration', window );">Fair value of contingent consideration - net sales royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,182,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,182,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761106192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Product Additions - Change in Consideration (Details) - Vibativ - USD ($)<br></strong></div></th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 9,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment', window );">Adjustment to initial fair value of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(507,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(269,422)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 508,000<span></span>
</td>
<td class="nump">199,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="nump">$ 9,072,505<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6761113424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recent Product Additions - Schedule of Preliminary Purchase Allocation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="nump">$ 784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory', window );">Finished goods inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,624,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials', window );">Work in process - unlabeled vials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,970,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials', window );">Work in process - validation vials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,827,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,129,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Total inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill', window );">Total intangibles and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,632,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,182,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MNO[PNPJ[8.S._F/CBZ!LX-==R"]02P,$%     @ G(FO3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    " "<B:].K\: =V "  !T"   &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'U6VXZ;,!#]%<0'K+$=<ED1I"15U4JM%&W5]ME)G 2MP=1V
MDNW?US8LI?;0%WP[9\Z,AV$H'E*]ZBOG)GFK1:/7Z=68]ADA?;SRFNDGV?+&
MGIREJIFQ2W5!NE6<G3RI%HADV1S5K&K2LO![>U46\F9$U?"]2O2MKIGZO>5"
M/M8I3M\W7JK+U;@-5!8MN_!OW'QO]\JNT&#E5-6\T95L$L7/ZW2#GW<X=P2/
M^%'QAQ[-$Q?*0<I7M_A\6J>9\X@+?C3.!+/#G>^X$,Z2]>-7;S0=-!UQ/'^W
M_M$';X,Y,,UW4ORL3N:Z3I=I<N)G=A/F13X^\3Z@/$WZZ+_P.Q<6[CRQ&D<I
MM'\FQYLVLNZM6%=J]M:-5>/'1W<RHST-)I">0 8")?\ET)Y !P+V"JCSS(?Z
M@1E6%DH^$M5EJV7NI<#/U%[FT6WZN_-G-EIM=^]E5J"[,],CMAV"C!!X0"!K
M>Q @D,"61'3RK\ N1E!8@((14$^G(_H,IL] ^LS39R-Z'EQ C)C# CDHD$?T
M12 0(Y:PP!P4F$?T52 0(W &*RQ A47,QX$$ "&PQ!*46,9\&D@ D(E,KT")
M5<P/4PU )G*-,[B<LMA"F&X(,Y%P/%&T.+80YAS D(FD8[!R-YC$%L*T0YB)
MO&.X?#&-+829AS!3*G"5X[B(R2Q4 3!3*G"IX[B22?"*[7I,[C%-_QKF=(%I
MF!TT^H;77%U\N]/)4=X:WVM'NT-+W?BF@?["NW[\E:E+U>CD((WM)/Y[?Y;2
M<.M0]F1=N=I?@&$A^-FXZ<+.5=<'NX61;=_CT?"C4?X!4$L#!!0    ( )R)
MKT[IV:C2/P0  ,82   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULC9C;
M;N,V$(9?Q?!]5YSA20P< VLOBA9H@6"+MM=*S,3&2I8K*?'V[4O)BN',#!>]
MB0[^A_PI#C].N#JWW;=^'^.P^-[4Q_Y^N1^&TUU1]$_[V%3]I_84C^F7Y[9K
MJB$]=B]%?^IBM9N"FKI I5S15(?C<KV:WCUTZU7[.M2'8WSH%OUKTU3=OYM8
MM^?[)2S?7WP]O.R'\46Q7IVJE_A''/X\/73IJ;BVLCLT\=@?VN.BB\_WR\]P
MM]5J#)@4?QWBN;^Y7XQ#>6S;;^/#K[O[I1H=Q3H^#6,35;J\Q6VLZ[&EY..?
MN='EM<\Q\/;^O?6?I\&GP3Q6?=RV]=^'W;"_7Y;+Q2X^5Z_U\+4]_Q+G =GE
M8A[];_$MUDD^.DE]/+5U/_U=/+WV0]O,K20K3?7]<CT<I^MY;O\]3 [ .0"O
M 6!^&*#G $T"BHNS::A?JJ%:K[KVO.@NLW6JQJ2 .YT^YM/X<OIVTV]IM'UZ
M^[9&MRK>QG9FR>8BP5O)1\564/BKI$C]7TV@: *G>'T;7\KQ6HS74[RYC0]D
M$!>)FR3'B\0X%0Q8,A9!Z(,N@U.R(R,Z,LR15L3116)O.@K.>>4U,<1U)0;E
M?)#]6-&/Y7Z ^+'<3_ Z!/J!N,Z7QJ#)^'&B'\?]D*3:.-8/ -J FGX@08C*
ME]IHV9$7'7GNB'2T\:PC--892PT)NN!TJ9SLIQ3]E-R/(7Y*UH_U*8? D>3?
M"L( X)3.K-(@.@K<$<F-3>!384N'*E!B2$)O@E*9509*II?BGAB^%$]88U1)
M\UK2>4#(9!%D> K<D:>.@/6D,8!"!]23H-3.6A4RJPUDP )R5R5UA1PT)=[.
MR.R)ZQ( \C,G(QLXLS5E]JRY[<EHI]C$<5GI$7)^9& #)[:AQ :.XC&W#7CJ
MB O1:M J-VLRM(%3VU!J \<Q@''@'=T"MZ(47=K<7&:W!1G>X-A^;3#3@@Q;
MX+0UE+; ,1HPH )#Q\6% "JD)97!&\C$!8Y<0Y$+'*50>N4<W4ZWDM+YY"M7
M&H%,7>#8-12[P'&:BI90.JK<BLI2&40CNT(9O,C!:RAXD0-UQ(GB2/D_RH^N
M9/@BAZ^A\$6.U+1@L$1+5[&@#!H"Y.H*S!2WG+V&LA<Y4VTP:6TJNG%*RK1+
MI5TA5W'+_$7.7T/Y*V@LF[H?:CXZD<F+AM'$0J8%F9/(.6EI-8D<?E;Y5$[R
M:1>4:=F6+E<)H$Q)Y#4NK10WR&M7XSRB=]24(/0)\S:W;&7N(N>NI8A#CE-K
MC0;+"F]1F?X7\-E<E,&+'+R6(@XY3G_"5,4I]J4DH4]K*5-]HXQ=Y-BU#' <
MIM9"4!Y93DE*ZY55F4S7,G8UQR[-W\VL<1\!)U8$HE2N"(J; X7QA.?WJGLY
M'/O%8SL,;3.=(#RW[1!3L^I3&N<^5KOK0QV?A_'6I_ON<K)R>1C:TWQJ5%R/
MKM;_ 5!+ P04    " "<B:].OTI1^_,!  "!!0  &    'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;(V4W8Z;,!"%7P7Q &O^R4: U%!5K=1*T5;=7CLP!+0&
M4]L)V[>O;;R($'>UN8@]XW/&WV!P-E'VPEL X;SV9."YVPHQ[A'B50L]Y@]T
MA$&N-)3U6,B0G1$?&>!:FWJ" L]+4(^[P2TRG3NR(J,70;H!CLSAE[['[.\!
M")URUW??$D_=N14J@8ILQ&?X">+7>&0R0DN5NNMAX!T=' 9-[G[R]V6B]%KP
MW,'$5W-'=7*B]$4%W^K<]100$*B$JH#E<(42"%&%),8?4]-=ME3&]?RM^A?=
MN^SEA#F4E/SN:M'F[LYU:FCPA8@G.GT%TT_L.J;Y[W %(N6*1.Y14<+UOU-=
MN*"]J2)1>OPZC]V@QVE>25)CLQL"8P@6@Q^]:PB-(=P8T$RF6_V,!2XR1B>'
MS8<U8O5.^/M0/LQ*)?6STVNR6RZSUR+>9>BJZAC)898$*TEPJR@MBG21(+G_
M A%8(0+M#]<0CW9_:/6'VA^M_(FW:6*6)%HR:,E&4;ZGN&&(K S1/8._89@E
M\6H'WS._#<M'E#=,L94IOF?:'-TAOM\ICJ,T]M,-DDT8[?SH\3\GG5B)DGNB
M<$.4?)3()K02H=7'H"ZG'YB=NX$[)RKD=Z7?_H92 ;*H]R#KM?(^7 ("C5#3
M5,[9?"O,@:"CN?#0<NL6_P!02P,$%     @ G(FO3B.[9Z_R P  *1$  !@
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MJ8YUW5F7E7UP^4YN(W^]*.RQZT^U.V_&W>QXT=7G::>>7/\NV/P'4$L#!!0
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M?[#%$-"X</SJSV8:L\EPNI]_$%F^<?D74$L#!!0    ( )R)KTX2ZMY[M@$
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M&B^3)IU#!N+R_*[^+=:.M9R%@SNC_LC2-QG=4U)")7KEG\SP %,]UY1,Q?^
M"RB$ATPP1F&4BRLI>N>-GE0P%2U>QUVV<1_&FRV?:.L$/A'X3-C'.&P,%#._
M%U[DJ34#L6/O.Q&>>'/@V)LB.&,KXATF[]![R3<)3]DE"$V8XXCA2\R,8*@^
MA^!K(8[\$YVOT[>K&6XC?;N,?GVS+K!;%=A%@=U_ OL/):YAOGX(PA8]U6#K
M.$V.%*9OXR0OO// WL9'9/_@X[0_"EO+UI&S\?BRL?^5,1XPE>0*1ZC!#S8;
M"BH?CC=XMN.8C88WW?2#V/R-\[]02P,$%     @ G(FO3JD5T,>U 0  T@,
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M\8L_FVG,)L/I/OT@,G_C\@]02P,$%     @ G(FO3HXR6M6V 0  T@,  !D
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MLQW';#2\Z:8?Q.9O7/P#4$L#!!0    ( )R)KTX,]QB;M@$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;&U386_<( S]*X@?4'+)M;V=DDB]
M3M,F;=*IT[;/7.(DJ( S()?NWP](FF5MO@ V?L_/QN0CFF?; 3CRHJ2V!>V<
MZX^,V:H#Q>T-]J#]38-&<>=-TS+;&^!U!"G)TB2Y8XH+3<L\^LZFS'%P4F@X
M&V('I;CY<P*)8T%W]-7Q)-K.!0<K\YZW\!W<C_YLO,46EEHHT%:@)@::@C[L
MCJ=]B(\!/P6,=G4FH9(+XG,POM0%38(@D%"YP,#]=H5'D#(0>1F_9TZZI S
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M_V"+(:%QX?C)G\TT9I/AL)]_$%N^<?D74$L#!!0    ( )R)KTXL4I-]M@$
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M0>WC\2Z<[3AFH^&QFWX0F[]Q\0=02P,$%     @ G(FO3EA3+N75 0  G 0
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MD2LA-)@L@SN38&/6?C885-I>=^8N_?![0XM^VFLR_[GD_P!02P,$%     @
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MQ'+L) 3&[8D436P/@'L;7&\#CR<H<#="=(,LN!O!/1==66)W'1!!J S'PKC
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MW)'8&$<IM/]&QZLVLAV]6)26O0QMT_GV/JQ@.IJ%#>!H ">#-/NO 1H-T,(
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MU7,Q?\ASH/BXW%%XO2B+?U!+ P04    " "<B:].&B]$)_D!  !]!0  &0
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MV@_]7FNC;%)R9XL^VL/BT,C5WKA;;N_K[L34-8RN^M-@,!Q)-W\!4$L#!!0
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M(#0$X25!XEN1-!AJ,&5S<G[SL\*Y MB3%*&2(D22E2J+:.#I"_,#9DM?(CB
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M WL1R$M=4_%W"XQW6;@(;XFGZEPJDT!YVM(S_ 3UJ]T+':&!Y5C5T,B*-X&
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MG%9<_UKYA0M:#RS22HU?^[%L]-@-_+<P<P < N 8(+7?"_"& .\M +T;@(8
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M!U,_:R=*!9$VP8.L;"$[X[BHR$FH:2CGK.\/_4+0=FA]SMA_TW]02P,$%
M  @ G(FO3NU-/CAL @  ;P@  !D   !X;"]W;W)K<VAE971S+W-H965T-# N
M>&ULC5;;CILP%/P5Q <L^,(M2I"ZB:I6:J5HJ[;/3N($M("I[83MW]<V!!%L
MMOL27Y@S<^; L;/N&'\5!:72>ZNK1FS\0LIV%03B6-":B"?6TD8].3->$ZF6
M_!*(EE-R,D%U%< PC(.:E(V?K\W>GN=K=I55V= ]]\2UK@G_^TPKUFU\X-\W
M7LI+(?5&D*];<J$_J/S9[KE:!2/+J:QI(TK6>)R>-_XGL-H!K ,,XE=).S&9
M>]K*@;%7O?AZVOBASHA6]"@U!5'#C6YI56DFE<>?@=0?-77@='YG_VS,*S,'
M(NB65;_+DRPV?NI[)WHFUTJ^L.X+'0Q%OC>X_T9OM%)PG8G2.+)*F%_O>!62
MU0.+2J4F;_U8-F;L!OY[F#L #@%P#.B+LQB A@#TT0 \!.!90-!;,;79$4GR
M-6>=Q_O7VQ+]%8$55M4_ZDU3;/-,E4>HW5N.,%H'-TTT8)Y[#)Q@X"-BZT D
MCY"=#4$P'#&!2G+,%#HSA88 /1  -P%R$B!#@*<$Z<QI#XD-I#&0-%4]%,[L
MVK DQ5/80S;8F0VVLH$X=1-$3H+HX_6(G02Q70^,9V\MMIS&,5RVFCB%$H=0
M-!/J,=%$"&5)N"B4.H52AU \$THM(9#"9%$H<PIE#J'Y!Y]90AF V:(0"-W]
M&3JDTGEOA986!%&T7#ZP<!@ AU@V%P-V!4'RGIB[GP'\;S_N!DRTW)"/2N[&
M!X[.C\*Y%+)MP1B](^;N:V W-HK 7 Q;?84P<#D+)@>YOHJ_$WXI&^$=F%1W
M@CFYSXQ)JEC#)Y5\H6[_<5'1L]331,UY?P7V"\G:X7H/QO\8^3]02P,$%
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M,8:$C02^4:/( E>@C1@VE;?W7LH#!,57(0X^$K6O4?YJ!EP;)H<S8DSW%?D
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MI3>2'MKHW)7VPKPU#K1V4G=U#23M[M/-H=X$J_V^1):ZT]C.N&&?DP3YS='
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M"\E/,9?*-59L2+T60L/Z1'+GO5*5SD[VG6!>V>TFO<LWH'_C657"DOBVV.5
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MH#"I?'QR4U:DZ%8^N4N:%U$P[8KH!.<8BFA.H<T.D=J+65I'#&'TV]P"SPR
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MN&7%^8U-NQ<32>O/(:Z.]CO3Y1]02P,$%     @ G(FO3O[W3D.D 0  W1@
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M%+,.KVC6MDTKI>N_2#Z-61[JL_8WR?0;4$L! A0#%     @ G(FO3A\CSP/
M    $P(   L              ( !     %]R96QS+RYR96QS4$L! A0#%
M  @ G(FO3B?HAPZ"    L0   !               ( !Z0   &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " "<B:].\TX_5.\    K @  $0
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M=#(N>&UL4$L! A0#%     @ G(FO3K]*4?OS 0  @04  !@
M ( ! Q   'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( )R)
MKTXCNV>O\@,  "D1   8              "  2P2  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " "<B:].TJQ_.+L$  " %0  &
M        @ %4%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ G(FO3HX)0XW) P  .A   !@              ( !11L  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )R)KTZ4^M(]L0$  -(#   8
M              "  40?  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " "<B:].,U;40+8!  #2 P  &               @ $K(0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ G(FO3C\)-V&U 0
MT@,  !@              ( !%R,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( )R)KTX2ZMY[M@$  -(#   9              "  0(E
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ G(FO3M^!
M/YFV 0  T@,  !D              ( ![R8  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " "<B:].J170Q[4!  #2 P  &0
M    @ '<*   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M )R)KTZ.,EK5M@$  -(#   9              "  <@J  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ G(FO3@SW&)NV 0  T@,  !D
M             ( !M2P  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " "<B:].US@8$K(!  #2 P  &0              @ &B+@  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )R)KTZ6Q])MM@$
M -(#   9              "  8LP  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ G(FO3L&=LGC. 0  G 0  !D              ( !
M>#(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "<B:].
M\JU)H;<!  #2 P  &0              @ %]-   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( )R)KTY?A3)9M@$  -(#   9
M      "  6LV  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ G(FO3BQ2DWVV 0  T@,  !D              ( !6#@  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "<B:].5I6%$;8!  #2 P
M&0              @ %%.@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( )R)KTY84R[EU0$  )P$   9              "  3(\  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ G(FO3H.4:U;4
M 0  G 0  !D              ( !/CX  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " "<B:].HR-A/K<!  #2 P  &0
M@ %)0   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( )R)
MKTX*ZG"2DP,  ,<2   9              "  3="  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ G(FO3DX. 8@O @  508  !D
M         ( ! 48  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " "<B:].R+U"_^ !  !H!   &0              @ %G2   >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( )R)KTY_P(($4P,  #@.
M   9              "  7Y*  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ G(FO3AC9*W@> @  G@8  !D              ( !"$X
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "<B:].[H _
M<D$"  "U!@  &0              @ %=4   >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( )R)KTX8A1&$ZP$  #0%   9
M  "  =52  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
MG(FO3AHO1"?Y 0  ?04  !D              ( !]U0  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " "<B:].#ENB6LD"  ">"@  &0
M            @ $G5P  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( )R)KTZ'AN,F 0,  !8,   9              "  2=:  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ G(FO3G<2((N( @
M20H  !D              ( !7UT  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " "<B:].TIIF<[8!  #3 P  &0              @ $>
M8   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( )R)KTXQ
M&CWL@P(  /((   9              "  0MB  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ G(FO3A1(VT\) @  M04  !D
M     ( !Q60  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M" "<B:].XE13BF("  "+!P  &0              @ $%9P  >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( )R)KT[M33XX; (  &\(   9
M              "  9YI  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L!
M A0#%     @ G(FO3E:RN_*2-0  G.   !0              ( !06P  'AL
M+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ G(FO3M\C18XL @  V0@
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;72YX;6Q02P4&     #$ ,0!)#0  U:L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>94</ContextCount>
  <ElementCount>182</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129110 - Disclosure - Recent Product Additions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentProductAdditions</Role>
      <ShortName>Recent Product Additions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Recent Product Additions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentProductAdditionsTables</Role>
      <ShortName>Recent Product Additions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RecentProductAdditions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Shareholders' Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Recent Product Additions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails</Role>
      <ShortName>Recent Product Additions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Recent Product Additions - Schedule of Initial Payments and Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails</Role>
      <ShortName>Recent Product Additions - Schedule of Initial Payments and Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Recent Product Additions - Change in Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails</Role>
      <ShortName>Recent Product Additions - Change in Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20190331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Recent Product Additions - Schedule of Preliminary Purchase Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails</Role>
      <ShortName>Recent Product Additions - Schedule of Preliminary Purchase Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20190331.htm">cpix-20190331.htm</File>
    <File>cpix-20190331.xsd</File>
    <File>cpix-20190331_cal.xml</File>
    <File>cpix-20190331_def.xml</File>
    <File>cpix-20190331_lab.xml</File>
    <File>cpix-20190331_pre.xml</File>
    <File>cpixq12019-exhibit101.htm</File>
    <File>cpixq12019-exhibit102.htm</File>
    <File>cpixq12019-exhibit311.htm</File>
    <File>cpixq12019-exhibit312.htm</File>
    <File>cpixq12019-exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20190331.htm": {
   "axisCustom": 0,
   "axisStandard": 12,
   "contextCount": 94,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20190331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20190331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20190331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20190331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20190331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20190331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 286,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 12,
    "http://xbrl.sec.gov/dei/2018-01-31": 9,
    "total": 21
   },
   "keyCustom": 18,
   "keyStandard": 164,
   "memberCustom": 12,
   "memberStandard": 16,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20190331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.cumberlandpharma.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Collaborative Agreements",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129110 - Disclosure - Recent Product Additions",
     "role": "http://www.cumberlandpharma.com/role/RecentProductAdditions",
     "shortName": "Recent Product Additions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.cumberlandpharma.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Recent Product Additions (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RecentProductAdditionsTables",
     "shortName": "Recent Product Additions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Marketable Securities (Details)",
     "role": "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Revenues (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i399eff68fe09475f8d1927e1b24e18f5_D20190101-20190331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Leases (Lease Position) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "lang": null,
      "name": "cpix:LeaseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ib7d16aac31044218bb5b9daf893c454a_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ib7d16aac31044218bb5b9daf893c454a_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt (Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i5a16259aa7064665beb60a659a9e175f_I20181017",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cpix:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Recent Product Additions - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails",
     "shortName": "Recent Product Additions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cpix:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie2424f11376147c9af04e9c63133c333_D20181101-20181130",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Recent Product Additions - Schedule of Initial Payments and Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails",
     "shortName": "Recent Product Additions - Schedule of Initial Payments and Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ibbc2d366c5094cc9abd5328dd9f3f412_D20190101-20190331",
      "decimals": "0",
      "lang": null,
      "name": "cpix:PaymentsForContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ifda35f731b37450782fc5c338eb2a4a8_I20181112",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Recent Product Additions - Change in Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails",
     "shortName": "Recent Product Additions - Change in Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ifda35f731b37450782fc5c338eb2a4a8_I20181112",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (loss)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "ie5d35faab61a4630ad543d1af0cc16d8_I20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Recent Product Additions - Schedule of Preliminary Purchase Allocation (Details)",
     "role": "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails",
     "shortName": "Recent Product Additions - Schedule of Preliminary Purchase Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i205691ce0a6642fbb9ea6ea14e6bdbf4_I20181130",
      "decimals": "0",
      "lang": null,
      "name": "cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i848ee9d3c9f34469b15767182f876fc8_I20171231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i848ee9d3c9f34469b15767182f876fc8_I20171231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Marketable Securities",
     "role": "http://www.cumberlandpharma.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20190331.htm",
      "contextRef": "i8bef0260dfed4e52a159b3788f4410a6_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 29,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment",
        "label": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment",
        "terseLabel": "Adjustment to initial fair value of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "terseLabel": "Finished goods inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "terseLabel": "Total intangibles and goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "terseLabel": "Work in process - unlabeled vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "terseLabel": "Work in process - validation vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Document and entity information.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "xbrltype": "stringItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "xbrltype": "stringItemType"
    },
    "cpix_EthyolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ethyol",
        "label": "Ethyol [Member]",
        "terseLabel": "Ethyol"
       }
      }
     },
     "localname": "EthyolMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseInCurrentOperatingLiabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Asset",
        "label": "Lease, Asset",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseAsset",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions",
        "terseLabel": "Line of credit, maximum borrowing capacity upon satisfaction of certain conditions"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long Term Obligations, Excluding Current Portion",
        "label": "Other Long Term Obligations, Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PaymentsForAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Asset Acquisitions",
        "label": "Payments for Asset Acquisitions",
        "terseLabel": "Payments for asset acquisitions"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitions",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_PaymentsForContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Contingent Consideration",
        "label": "Payments for Contingent Consideration",
        "terseLabel": "Fair value of contingent consideration - net sales royalty"
       }
      }
     },
     "localname": "PaymentsForContingentConsideration",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second Amendment",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net of Shares for Tax Withholding",
        "terseLabel": "Common stock issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetOfSharesForTaxWithholding",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders' Equity (Textual) [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_TotectMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Totect",
        "label": "Totect [Member]",
        "terseLabel": "Totect"
       }
      }
     },
     "localname": "TotectMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Us Treasury Notes And Bonds Securities Member",
        "label": "Us Treasury Notes And Bonds Securities Member [Member]",
        "terseLabel": "U.S. Treasury notes and bonds"
       }
      }
     },
     "localname": "UsTreasuryNotesAndBondsSecuritiesMemberMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20190331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r99",
      "r129",
      "r131",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r130"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r49",
      "r66",
      "r184"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r66",
      "r116",
      "r118"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r97",
      "r204",
      "r218"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r40"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r137",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r158",
      "r159",
      "r162"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r65",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r157",
      "r160",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r157",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r157",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Noncurrent portion of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "RECENT PRODUCT ADDITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intellectual property amortizable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Total inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r25",
      "r68"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r120",
      "r209",
      "r223"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r42",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r42",
      "r44",
      "r171",
      "r172",
      "r178"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r42",
      "r44",
      "r170",
      "r178"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r205",
      "r206",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r66",
      "r70",
      "r148",
      "r149"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": {
     "auth_ref": [
      "r145",
      "r146",
      "r147"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Assets, Net, Noncurrent",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r66",
      "r95"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DirectorMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).",
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r48",
      "r75",
      "r78",
      "r79",
      "r80",
      "r81",
      "r84",
      "r212",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "- basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r48",
      "r75",
      "r78",
      "r79",
      "r80",
      "r81",
      "r84",
      "r212",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "- diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "(Decrease) increase in non-cash contingent consideration"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Fair value of marketable securities, by type"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r182",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r182",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r182",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r182",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r70",
      "r96",
      "r150"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r46",
      "r94",
      "r183",
      "r184",
      "r213"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r20",
      "r112"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods, net of reserve"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Inventory, Gross, Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r37",
      "r110"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "Inventory, Noncurrent",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r21",
      "r112"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r37",
      "r74",
      "r110",
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "verboseLabel": "Reserve for potential obsolescence of products"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r53",
      "r93"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r203",
      "r216",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r208",
      "r221"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r28",
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r28",
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r33",
      "r122",
      "r123"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r36",
      "r207",
      "r220"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Short-term cash investments"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r41",
      "r43",
      "r47",
      "r67",
      "r83",
      "r211",
      "r224"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r41",
      "r43",
      "r174",
      "r177"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Maturity of Leases Liabilities at March 31, 2019"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r192",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r191",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r185",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r185",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r185",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r185",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r185",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r185",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r185",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "2024 and thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r30"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Cash payment during early 2019"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payments of deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r54",
      "r163"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sales of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r41",
      "r43",
      "r61",
      "r97",
      "r98",
      "r170",
      "r173",
      "r175",
      "r177",
      "r178"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r119",
      "r222"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r144",
      "r228"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r125",
      "r219"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r190",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Recognition of operating lease assets and liabilities through adoption of ASC 842"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r214",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Commitments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r22",
      "r23",
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r137",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r135",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r35",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Proceeds from the sale of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r124",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from the sale of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r125",
      "r136",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r13",
      "r14",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r13",
      "r14",
      "r124",
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r101"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r168",
      "r169",
      "r176"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RecentProductAdditionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Noncash investment gains"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r77",
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r76",
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11374-113907"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r229": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001628280-19-006841-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-19-006841-xbrl.zip
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M@"7!#%))A+9*(@,-YIXY@]D":,G+%(Q*U?-I8!'5*0T4*1*(#TQAZ9261B^
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M[5D'HZN#C'$#*4-4P1BX4T6P@SR5P5U\VWLFZ<W%]ER,&RQ5U@M#TC:5AO$
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M]S@=]OK#=.MX8'<8SZ20C4?*AJU1!F(/-"I_I*X6;S'!R^,3!LVL'UNL3].
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M%@4%@PE6,QE!"::""K,NBE(F0(IMS<] ,$IKGH$U3TW!=-19Q12 3*3Z*#P
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MNK5 RELH?CFUOGNMX\J,^^\YAZL;Y:6BT$/@RH,@)0,4<@,4EAH8[!1GWO%
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M.O7)F+?9"_F?-[/._S,..GU OUI17C<*4X!O*>!;6'QOK.0J8(<\,0+(CTH
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M^NWC?:K7+KG_W&CEH25Q\ L:9JO_9Y1M^<5P? 1///WELDN/^\/*.WLQB%U
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M-L_F8/-T/UEC"!$<]"S#I@@.&:P9HMA1([&S,F\C+FB;$]PVG*PX;*Y":*I
M=H'LQX%L3 *SV*E<\9YK@2VET6'/"!5*184+9#]-R"9SD(WWC3(J)B=R.4^
M;/B8]W$)2%I)8M186YTW-B!MA4V;THOE/ MD%\@ND+TBA9?!474J4>]%")PR
M[:@U04JB1-Z0R8LK,7OY>LL%O!\#O-D<>--])9+73!E$&&6(<\:1X=8B)7"P
M\%\?#0'P-KHMY+<*,1?0?F30+HC]HU6ANO_2JP6D'P.DQ1Q(\WW-/'A-5"--
M60"&'24";!;(^2BX<)9!#Z]M2-8VE+0EOE%0Y!YFP6Z5Z?-4YL3^'/0!<<*P
ME0;]H]80E'DXOYUSMI)VJQ='5?65E.(@)_#Y_LV2]^Y%VL^V O6E<V21,)NX
M34&0R(W!%ENOH[!:!2R-3=]88[_<9%D%BEO#X3B&U^/<T_4F(?7$&;QX=6AU
M=DI[$J!W.C^!YO$^N"#<YYUA:6(4<>D(,EX2%)G25%GJ' MK&PRW%;ZX6>+M
M0PHKFZ[XQ#/%GBT:75(H^?N@:&EV=A&(JM*@!8=NB4-S,U+^=)_JX%+T!HF8
M:X-2EI!)D2+!K2 F.F!B;&V#8MPV^.(F] 6("A#=K=R:*C)%L8IB%<4JBO44
MY+:2.UX7ZG0/U&DN;N5/]GU@ FMLD%>!H%SG$VDK A+&2DG@B,1V*>I44K=O
MM((*.9LKY.2"6[$WM%F:J[&?]5.0X%,-.U5_7^:.?S77[P7 E@"PG5<+,2BZ
M[Y6*VAN#G.,1<2\2LAP'%%7"QBIJB0QK&X2+MA!W6LQV=:9(5YL[_4CXL[*!
MIH(\=X$\\U$GOH^=!<[D W):Y>@W]LA8P5#446+,C#<I1[^9:=,[C3H5Y/EQ
MD>>[ P!%>8KR%.4IRO,#1(@*Y[D+SC,7+CHXV>?*>DZE0 1;CKBF#&EL*')1
M"H>)BR2JI3A/R7%:S@S?Q>/QP!_F#:/F4IMN6I.GQ+Z72KU?D7#2K,\OB2D5
M%/LVBKV?CQD=G.Y;!T,3CP9AZBSB!KK*$1(1LX93RR,37*]M$$7;6%U$L5ME
MU)>)MP(^W[ONYZ%C25?@SFIM:OQ$ &@N='2 ]YT $A6(1]8GA[@P'ID0(GS%
M*:BH3<0. *A-#&@+O5AXI$!0@:#5"0L4Q2J*512K*-9*DJ:'#D85TG1WI&D^
M]D3W)?,J)N^0\9XAKFQ$.J\V<9AI%ZW0QN*;DZ:2I_3-2O=QU.KVA_<55WJ&
M,?(RP5(F6(KR%.59<48$%(@PE;3AA@LLK2-*DL@%)UI(? -&M'P=F3\'_=09
M_0&C2>% RW"@A4)>7T[WL;5.)*Z0MI(B;@U%AE&!3' :2X%#Q'FE6YLITZ;L
MCF+7!5@*L-P$6)1CAH7(&:@A%])I;3%EGO,DB(Z2%F!9)6"9*S+UA>XKT!_!
MDT.!"8F@QW(M;$:14(8FIY3S3H!S1=OFDBSJ@BH%558X@%-0Y>%091:R^;QY
MLJ^,<)S;@)3+I>M2Q$@SS0%DC'94)ARMK.B*H6VBOT572J[0<E8VW2-DVP[\
MX62#$+V*4><EZN6MH*"72R BT<9(%15>.:XSA^?8A.2ID2YB55?)_\Z\H>NW
M"BF0=G-(6ZAY=,#W!4F!)L40P]Z"!R8C@NX,R"@K%:>2".^:34,4*,E=+CG[
MGNFP)VY@=U?'\X&$^.@BNZ^JGO<,\ZND=#?GJ+>#]%+C<]6A?RYKZ\O)OHY>
M"L\MBB*7NQ/@<>2$+92HA;Y61"AAUC8$:2O0(LU6I>1=@?X"_07Z[POZHS(T
M*C!_K2*GW&E#I3$N4!J8D]@6Z'^:T#\_[X+WL9+2,F.0#$(C;J1$%A,,^*]]
M\HP%*\G:AFDS:MI&LX+\!?D+\C]%Y%\F,FUMXB$0KVPDG$NJ!=>6"<<2H]9I
M?"7TEWU8GL88,#]%QO<5#XX+&I'CEB#0OX"TQ09988SB!G,8^M<V*"%M0>YH
M'Y8"_@7\"_BO(NTWQL<H#!:!&JZIUD$PHD.*1G)CFUU="NU_<I _/W]YNA^$
MQXI$C+PD 7'E/-(4.Q2(@D$@3VHFN;8A<5LKWF;X1CN$?V,6\[#6<") Y1]A
M0<PUH].]M6P.(QA@1.B/0:$?8*BZTZW%BL"*P(K BL"*P(K BL"*P(K 'D%@
M%;?^=^40P;^A\W7C/_!GTJ0C.SCH]":^KJS;7)U\[HSJ+>UXU/^E^:%^R^J7
M1DC0J*X]'L87DP\79%Q][_1"[(U>9 F$SO"X:T]?='K@GT54/?>7DTX8';XP
M9IU0JK'Z5]6BP7S$HSZ#K.-_S=/SA8,,KW.NF=)7GW+M]=<>-.N&2X/9+2_'
MZ^2Z@TP;HZX]XYJ#U[\47M?@D8O;"J4T?.F&TW7%#97/7E5NYL&;%7'@B5C5
MELU$-L'&7K\75_W4U1/BH']RBP3N[WH/'W-\\2%6H*A[*FZP$"UM=9IPZ4V*
M':R> JQ.PYY8<-/<PF!NV?@G;S&OYK;1OH&5W"OXKHP"S:/O4K-L/[@RO8LC
M"UY0:$4[Z$';EL#=5>K[HL _J@+O]4>VVXK5O.PRTWLKTN?WF0YP;=]>F0]P
MYU&F>^KX]S>MM?XP>2@W%UM1@[M4@\TC.&FTFD4M[V:D*@V_OX:7XH,W7KO^
M.OIXY.+@OI>O+UEEX^$ ;"76K,>D%/4@(DH"EXH;CI7C1!F*>9"4U.ENA)8U
MZ]>GL>%M^GMWYV]HQUFW\_'S6[K]VP>^_?D+WCY[BW=^>\NAO6)[;^OD8AK;
MV[./1Q_(I]_>LMV_?^_LO(;WV#LXW=W+J7#PGJ\/CZ#=_VQ_?IDW>9ZL63_9
MYY(I(8-#,0J!.!,&:14HBIPKKAWFD;%JO3K7I,V-6O&-"N\@'WBY9BUGZ(]N
MUO>5!'P?\/@4T/"2!7^W@L*2^;OJD'DVA4R#M63$.P3=:Q'GB2'+(T912LP\
MUM$Z4JWSQD:W);G+U7X%,@MD/C_(9%$X9BB)QFE.!+?$@B$QQKGDB=@"F4\4
M,LD4,H,CA 5"D/2>($X,1\Z:@+#5CE'/L/9F;8.W%9=M4(""F 4Q?SS$7&9M
M,5>),&^5 ^SD.&D-M-.I:*GT)A?9O1(RR]KBIX&=;(J=#(N4C(Y(.@YTDR:)
M;* "_DCH=IR$MFIM@RK>IE*N;NW= IH%-!^79E)&L0TV24DC3U$YZ@PFWA!#
M!:/<%)KY-*%23*&2*FR(]A9A8RCBP1EDHM.(">&B-D%2#5 )VB,4;@M,[F ]
M[J/GFY93;S.%MIJ-+J>6&MZW2#<!7WH8L[R.CF-O:#.2K6(1[Z<@S^6F/85U
M0, U=]$;'DTPGA&#C0Z2V$2(JO8>,).]!\SWU>RNR,76<#A>W#FRG@NM_K[,
M:O!J3@L*DUB"2>QTYJ9%G?1"8TX1==HA[K@$(]/ )&C@1G&E;0(F0;1J<WW1
MZ5KE+6T+(MR;@_&=<+"TIW$1#*IM9 L6W 46S.;[&$M&&V7S+B4*<4$I<L00
M1%Q2/H%[G:A8VV"2M_G*%'4N6+"2>W"6+BU=6KIT=49L[6+"5.*08N!14$N$
M<4QIG3@GV,HR8C^A$7L6!PP)!\ZI1DE&CWC,F\)+$5'@U#(I7 J4+C5BEVC2
MDSRU=-N3/+4L?_CV^MCC\< ?PHC1ZJ<<^*N67M]TZ=D#3",^!2%>G6^Q(L&^
M62]?$O$K[& )=K#[?BZVYQV53 2*I! N[V4LD5$T[]/'/-6*,2WR%GV4M/E3
M2*@H!GX7"54/';N[PK8K=Z"8]G*F/0O5*1$M#2XB:8U%7"N.;)(.::NYEEA(
M+<+:AL*LK<P*[U->3/O>PS:EVTJWE6Z[AX'TH4-J92"]NX%T%D'CF!IFDT#
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M-B)P$>B58%T*T3X5U)[1:Y^XX\"DD0P"Z#47"CF2,'+2:D8\5S ZKVU0CMM
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M\+"%\GNW/L;9:/T=H_(J^BD5JO3B_!A]#E6F8R=AT[%S-HYO]89 /RMAH5>
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M=V5SZDENWP$]6YBU:;R49J*AH@IUBT']H%/G)75R&"=I-?-]=\5#ZKP9<)A
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M?G2[Y\C_=$IK0M(&>6[0V[E4F85U(#7CKG)I9_PZ)PU7Z\AR0K*=*]I1U5
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MZI%NLE2H?45C3^(@UFM1JCG#V7J3BVW/ :2++U0MGK:#0<7B1O/QEO,)10<
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MCX0[3VUD+&A?*-^C0Q^90I^E,6 K+/*"4L2%4<@I[)"24@1AM>,^%LI7P*^
MWPW]W:!ILC$ T1.<Z608T=2FI,'&'#6R C]-: &_1P,_-@4_1:DA0,R1E8![
M7!"9P0]HH%$"!PR\';HI@Q_C;2-$ ;\"?@7\K@$_S(-*-BG/L>>*<1V9%49H
MZYT,U+D;@5_Q=^\)]\3,WQ78<  _%(&H(^Z"019&+:2H-0P;Z$#ABK];4*^@
MWHW\W:B<T1HSJ15W3-KD))9$26RL2IP5RO?HT/</P%X]S;&Y'S11T9. B(L
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M\0IH& \4)9Z]F*0]@D[6X,_D$C@N$:G8V@81;:YHVPA:BB45,+@S1E_ 8!7
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M3N&U#=*FBK65O,L-1(N?7_S\&H9VCZ+OVJ/^/^A/^^61J]P\AT)=E^SIK%/
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MZ;UOOO3L1&#A1I=Q6P!\)]21MD,%%U'@UKSMY8#X7.B;+Y6,(N!M@1L3)N.
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M=.S$;>Y^94?M?:]YW3H]<O:NCD^[O>-^\_+XIZ9I/?6OPZOCGW(8 U<Z;O>
MGNT!I?O1/=@5%ZW=;K=Y>G;==.#>]E_]@R\_@,1][AVW/R9 !2E<XQZT=]S6
MKKAJ7G248''B! D!KAP0)B@ED1-Y1 2V1R4/@5I3P\%!6)7<0>;,/.$J%D@_
M3D!Q>"P,/9]%OB]].XF\)-RR%/#@(6K.?*RV/NRW?NRUV@>'^WO?EOC'G-RO
MU%AWOVV^=3'E;AASFH3"8Y$*PY!'4C#%?3L(O "7TXO7[;-H=I'E9X6%DJT
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MN@8+:=X_99@U#XL1X0D9-.!T0OUO6(O'U%N#Z2Q9$ZXBG!>\.U==N WQ='\
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MS.(#B7$-N>)XA.Z/0-*:A3XRKEZK/).\Z#X04ML3\:L1=2U$/9I'U(N.#-W
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MI*7WI)0U67DQ%EWLAXNWEC@W]X03-4#G6._*$KTT2<@YW%14/I,D0R<3O&4
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M=-ZX/E0^XK!JI$I@/4U7 [Y@XO-6E[#2L.MP#5A8*:Q!D9VK >H!6-$PX@<
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MX*3 >%WU[W&9M&%A\O16Z+R34[,^&-/Q,,DSW'4U>GW=L^W*80Y+L-"!;[-
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MG> </AD9^;,2L,]A(5?5 Q"W %JP>??QJ?S_]KZUN7'C6/2OH#;..=I;$$V
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M8=;2PF4@]F.C56DW[$[=6OW(VO?7_]BJ-!KMMEW?\WWPZ]?]V$:X[3U??U;
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MSW+XR *R02*$00;;'!-W[ >Y58$'KL^5D;H R\3Y[D]F$\-Y@-T^X#@5,!4
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M7T'S)=V0CC$?IPS?B/Q'QHJI>O&#.(EF=(11M:LC_V@W< H#],$?O<RCM.4
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MN<:)M;"1]]WNZIV)QBYLU7GP2LW*D3_PF&R\<7RWS%N9"B%/8K+,.P$!3^5
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MIV@FJVO=\0FCM:HM5W*BOA-X\>GU][$W%XO8U:I])"JJ65C(4IR)ZJ @9*=
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MJTOK?NR'[ARKYY+)^*__!U!+ P04    " "<B:].@H+2#K\+  #]=   $0
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M:+!+W>XA 78A*3GIA1)?,1Y<X#X*?7E2"^F?(?))GV /8L+'"O4Y@M1MB?@
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M\7W[ YAO?+&SCV$QQJZO8JMU&O-J%X<]FGG'\!H?<WVWP)]]HNXLO_X(W?(
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MTDQ;B&T-EB$M[D-E[HW$D3U56C4[;#F@)9*O"P\-3#'OB<C)X8X&G 2+/VP
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M!7%92>=SI?P(^,V?__9_4$L#!!0    ( )R)KT[V7EC9VR0  %QZ 0 5
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M"^2VB>"1ARA=7"M4NC#P[MS? 77=#:2HH0/<5X>8)N&P^_PZG%R%-<YY@T4
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M7SYIJ?=S\5Y_1M[J3TT;8L-1@K% &!)ASL5R)2"-3?W06.4L%HE(,N)4M22
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MLP0BAF*(E>F+I[*HB!,1ISQUV:D:4/>Q[8,][NW2L-K,]=;-TACJFB(WW*?
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M'FL,C5\F8EOT1N7FIY0)8/X9&>TDU=BI(<(9.5.;W3N8T1ZGU_0^QZN;FS0
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M?.;V(&[@#<%:1@;?[SN6,OYV7JV6M;MU]5<.DV2U/Y=#A%#!B (J50P@$6O
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MV\V, @X5!) CPE2&%"?(KQA)@R2?UWV<<B0%T$A6-3<>]X@]&T,T,.MV&#4
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MP,D\7?NEDZJJ^>+\+T]"Q)/U=R>5R<GYVY[=\;9G<;E:A+2:(',N)ZW 6!9
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MN[^8NT )P?OS?/9^-4__>/^)!+I\<[JJ-U'U<F_"K6',*@TL<DO.>N) 7KL
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MF]4G7%P3RH3%9!462[%$),JCSN"2E>!=)AXHUK#ICJ2LPT%RFY1QTBO:0>5
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M/M=[_O]<:^5-N=D);Q*UM\G456*+JWMY@5!\ DQ%H[7>Q3;M5QXF:]S"F";
M&E /7>#JII FSOK O*R%S]F"<F@A%EHH/"GI<K$VMJDAODG(N!4IS7SQO67=
M03[.V3%@32BJ(>_K^7(Y$2Q3F%N0+">JZOTQ\)XG2,(94W0NRK?IYGZ;EG&S
M;IH@YE")=P":VDAZN:X<W/!PD8R6@O9)<P9,!@)_)BL9(U,@#/,I&^ED:'*
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M&:$+1#2B7@5EU%EQRYL-W[N/J/%GS V!CKOF$ ^BAB=D5O;/#+_]D%8FIO'
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M2%-=6-(+IOZV6(_2<4EJ7DL#59U763OZ>9D\84-1I)69,J5MZ+LF8]R9Z>.
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MUR-R13.??H!P3"=N5\.@:P@U3/-#Z+8# Z3@0A%K,(BAT95Q)BE'HB!6J_3
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MQ^73OOUE3E%\YK?]$F/S=<H7_P-02P,$%     @ G(FO3D2DF$#?"   @SX
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MC[F<6@>/H6G(8U;*'/8JQLONS9@/N"95S_%67=SLG \SS60+O!GQN*1%TFS
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M!DZ5Y*:57V=K@K>VA-3MZ9X@#'P:9O=@@'GG9CD]6(+\AEU.;QW.]^RJV@/
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M1[SP_50B I;.TPV]1D)IN(]/_J$O!<$#^2N%XQBZ/KRCR1"@#(1VJW9FN \
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M+3(P,3DP,S,Q+GAS9%!+ 0(4 Q0    ( )R)KT[[; )O/AL  &05 0 5
M          "  4LV 0!C<&EX+3(P,3DP,S,Q7V-A;"YX;6Q02P$"% ,4
M" "<B:].]EY8V=LD  !<>@$ %0              @ &\40$ 8W!I>"TR,#$Y
M,#,S,5]D968N>&UL4$L! A0#%     @ G(FO3H4I"!OI?P  )5<% !4
M         ( !RG8! &-P:7@M,C Q.3 S,S%?;&%B+GAM;%!+ 0(4 Q0    (
M )R)KTZ\56\KLDT  &9P P 5              "  >;V 0!C<&EX+3(P,3DP
M,S,Q7W!R92YX;6Q02P$"% ,4    " "<B:].2;\O&EH)  #:2   &0
M        @ '+1 ( 8W!I>'$Q,C Q.2UE>&AI8FET,3 Q+FAT;5!+ 0(4 Q0
M   ( )R)KT[=A-C27@X  *EY   9              "  5Q. @!C<&EX<3$R
M,#$Y+65X:&EB:70Q,#(N:'1M4$L! A0#%     @ G(FO3D2DF$#?"   @SX
M !D              ( !\5P" &-P:7AQ,3(P,3DM97AH:6)I=#,Q,2YH=&U0
M2P$"% ,4    " "<B:].N0#71]P(  ",/@  &0              @ $'9@(
M8W!I>'$Q,C Q.2UE>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( )R)KTZH,\PM
MB@4  +4C   9              "  1IO @!C<&EX<3$R,#$Y+65X:&EB:70S
<,C$N:'1M4$L%!@     +  L [0(  -MT @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
